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Abstract 
Breast Cancer Resistant Protein (BCRP) and P-glycoprotein (PGP) are membrane-bound efflux 
transporters that transport multiple chemical classes of compounds and act as barriers to tissue 
permeability, thereby regulating tissue exposure of their substrates. The role of these transporters in 
therapeutic resistance of their xenobiotic substrates due to their expression and efflux function at target 
organs/tissues, especially in brain and intestine, is well established, which has fueled investigation toward 
identification of their inhibitors. Multiple clinically used drugs and dietary chemicals have been reported to 
inhibit these transporters and potentially increase the exposure of concomitantly administered BCRP and/
or PGP substrates, which might be desirable (to increase efficacy of the substrate drug) as well as 
undesirable (as it can affect the disposition of the substrate in tissues where it might cause toxicity). 
Therefore, drug-drug and food-drug interactions with BCRP and PGP are a major concern in drug 
development, as recognized by US Food and Drug Administration (FDA), European Medicines Agency 
(EMA) and International Transporter Consortium (ITC). 
BCRP and PGP transporters are also known to transport endogenous substrates and have been 
associated with important physiological functions. This includes an inflammatory bowel disease-like 
phenotype associated with a non-functional PGP polymorphism (Ala893), while a loss of function 
mutation in BCRP (Q141K) is known to be positively associated with gout and negatively associated with 
Parkinson’s syndrome. Although a few endogenous substrates of BCRP and PGP have been identified, a 
systemic understanding of their physiological function and effect on the endogenous metabolome is still 
lacking. 
In the current studies, utilizing untargeted metabolomics, coupled with transcriptomic analysis, we sought 
to understand the endogenous function of Bcrp and/Pgp transporters in rats, by comparing the plasma 
and cerebrospinal fluid metabolome of wild-type and Bcrp-Pgp double knockout rats. Our findings 
revealed several putative novel endogenous/dietary substrates of Bcrp and Pgp transporters and 
established a novel understanding of the physiological function of these transporters. We also identified 
the anesthetic/analgesic ketamine as a putative substrate of Bcrp and Pgp, and found that ketamine 
pharmacokinetics (PK), as well as pharmacodynamics (PD), are affected by these efflux transporters. 
Importantly, the Bcrp-Pgp inhibitor, elacridar, was found to alter the PD of ketamine, indicating that 
ketamine might be prone toward drug-drug interactions (DDIs) associated with Bcrp-Pgp inhibitors. 
Finally, utilizing a Bcrp dietary substrate, Pheophorbide A (PhA), we developed an in vivo assay for the 
assessment of DDI due to inhibition of Bcrp at enterocytes. Our results demonstrated that PhA can be 
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 Breast Cancer Resistant Protein (BCRP) and P-glycoprotein (PGP) are 
membrane-bound efflux transporters that transport multiple chemical classes of 
compounds and act as barriers to tissue permeability, thereby regulating tissue exposure 
of their substrates. The role of these transporters in therapeutic resistance of their 
xenobiotic substrates due to their expression and efflux function at target organs/tissues, 
especially in brain and intestine, is well established, which has fueled investigation 
toward identification of their inhibitors. Multiple clinically used drugs and dietary 
chemicals have been reported to inhibit these transporters and potentially increase the 
exposure of concomitantly administered BCRP and/or PGP substrates, which might be 
desirable (to increase efficacy of the substrate drug) as well as undesirable (as it can 
affect the disposition of the substrate in tissues where it might cause toxicity). Therefore, 
drug-drug and food-drug interactions with BCRP and PGP are a major concern in drug 
development, as recognized by US Food and Drug Administration (FDA), European 
Medicines Agency (EMA) and International Transporter Consortium (ITC). 
 
BCRP and PGP transporters are also known to transport endogenous substrates 
and have been associated with important physiological functions. This includes an 
inflammatory bowel disease-like phenotype associated with a non-functional PGP 
polymorphism (Ala893), while a loss of function mutation in BCRP (Q141K) is known to 
be positively associated with gout and negatively associated with Parkinson’s syndrome. 
Although a few endogenous substrates of BCRP and PGP have been identified, a 
systemic understanding of their physiological function and effect on the endogenous 
metabolome is still lacking. 
 
In the current studies, utilizing untargeted metabolomics, coupled with 
transcriptomic analysis, we sought to understand the endogenous function of Bcrp 
and/Pgp transporters in rats, by comparing the plasma and cerebrospinal fluid 
metabolome of wild-type and Bcrp-Pgp double knockout rats. Our findings revealed 
several putative novel endogenous/dietary substrates of Bcrp and Pgp transporters and 
established a novel understanding of the physiological function of these transporters. We 
also identified the anesthetic/analgesic ketamine as a putative substrate of Bcrp and Pgp, 
and found that ketamine pharmacokinetics (PK), as well as pharmacodynamics (PD), are 
affected by these efflux transporters. Importantly, the Bcrp-Pgp inhibitor, elacridar, was 
found to alter the PD of ketamine, indicating that ketamine might be prone toward drug-
drug interactions (DDIs) associated with Bcrp-Pgp inhibitors. Finally, utilizing a Bcrp 
dietary substrate, Pheophorbide A (PhA), we developed an in vivo assay for the 
assessment of DDI due to inhibition of Bcrp at enterocytes. Our results demonstrated that 
PhA can be potentially used to create a reliable, high-throughput and less expensive in 
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CHAPTER 1.    INTRODUCTION 
 
 
Membrane Drug Transporters 
 
 Membrane drug transporters are protein molecules in the membranes of cells or 
cellular organelles where they help in either uptake or efflux of their substrates into or out 
of the cells, respectively. Transporters are well-known for regulating the disposition of 
their xenobiotic substrates and a notable few, such as organic anion transporting 
polypeptide 1B1 (OATP1B1) or solute carrier organic anion transporter 1B1 
(SLCO1B1), organic cation transporter 2 (OCT2) or solute carrier family 22 member 2 
(SLC22A2), organic anion transporters 1/3 (OAT1/3) or solute carrier family 22 
members 6/8 (SLC22A6/8), breast cancer resistant protein (BCRP) or ATP-binding 
cassette sub-family G member 2  (ABCG2), P-glycoprotein (PGP) or ATP-binding 
cassette sub-family B member 1  (ABCB1) and multidrug and toxin extrusion protein 
(MATE) or solute carrier family 47 members 1/2 (SLC47A1/2) are recognized by US 
Food and Drug Administration (FDA) and European Medicines Agency (EMA) for their 
impact on drug development [1, 2]. These transporters also function as an integral part of 
the biological system, and are involved in maintaining metabolic homeostasis and 
transporting essential or non-essential endogenous metabolites such as amino acids, 
cofactors, proteins, lipids, secondary bile acids, purines, pyrimidines as well as versatile 
metabolites contributed by environment, diet or the microbiome [3-7]. For example, 
organic cation/carnitine transporter 2 (OCTN2) or solute carrier family 22 member 5 
(SLC22A5) transports carnitine, an essential metabolite required for the uptake of long-
chain fatty acids in cells for fatty acid β-oxidation [8]. In addition, BCRP / ABCG2 
transports riboflavin (vitamin B2) [9], from which flavin adenine dinucleotide (FAD) and 
flavin adenine mononucleotide (FMN) are generated, that are important co-factors for 
many enzymes [10]. Therefore, polymorphisms / mutations in the membrane transporters 
are often associated with disease phenotypes such as hyperuricemia (in case of BCRP), 
inflammatory bowel disease (in case of PGP), macular degeneration (in case of ABCA4) 
or other metabolic abnormalities [11-13] [14] [15] [16].  
 
 Transporters can be passive, transporting substrates following the concentration 
gradient, or active, transporting substrates against the concentration gradient [14, 17-19]. 
The active transporters can obtain their energy for working against the concentration 
gradient from ATP hydrolysis (ATP-binding cassette transporters) or transporting one 
metabolite/substrate in exchange of another substrate (antiporter) or along with another 
substrate (symporter / cotransporter) [14, 18]. In addition, there are ion channels, that can 
assume open and closed conformations and maintain an ion gradient across the cell 
membrane, as well as the aquaporins or water transporters, that transport uncharged water 










The uptake transporters comprise of the solute carrier (SLC) superfamily. 
Currently, there are 65 SLC genes, with almost 450 SLC transporters of varying 
functions (http://slc.bioparadigms.org) and are divided into 4 main categories: 
cotransporters (transport along with another substrate), exchangers (transport in exchange 
of another substrate), facilitated transporters (transport along the concentration gradient) 
and orphan transporters (function has not been determined yet) [14, 19]. Several 
physiologically important transporters are uptake transporters, such as those transporting 
choline, amino acid, fatty acid, serotonin, dopamine, glutamine, glucose, and ion 
exchangers etc. [14, 19, 20]. Polymorphisms in these transporters are associated with 
multiple disease conditions such as cardiovascular diseases, Crohn’s disease, post-
traumatic stress, gout, etc. [12, 21-24]. As mentioned before, among the many SLC 
transporters, OATP or SLCO transporters, the SLC22 group comprising of OCT and 
OAT transporters and the SLC47 group comprising of MATE transporters are of 
particular importance for their effect on xenobiotic disposition [1, 25]. The SLC group of 
transporters also comprise of Reduced Folate Carrier (RFC) or SLC19A1, and Proton-
Coupled Folate Transporter (PCFT) or SLC46A1, both of which transport folate and 
antifolate chemotherapeutic drugs [26]. 
 
OATP uptake transporters. OATP or SLCO or SLC21 gene family transporters 
are of great interest for their capacity to transport bile salts, steroids, organic anions and 
several xenobiotics at the intestine (enterocytes) and liver (hepatocytes) [27, 28]. These 
transporters also have important endogenous functions and altered expression of OATP 
transporters has been noted in different cancerous tissues as well [29]. While most of the 
OATP transporters have a direct ortholog in rodents, OATP1A1, OATP1B1 and 
OATP1B3 are only found in humans [27]. OATP1B1 and OATP1B3 are liver-specific 
transporters, while OATP1A2 has the highest expression in blood-brain barrier (BBB) 
and is also expressed in intestine, and OATP2B1 is expressed ubiquitously in almost all 
tissues [27, 29]. OATP transporters, especially OATP1B1 and OATP1B3, as well as 
OATP1A2 and OATP2A1, have very wide substrate-recognition capacity, with a large 
number of drugs / xenobiotics being their substrates as well as inhibitors [28, 30]. 
Significant polymorphism of OATP transporters and their impact on xenobiotic 
metabolism and disposition in humans has been recognized by the International 
Transporter Consortium (ITC) [13]. Due to their significant impact on xenobiotic 
pharmacokinetics (PK) and a large amount of substrate and inhibitor overlap with other 
transporters and drug metabolizing enzymes, OATP1B1 and OATP1B3 have also been 
recognized by FDA as important to be considered during drug development, for the 
assessment of drug-drug interactions (DDIs) when dosed concomitantly with an inhibitor 
[1, 25]. Numerous publications have documented such interactions and guidelines, and 
reports by the ITC are of great interest in this regard [25, 31]. 
 
Organic anion and cation transporters. SLC22 group of transporters are most 
diverse in nature as they comprise of both organic cation (OCT) and organic anion (OAT) 
transporters. Organic anion transporters comprise of OAT1-10 and the uric acid 




proximal tubules, expression of these transporters has been found in other tissues as well 
such as liver, placenta, olfactory epithelium, choroid plexus and blood-brain barrier [20]. 
These transporters play a significant role in transporting diverse endogenous metabolites 
and xenobiotics of different chemical and therapeutic classes such as amino acids, 
microbiome metabolites, fatty acids, angiotensin converting enzyme (ACE) inhibitors, 
diuretics, antibiotics and statins [7, 20]. URAT1 is the major transporter of uric acid and 
loss of function polymorphism in this transporter is associated with hyperuricemia and 
gout [32, 33]. Both OAT1 and OAT3 are recognized by FDA as transporters important to 
be considered during drug development for substrate or inhibitor liability for the new 
chemical entity [1].  
 
 Organic cation transporters of the SLC22 family are the OCT1-3, OCTN1 and 
OCTN2 transporters [5]. The SLC47 family or MATE transporters are also cation 
transporters. While SLC22 are uptake transporters, MATE family transporters SLC47A1 
and SLC47A2 are cation antiporter efflux pumps [5]. OCTs are mainly present in the 
kidney and liver, but expression is also noted in lung, placenta and intestine [27]. 
Although these transporters are involved in the transport process of multiple important 
endogenous metabolites including neurotransmitters, hormones and purine metabolites, a 
knockout mouse model of these transporters does not present with apparent physiological 
abnormalities, possibly due to a large amount of substrate overlap between the SLC 
group of transporters [5]. Due to their significant effect on xenobiotic transport and a 
diverse chemical class of drugs being their inhibitors, MATE1 and 2, as well as OCT2 
are FDA-recommended important transporters to be considered for drug development 
purposes [1, 25]. 
 
 
Efflux transporters  
 
 The efflux transporters comprise of the ATP-bound cassette (ABC) transporters 
that transport their substrates against the concentration gradient by utilizing the energy 
from ATP hydrolysis [34]. In the mammalian system, there are 49 ABC genes (with 21 
pseudogenes) encoding 7 subfamilies of ABC transporters (A-G) [18]. Currently there are 
35 mammalian ABC transporters with assigned functions as endogenous and/or 
xenobiotic transporters [14, 34]. ABC transporters are also important for the microbial 
system and are often associated with treatment resistance in antibacterial therapy [35, 36]. 
Bacterial ABC transporters display striking structural similarity with those in the 
mammalian system, raising the possibility that they are important for host-microbiome 
interactions [17, 35]. The major human ABC drug efflux transporters are ATP-binding 
cassette subfamily B member 1 (ABCB1) or multidrug resistance protein 1 (MDR1) or P-
glycoprotein (PGP), ATP-binding cassette subfamily C member 2 (ABCC2) or 
multidrug-resistance associated protein 2 (MRP2), ATP-binding cassette subfamily C 
member 4 (ABCC4) or multidrug-resistance associated protein 4 (MRP4) and ATP-
binding cassette subfamily G member 2 (ABCG2) or Breast Cancer Resistance Protein 





Structure of ABC transporters. The ABC superfamily of transporters have 
transmembrane domains (TMDs) and nucleotide binding domains (NBDs). The NBDs 
comprise of the well-conserved Walker A and Walker B motifs. The TMD is membrane-
bound is usually more variable in nature and contains 6 membrane-spanning loops, while 
the NBDs are more conserved and sit in the cytosol [14, 17, 18]. Most of the ABC 
transporters contain two NBDs and two TMDs, hence termed as “full” transporters. But 
ABCG and ABCD family transporters contain only one TMD and one NBD and are thus 
termed “half-transporters” and require homodimerization (ABCG2) or heterodimerization 
(ABCG5 and ABCG8) to become functionally active [14, 37].  
 
Clinical significance of ABC transporters. The mammalian ABC transporters 
are of immense physiological importance, known to transport diverse chemical classes of 
compounds [38] and loss of function mutation in these transporters are associated with 
several diseases [14, 18, 34]. For example, the ABCA group of transporters are well-
known cholesterol transporters, and a loss of function mutation is known to cause 
defective cholesterol and phosphatidylcholine transport (Tangier disease) [39]. In 
addition, ABCA3 is related to surfactant transport in the lung and is associated with 
respiratory distress syndrome [40]; ABCA4 is a retina-specific transporter and loss of 
function of this transporter is associated with early-onset macular degeneration and loss 
of vision (Stargardt disease) [41]; and the ABCA7 transporter has been recently 
associated with Alzheimer’s disease [42]. While ABCB1 or PGP is a multidrug 
transporter, ABCB4 transports phosphatidylcholine [14] and ABCB11 or BSEP (bile salt 
export pump) transports glycochenodeoxycholic acid, and loss of function of ABCB11 is 
associated with intrahepatic cholestasis [43]. ABCC group of transporters are multidrug 
efflux transporters as well and also transport important endogenous metabolites, such as 
cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), 
uric acid and bilirubin [14]. A genome-wide association study of Kawasaki disease 
patients has suggested a possible role of ABCC4 transporter in this disease [44]. 
Mutations in ABCC7 are known to be associated with cystic fibrosis disease [45]. ABCG 
group of transporters are cholesterol transporters and loss of function mutation in ABCG5 
or ABCG8 is associated with sitosterolemia [37].  
 
 ABC efflux transporters are present in different tissues and organelles, and their 
effect on drug transport has been mostly studied at the epithelial or endothelial cells of 
different tissues and blood vessels, bile canaliculi, kidney tubular cells, blood brain 
barrier (BBB) and the enterocytes [14, 34, 38]. Efflux transporters, such as ABCB1 or 
PGP, ABCG2 or BCRP, ABCC1-4 or MRP1-4 are well known for their effect on the 
pharmacokinetics and/or pharmacodynamics and also toxicity and/or side effect of their 
substrates [38, 46] [47]. A significant impact of Pgp transporter is observed in regulating 
the brain permeability of its substrates and thereby reducing the toxicity due to unwanted 
brain exposure of toxic chemicals, such as ivermectin, in mice [48]. Pgp present at the 
BBB endothelial cells, effluxes its substrates and limits their permeability in brain. 
Therefore, lack of Pgp function at the BBB often shows a dramatic increase in brain 
exposure of its substrate drugs, e.g., digoxin and vinblastine [49, 50]. Also, of interest, it 




condition similar to inflammatory bowel disease (IBD) [51] and a polymorphism of 
MDR1 or PGP has been recently associated with IBD in humans as well [16].  
 
Endogenous substrates of ABC transporters. As briefly discussed before, the 
ABC efflux transport system has important physiological functions and thus are often 
associated with pathological conditions [35]. ABCA and ABCG class of transporters are 
mainly cholesterol transporters [14, 18], with specialized function for ABCA4, 
transporting N-retinylidene-phosphatidylethanolamine at the retina [52]. ABCG class of 
transporters are reported to transport choline phospholipids and ABCG2 in this subfamily 
is a multidrug transporter with important endogenous substrates such as uric acid [53, 
54]. ABCB subfamily transporter ABCB1 or PGP has been studied extensively for its 
effect on xenobiotic transport, treatment resistance and unwanted toxicity at the 
distributing tissues [38, 46, 48-50, 55, 56], but also known to transport glucocorticoids 
[57], endogenous opioids [58] etc. ABCB11 or Bile Salt Export Pump (BSEP) is an 
important bile salt transporter [43]. ABCC subfamily transporters have great 
physiological significance, transporting prostaglandins, leukotrienes, conjugated 
bilirubin, cAMP, cGMP and uric acid among many important endogenous substrates [59, 
60].  
 
Efflux transport and xenobiotic substrates. The ABC efflux transporters are 
well-known to transport a wide variety of xenobiotics as their substrates, such as 
chemotherapeutics, immunosuppressants, antibacterial, antiviral, etc. [3, 6, 59]. 
Identification of several efflux transporters is related to their drug resistance in cancer 
treatment, and their role is much appreciated now as transporters of relatively broad 
chemical specificity [6, 38, 46, 61-63]. Certain structural or physicochemical features 
have been identified to be preferred than others for substrate specificity, which are 
thereby utilized to formulate a structure-property-based approach to identify substrates 
and inhibitors of these transporters. For example, in case of PGP, pharmacophore and 
machine-learning based approaches have identified newer inhibitors [64-66]. Some 
structural features for PGP transporter substrates are aromatic hydrophobic rings, 
uncharged or weak basic molecules, but often amphipathic in nature [38]. Similar to PGP, 
another promiscuous transporter ABCG2 inhibitor/interaction identification has also been 
approached via ligand-based computational methods and were further confirmed by cell-
based studies, as well as cell-based screening methods utilizing diverse structural classes 
of molecules [67, 68]. BCRP substrates tend to have aromatic hydrophobic rings, with a 
large number of H-bond donors such as nitrogen residues and sometimes display weak 
acidic properties [69]. Although PGP has been observed to have broad substrate 
specificity [70], other transporters often display some structural preferences. For 
example, the MRP group of transporters usually transport amphiphilic organic anions and 
glutathione-conjugated cations [59]. Further information specifically about the BCRP and 








Drug-drug interactions and transporter/enzyme substrate overlap 
 
 Drug transporters are known to share common substrates and inhibitors with other 
transporters as well as drug metabolizing enzymes. Many drugs such as rifampicin, 
cyclosporin and tyrosine kinase inhibitors interact with multiple drug transport systems as 
well as enzymes [71]. This may result in clinical pharmacokinetic drug-drug interactions 
(DDIs) which can further lead to undesired over-exposure to a drug that is concomitantly 
dosed with a medication which is an inhibitor of a transporter or enzyme system [72]. 
Besides inhibition of an enzyme by competitive or noncompetitive mechanisms, 
transporters and enzymes may also be regulated by direct or indirect mechanisms. For 
example, chemotherapeutic kinase class of drugs and protein-protein interactions affect 
the expression of ABC drug transporters as well as organic cation transporters, leading to 
possible DDIs [73-75]. Apart from interaction with a co-treatment, significant clinical 
interactions have also been reported for dietary and natural compound transporter and/or 
enzyme inhibitors such as St. John’s wort and grapefruit juice among several others [76-
79]. These interactions have often been identified and studied extensively, thereby 
leading to distinct guidelines by the regulatory agencies [1, 80].  
 
It is important to recognize that drug transporters and metabolizing enzymes are 
the major clearance mechanism of a foreign chemical entity in our system. Therefore, 
major drug metabolizing enzymes and transporters often co-exist in major barrier tissues, 
such as intestinal epithelial cells, hepatocytes and kidney [81-83]. Drug metabolizing 
enzymes are less frequent in the blood-brain barrier, kidney and lung, [84] where the 
major clearance mechanism is mediated by the transporters. Hence, often, the substrate of 
a metabolizing enzyme is also a substrate of the transport machinery, such as the statin 
class of drugs which are substrates of multiple transporters as well as metabolizing 
enzymes and prone to clinical drug-drug interactions [85]. Many drugs are also inhibitors 
of multiple transporters, e.g., tyrosine kinase inhibitor lapatinib inhibits BCRP, PGP and 
URAT1 [71], elacridar inhibits PGP, BCRP as well as OATPs [86, 87], etc. Therefore, a 
complete understanding of determinants of drug pharmacokinetics is important, with the 




Assays for identification of transporter substrates and inhibitors 
 
In vitro assays. Identification and/or confirmation of substrates or inhibitors of 
transporters are often performed in vitro and several assay systems have been developed 
for such purposes. The White papers from ITC provide a great guideline on data analysis, 
usefulness and advantages or disadvantages of these systems [88, 89]. The following four 
types of in vitro transporter assays are usually widely used:  
 
1. Membrane vesicles: An inside-out membrane vesicle system is used for the 
identification of efflux transporter substrates, as well as inhibitors. In this case, an 
analytical method capable of detecting low concentration of the metabolite is required, or 




properties of the transporter-substrate interaction are obtained from these assays. For 
highly lipophilic and diffusible compounds, binding to the vesicles may lead to false 
negative results [88].  
 
2. Recombinant cell lines: Stable transfection of host mammalian cells with full-
length transporter cDNA is used for generation of different transporter cell lines. Human 
embryonic kidney (HEK), canine kidney (MDCK), Chinese hamster ovary (CHO) and 
porcine kidney (LLC-PK) cells are among the many cell lines that are used for transporter 
substrate identification. MDCK and LLC-PK cells usually grow faster and form polarized 
monolayer with tight junctions and are thereby very suitable for transwell permeability 
studies and uptake / efflux assays for substrate or inhibitor identification. Changes in cell 
viability in presence of a transporter inhibitor and a cytotoxic substrate (e.g. 
mitoxantrone) can also be used for inhibitor identification. Although used as an indirect 
proof of substrate, the inhibitory effect of a compound on transporter substrate 
accumulation or transport is mainly a proof of interaction and should be used with 
caution, since many transporter inhibitors were eventually not found to be substrates. 
Moreover, presence of endogenous transporters should also be noted for such assays. In 
addition, multiple cell culture variables need to be kept in mind when developing or 
running the assays, such as culture time, passage number, media component (albumin 
content) etc. [88]. Use of multiple transporter substrates or inhibitors as positive controls 
are recommended by ITC and the regulatory agencies which also detail the methods for 
data analysis [88, 89].  
 
3. Bidirectional assays: Bidirectional assays utilizing recombinant cell lines 
(LLC-PK, MDCK or Caco-2) is the recommended system by the regulatory agencies for 
identification of transporter substrates and inhibitors [1, 88]. A transwell format is used 
where cells are grown on a transwell insert, the substrate is added on either basolateral or 
apical side of the chamber (donor compartment) with or without the inhibitor, and 
concentration of the substrate transported to the other side of the chamber (receiver 
compartment) is measured. Different analytical methods can be utilized to calculate the 
final outcome to measure apparent permeability (Papp) values that can be utilized in vivo 
in different PBPK models incorporating transporter kinetics. ITC provides a thorough 
guideline for execution and data analysis of such assays [89, 90]. Presence of endogenous 
transporters is a factor in this assay as well.  Moreover, compounds with low permeability 
might be difficult to study in this assay [88].  
 
4. Hepatocytes: The hepatocyte culture system is used to study in vitro uptake, 
efflux and metabolism of xenobiotics in the liver. Suspension-cultured and sandwich-
cultured hepatocyte systems exist, with a preference for the later, as it mimics closely the 
complicated network in human liver and creates the biliary duct system in vitro in a 3D 
cell culture model. This is a very complex system and use of specific inhibitors are 
required to tease out the effect of each transporter or enzyme on the transport or 
metabolism of the compound tested. But due to its closeness to the physiological 





Apart from ITC, the regulatory agencies also provide a detailed guideline on how 
to use in vitro assays for identification of transporter substrate or inhibitors and their 
utilization for identification of DDIs [1]. 
 
In vivo models. Transporter knockout models as well as inhibitor-based studies in 
mice and rats have been utilized for substrate identification [48, 91, 92]. Studies with 
inhibitors are required to confirm the findings in the knockout models to rule out the 
effect of compensatory pathway effects. Although prototypical Bcrp and Pgp substrates 
are known to have increased brain permeability in absence of the transporters at the 
blood-brain barrier [50, 93, 94], caution must be taken to avoid misinterpretation of 
results for high permeability drugs that may not show increased accumulation in brain in 
a knockout model, but whose pharmacokinetics and pharmacodynamics are still affected 
by the transporters [95-98]. Apart from the knockout models, noninvasive powerful 
imaging techniques such as positron emission tomography (PET) and whole-body 
autoradiography may also be used with carefully designed probes for identification of 
transporter substrates and/or inhibitors, or even to understand the pharmacodynamics of a 
drug [99, 100]. Another technique used is gamma-scintigraphy that utilizes gamma-
emitting isotopes such as 99mTc to assess drug disposition. However, these methods are 
expensive and have their own practical limitations as well [25].  
 
 
BCRP and PGP Efflux Transporters 
 
BCRP or ABCG2 and PGP or ABCB1 are two major drug efflux transporters, 
which are present at major drug absorption and/or elimination sites as intestine, liver, 
kidney, blood brain barrier, and their major function is to reduce systemic exposure of 
their substrates.  
 
 
BCRP efflux transporter 
 
Breast cancer resistant protein (BCRP) or ABC sub-family G member 2 (ABCG2) 
is a half transporter, as it contains two subunits of one TMD and one NBD domain, that 
requires homodimerization to become active [14]. BCRP is a 72 kDa protein with 665 
amino acids and is highly conserved across the mammalian as well as vertebrate species, 
suggestive of its conserved function across all species [101, 102]. Using BXP-34 and 
BXP-21 antibodies, Maliepaard et al. were the first to provide an extensive report of 
BCRP expression in normal human tissues [103], showing high expression in the 
placental syncytiotrophoblast, the small intestinal epithelium, the canalicular membrane 
in liver and in the duct and lobules of breast. Interestingly, it was found to have high 
expression in vein endothelium but not in the arteries. Expression of BCRP was later 
confirmed at choroid plexus and blood-brain barrier in the brain, kidney proximal tubules 
and cardiomyocytes among several other tissues [102, 104]. Expression of BCRP has 
been extensively studied in human intestine and found to have a high expression in the 
duodenum with decreasing expression further down the gastrointestinal tract [105]. Other 




cells [106, 107] as well as cancer stem cells [108]. Although its expression is not required 
for having stem cell-like properties, BCRP expression on the stem cells (side population 
cells) help in their identification [108-110].  
 
Clinical significance of BCRP. BCRP transporter polymorphisms Q141K and 
V12M are well-characterized, with the loss of function polymorphism Q141K exhibiting 
a high frequency of occurrence in the Asian population [111-113]. Several other 
important polymorphisms, such as Q126X, in this transporter have also been noted [11, 
114]. BCRP polymorphism has also been associated with pathological conditions such as 
gout [24], apart from its effect on the oral bioavailability of its substrates such as 
topotecan [115]. Of particular interest, Matsuo et al. showed a positive correlation of 
BCRP polymorphism with gout, but negative correlation with Parkinson’s disease [116]. 
In addition, due to BCRP-mediated transport of drugs, it has been associated with several 
treatment-resistant diseases, especially cancer [117, 118]. BCRP polymorphism has also 
been associated with a Jr(a-) blood group phenotype in which the affected individuals 
lack a Jr(a) antigen on their red blood cells, thereby making them prone to transfusion 
reaction or hemolytic disease [119, 120]. 
 
Xenobiotic substrates or inhibitors of BCRP. A diverse group of compounds, 
belonging to different chemical classes, such as anthracene drugs (mitoxantrone, 
bisantrene), camptothecin (topotecan), nucleoside analogues (zidovudine), statins 
(rosuvastatin), tyrosine kinase inhibitors (gefitinib, sorafenib), proton pump inhibitors 
(pantoprazole) and fluoroquinolone antibiotics are substrates of BCRP transporters [6, 
121, 122]. Apart from in vitro studies, the mouse Bcrp KO model has also been utilized 
to determine substrates and inhibitors of Bcrp. Mouse Abcg2 or Bcrp has 81% protein 
sequence similarity with human ABCG2 or BCRP [55], and mutation in the amino acid at 
482 position affected substrate specificity in both species [123]. Therefore, substrate and 
inhibitor profile of BCRP in humans could be compared to that in mice. Extensive 
reviews articles have been published with a detailed list of substrates and inhibitors of 
BCRP [6] [102] [121], with new molecules being added as well.  
 
Endogenous substrates of BCRP. BCRP is also known to play an important role 
in transporting endogenous and dietary substrates. Endogenous metabolites uric acid, 
riboflavin, folic acid and protoporphyrin IX have been reported as substrates of BCRP 
transporter [9] [54] [114] [124] [92]. BCRP is also associated with heme transport [109] 
[125], though a direct evidence of heme transport by BCRP does not exist yet. In 
addition, dietary chlorophyll catabolite Pheophorbide A was found to be a highly 
selective BCRP substrate [92], and many gut microbiota-derived uremic toxins and 
metabolites are known to interact with BCRP as well [126] [83]. BCRP has also been 
shown to have a high affinity for sulfated metabolites, sulfated steroid conjugates as well 
as phytoestrogen sulfates [127] [128] [129].  
 
Physiological significance of BCRP. BCRP transporter expression at the 
enterocytes and blood-brain barrier (BBB) as well as blood CSF barrier (BCSFB) has 
been shown to limit oral bioavailability and brain permeability of its substrates. At the 




substrates and is known to protect the fetus from undesired chemical exposure at the 
placental barrier [6] [105, 130] [104]. While absence or inhibition of BCRP has been 
shown to increase the brain penetration of its substrates [94] [131], previously published 
reports also show that inhibition or absence of Bcrp at the choroid plexus (CP) epithelial 
cells leads to reduced ventricular CSF concentration of Bcrp substrate topotecan in mice 
[132] [133], whereas the brain concentration of topotecan still increases. 
  
 Immunohistochemical labeling of Bcrp using BXP-53 antibody demonstrated that 
Bcrp is present on the apical membrane of choroid plexus epithelial cells, facing the CSF 
[133]. This compartment-specific effect of Bcrp in the mouse brain can also be observed 
for another Bcrp substrate/inhibitor, lapatinib. A tissue distribution study using 14C-
labeled lapatinib exhibited higher lapatinib radioactivity in CSF compared to brain in rats 
[134]. This highlights the physiological role of BCRP as an efflux transporter at BCSFB, 
effluxing its substrates into CSF. This is further strengthened by the fact that high 
concentration of uric acid (a BCRP substrate) in serum is negatively associated with 
Parkinson’s disease, but positively associated with gout [116]. Results published by 
Yasuda K et al. demonstrated that Bcrp is also present at the arachnoid barrier epithelial 
cells, part of the BCSFB, both on the apical as well as basolateral side [135]. On the 
apical side, it faces the blood and the normal function would be regulating blood-to-brain 
permeability of its substrates, whereas at the basolateral side, it faces the CSF, and 
therefore probably effluxes its substrates that are important for the metabolic content of 
CSF (Figure 1-1).  
 
BCRP-mediated transport / interaction with heme has been reported to provide 
hypoxic cell survival [109, 125]. In addition, its presence on cancer stem cells [129] 
might further explain the treatment resistance observed in cancer therapy. Apart from 
cancer and hematopoietic stem cells, BCRP is also found to be expressed in cardiac stem 
cells and cardiomyocytes and reported to be involved in ischemic cardiac diseases as well 
[110, 136, 137].  
 
Uric acid is a well-known BCRP substrate [114] and BCRP has been found to 
play an important role in the extrarenal or intestinal secretion of uric acid [138]. Hosomi 
et al. also reported that treatment with Bcrp inhibitor elacridar can reduce the intestinal 
secretion of uric acid [138]. In this regard, it has recently been noted that intestinal 
microbiota in gout patients is significantly different compared to the normal population 
[139]. Gout patients related to BCRP polymorphism are known to secrete less uric acid in 
the intestine [114]. While Guo et al. did not investigate the presence of BCRP 
polymorphism in their studied gout patient population, it is important to understand the 
effect of BCRP, if any, in this context.  
 
 While multiple studies have been performed to identify BCRP substrates and 
inhibitors, including endogenous substrates, a systemic effort to understand the 
physiological role of BCRP transporter and the consequences of its absence or inhibition 
by different xenobiotic/dietary inhibitors is still lacking. Due to the effect of multiple 
transporters on the endogenous metabolites, an investigation of a single metabolite or 








Figure 1-1. Effect of BCRP transporter on its substrate disposition at the Blood 





provide limiting and often misleading information. The recently developed remote 
sensing and signaling hypothesis [20, 140-142] with regard to OAT transporters is of 
particular note in this context. Therefore, a global or systemic approach needs to be 
undertaken to unravel the mystery of physiological interactions and functions of BCRP 
transporter. 
 
Moreover, an understanding of the endogenous metabolites of BCRP might help 
identify an endogenous biomarker of this transporter, which might provide further 
information for identification of clinical DDIs, as well as identification of clinical 
conditions involving change in expression of BCRP. 
 
 
PGP efflux transporter 
 
 Compared to BCRP transport system, P-glycoprotein (PGP) or ATP-binding 
cassette subfamily B member 1 (ABCB1) has been studied more extensively and its 
clinical significance with respect to drug disposition is better understood [46]. ABCB1 is 
a 170 kDa protein and a “full transporter” in that it contains 2 TMDs containing 12 
membrane-spanning loops and 2 NBDs. [143]. Impact of PGP on the brain penetration of 
its substrate drug was accidentally noted first with ivermectin, leading to a 100-fold 
higher neurotoxicity in the Pgp KO mice [48]. Later the effect of PGP transport system 
was investigated on the brain penetration of multiple xenobiotics such as digoxin, 
cyclosporine, dexamethasone and tyrosine kinase inhibitors such as dasatinib and 
ponatinib [50] [144] [143]. PGP is found to be expressed in several tissues and organs, 
mainly providing protective function from exogenous toxins / chemicals [46] [70]. It has 
high expression at the intestinal epithelial cells (reducing oral absorption of its 
substrates), canalicular cells at the hepatocytes (increasing biliary excretion), kidney 
(increasing urinary elimination) and placenta (protection of the fetus) among many other 
tissues [56]. Expression of PGP in the human liver was reported to be lower than that in 
enterocytes, and hepatocyte expression was found to have almost 50-fold inter-individual 
variability [143, 145]. Recently pro-inflammatory Th17 cells in intestine were found to 
express PGP and were refractory to glucocorticoid therapy [146], raising the possibility 
that Pgp might be involved in maintaining normal colorectal physiology [15].  
 
Clinical significance of Pgp. Multidrug resistance in cancer cells was identified 
as early as 1986 by Shen et al. [63] which was later linked to PGP [147], and its 
expression in normal human tissues was established as well [148]. Since then, multiple 
studies have established the clinical importance of PGP in chemo-resistance, resistance to 
anti-HIV therapy and its effect on xenobiotics of diverse chemical and therapeutic classes 
[38] [149] [46] [3]. Pgp is expressed at the BBB and affects the brain permeability of its 
substrates, thereby limiting efficacy or increasing toxicity risk in case of DDIs [150] 
[151] [48]. Lack of Pgp function has also been noted to cause IBD-like conditions in 
animal models [16], raising the concern that this transporter might have an important role 
in the gastrointestinal tract [51]. A large number of single nucleotide polymorphism 
(SNPs) in the coding region of PGP has been observed, leading to decreased mRNA or 




pharmacokinetics or pharmacodynamics is yet to be established [70]. Moreover, in 
several disease conditions, especially in central nervous system (CNS) diseases such as 
epilepsy [152] [153] [154], expression of PGP can change, leading to a possible increase 
in PGP substrate exposure in the CNS [155]. 
 
Xenobiotic substrates or inhibitors of PGP. Due to its effect on chemo-
resistance, and on the disposition of a large number of therapeutic class of compounds 
such as antibiotics, immunosuppressants, anticancer and cardiovascular drugs etc. [156], 
researchers have been looking for PGP inhibitors with higher specificity and clinical 
usefulness [38]. At least 3 generations of PGP inhibitors exist based on their chemical 
classification, specificity and toxicity properties and several comprehensive lists of 
inhibitors have been published [157] [38]. While the first generation of inhibitors were 
cytotoxic (verapamil) or nonspecific inhibitors of multiple transporters or enzymes 
(pantoprazole), PSC833 or valspodar belong to the second generation, and the third 
generation comprises of elacridar and similar drugs such as zosuquidar and tarquidar, 
which have been developed to be used in the clinic [158]. 
 
Endogenous substrates of PGP. Although the effect of PGP on xenobiotic 
substrates is well established, the endogenous function of this transporter is not well 
understood. PGP has been reported to transport endogenous opioids such as adrenorphin, 
endomorphin 1 and 2, neurokinin [58], glucocorticoids such as cortisol and aldosterone, 
[159] [57] and possibly bilirubin [160]. In addition, using conjugated phosphocholines 
and other short chain fatty acids, it was shown that PGP is a broad specificity lipid 
translocase [161]. 
 
Physiological significance of PGP. The physiological significance of PGP 
transporter is mainly assigned to its protective function at enterocytes and BBB, and its 
importance as a broad specificity chemical transporter, with the possibility of lipid 
translocation and of other known endogenous substrates [3, 70]. The absence of Pgp had 
been reported to express an IBD like symptoms [16] along with a change in gut 
microbiome [162] [51], and association with colorectal carcinoma and ulcerative colitis is 
also suggested [163] [15]. Expression of Pgp on the glucocorticoid treatment-resistant 
Th17 cells in intestine [146] also points towards the important role that Pgp might play in 
regulating intestinal health or even on the microbiome homeostasis. Alteration in Pgp 
expression at the BBB due to pathological conditions [153], effect of amyloid beta 
protein on the expression of Pgp [164] at the BBB and the significant role of Pgp at the 
BBB, suggest some important endogenous functions of this transporter. Understanding of 
the endogenous function of PGP and the effect of its expression changes, especially at the 
BBB, might be extremely helpful in avoiding serious DDIs. Identification of a possible 









Substrate or inhibitor overlap of BCRP and PGP 
 
Due to their broad substrate specificity, BCRP and PGP transporters show a 
significant overlap in their substrate and/or inhibitors, with differences in affinities for 
either transporters [102]. Several tyrosine kinase inhibitor class of drugs are 
substrates/inhibitors of both the transporters [165] [166] [134], with many other 
xenobiotic inhibitors, such as pantoprazole and elacridar displaying similar properties as 
well [71]. This could be particularly useful for drug permeability in difficult-to-treat 
tissues, such as brain tumor. It has often been found that both BCRP and PGP expression 
plays an important role in controlling brain concentration of their substrates [167]. 
Therefore, dual substrates of Bcrp and Pgp transporters are well studied in literature due 
to the dramatic effect on their brain permeability in absence of these transporters in 
rodents. For example, a 25-fold increase in brain permeability of ponatinib, a tyrosine 
kinase inhibitor, is observed in female mice in absence of Bcrp and Pgp [144]. In mice, 
Pgp has a much higher expression at the blood-brain barrier than Bcrp [168], leading to 
dramatic increase in the brain permeability of Pgp substrates. For example, a 35-fold 
increase in brain permeability of digoxin is observed at 4 hours after its intravenous 
injection in mice [50]. But in higher mammals, such as monkeys, dogs and humans, 
BCRP and PGP are expressed in almost similar abundance [168, 169]. In dog brain 
capillaries, BCRP expression has been reported to be remarkably higher than PGP [170], 
whereas it was not detected at the choroid plexus. Therefore, the effect of BCRP could be 
underestimated from preclinical study, than what would be observed in the clinic. On the 
other hand, Uchida et al. reported a higher PGP than BCRP expression at the choroid 
plexus in humans, but are almost the same in rats [171]. Moreover, Pgp expression at the 
choroid plexus in mice has not been reported yet and is controversial in literature [133, 
135, 172-174]. This limits the usefulness of knockout mouse models for observations 
related to brain concentrations of BCRP and PGP substrates and specifically their effect 
on the CSF concentration of their substrates. 
 
Due to their affinity for compounds from similar Biopharmaceutical 
Classification System (BCS) class and their significant expression at enterocytes, BCRP 
and PGP are expected to have a significant impact on the oral absorption of their 
substrates [1, 25, 175]. Moreover, often, the inhibitors may not achieve sufficiently high 
systemic concentrations to display the systemic inhibition of these transporters [71]. 
Therefore, except for the loss of function polymorphism related cases, systemic inhibition 
and related overexposure of BCRP and/or PGP substrates are not so frequent. Hence, the 
meaningful clinical impact of these transporters is their effect on oral absorption. Still, 
caution must be taken for compounds such as lapatinib, which has high hydrophobicity, 
and therefore can have high tissue distribution and sufficient concentration to impart 
systemic inhibition of the transporters [134].  
 
Overall, BCRP and PGP transporter function causes a net decrease in 
permeability, thereby reducing abundance or exposure of their substrates in plasma and 
brain/CSF. Therefore, absence or inhibition of these transporters would lead to an 
increase in permeability / abundance / exposure of their substrates in plasma as well as 

















Figure 1-2. Effect of BCRP and PGP mediated efflux on brain/CSF and blood 
















Figure 1-3. Effect of inhibition or absence of BCRP and PGP on the Brain/CSF 





Guidance about drug-drug interaction and substrate and/or inhibitor identification 
of BCRP and PGP  
 
ITC and FDA have provided important guidelines for identification of substrates 
and inhibitors of BCRP and PGP transporters [25] [1, 80]. These two transporters are 
expected to have significant clinical drug-drug interaction (DDI) liabilities for orally 
administered drugs, due to their impact on oral absorption of their substrates [176] [177]. 
An efflux ratio of ≥2 is recommended for a compound to be considered as a substrate, 
which should also be inhibitable by a known inhibitor at a concentration 10 times its 
coefficient of inhibition (Ki). For the selected highest clinical doses, dose/250 ml (Igut) 
should be 10-fold or greater than IC50 (concentration for 50% inhibition) (Igut/IC50 ≥ 
10) for considering an oral DDI, and maximum plasma concentration (Cmax) should be 
greater than 1-fold than IC50 for systemic interaction (Cmax/IC50≥1.1) [71] [1]. In 
addition, concomitant medications that could be potential inhibitor(s) of BCRP/PGP need 
to be considered for making a clinically meaningful decision. For FDA recommended 
clinical substrate sulfasalazine, an AUC ratio change, in presence of the inhibitor, of ≥ 
1.5-fold should be considered for DDI studies. Drug distribution into tissues where it can 





Metabolomics is the understanding of endogenous metabolites in a normal or 
disease condition, or after a drug treatment, or exposure to any chemical entities [178]. 
Metabolites are the terminal products of the principle of “Central Dogma” and could be 
useful by themselves, or in conjunction with proteomic and/or transcriptomic data for 
better understanding of biological processes and could be more closely related to a 
phenotype [179] [180]. While a focused study of metabolomic fingerprinting has been in 
use for a long time [181], metabolomics as a means of fingerprinting, phenotyping and 
understanding physiological functions and altered endogenous metabolites or biomarkers, 
has been recently employed as a remarkable tool [182] [183] [184]. Recently, 
metabolomics has been proposed to be used in “precision medicine” as a tool capable of 
defining the population variability in response to therapy [185]. Development of 
analytical tools such as LC-MS/MS, GC-MS and NMR or LC-NMR has created the 
opportunity for scientists to specifically detect multiple metabolites on a high throughput 
scale [186]. Different databases are used for analyzing the data obtained and develop 
meaningful pathway analysis of identified metabolites such as Kyoto Encyclopedia of 
Genes and Genomes (KEGG) and The Human Metabolome Database (HMDB) [187]. 
HMDB maintains a comprehensive list of metabolites identified in the human body, 
which have been detected and reported in various studies (http://www.hmdb.ca). 
Currently, there are 114,064 metabolite entries in this database, but only 18,602 
metabolites have been detected and quantified, and 4,158 metabolites have only been 
detected. Majority of these metabolites are found in blood (18,669), followed by feces 
(6738), urine (2407), saliva (1233) and few in CSF (450) (http://www.hmdb.ca/statistics). 
Of note, metabolites identified from animal studies may not often be found on either 




The metabolome comprises of all endogenous metabolites, those derived from 
microbiome and metabolites which are dietary or due to any medication. Study of 
metabolomics includes understanding changes in basal metabolites in response to 
changes in the environment, which includes disease, treatment, exercise and even 
alteration in the gut microbiome in response to the altered environment [180, 185].  
 
 
Untargeted and targeted metabolomics  
 
Study of metabolomics can be untargeted or targeted [179]. Untargeted 
metabolomics is, in theory, the study of the entire metabolome or metabolites identifiable 
within the limits of the protocol employed. Whereas it can be useful for novel 
understanding and identification of unknown pathways, or in cases lacking prior 
knowledge of the possible outcome, untargeted metabolomics generates a huge raw 
dataset that is difficult to analyze, hard to interpret and usually needs complex analytical 
procedures to render the results to a meaningful manageable dataset. Untargeted 
metabolomics is also not quantitative in nature.  
 
In contrast, targeted metabolomics is more focused and may be semi-quantitative 
or quantitative depending on the project goals. Because it is more focused, targeted 
metabolomics involves determination of predefined metabolite changes or metabolic 
pathway changes and is easier to analyze and interpret. However, targeted metabolomics 
is limited by the amount of information that can be obtained, an example of which is the 
identification of dietary phytoestrogen glucuronide metabolites as MRP3 substrate [188]. 
 
 
Analysis of untargeted metabolomics  
 
As discussed before, untargeted metabolomics requires extensive protocol 
development for the analytical procedure as well as identification of the metabolite signal 
with specificity and confidence [179]. For example, Metabolon®, a company that 
performs metabolomic analysis for clients, maintains a library of carefully detected and 
identified metabolites by UPLC-MS, GC-MS based methods, with their spectral 
information, retention index(RI) and molecular weight/charge (M/Z) values for mass-
spectrometry identified peaks [186]. 
 
For analysis of untargeted metabolomics data, a complex multivariate statistical 
approach similar to the analysis of genomic data is employed. Many online available 
tools such as MetaboAnalyst can be used for analysis [189]. Other methods such as 
metaXCMS [190], metal-server [191], InCroMap, MetacoreTM, 3Omics etc. also exist 








Integration of untargeted metabolomics and transcriptomics  
 
Integration of metabolomics with transcriptomic or gene expression change data 
can be a very useful method for complete understanding of perturbed or altered biological 
pathways [193]. Although some research articles using this approach have been 
published, integration of two very different datasets is quite complicated, and complex 
statistical approaches along with a carefully designed study is required for proper 
integration [194]. One major complexity is that change in one metabolite may be 
regulated by multiple genes, thereby rendering a simple association analysis useless. 
However, despite the complexity, integration of these two datasets is often attempted in 
literature [178] [195] [196]. 
 
 
Use of metabolomics to understand endogenous function of transporters  
 
The physiological importance of drug transporters and their impact on the 
endogenous metabolome can be investigated using metabolomic analysis. Both targeted 
and untargeted metabolomic approaches have been reported, such as the use of 
untargeted metabolomics for identification of endogenous substrates or metabolites 
associated with OAT3 and OAT1 transporters in mice and targeted metabolomics to 
understand the effect of rosiglitazone treatment on the lipid metabolome [20, 140-142, 
197].  
 
Analysis of the metabolome may also lead to the identification of biomarkers or 
novel substrates of drug transporters, as shown by the identification of putative biomarker 
for OATP1B1 using metabolomics and genome-wide association study (GWAS) 
database [198].  
 
The Metabolomic-GWAS server (http://metabolomics.helmholtz-
muenchen.de/gwas/) needs a special mention in this regard, which comprises data from 
mostly two clinical GWAS-metabolomic analysis datasets [199, 200], that is extremely 
useful for identification of gene-metabolite association in humans.  
 
 
Study Purpose and Specific Aims 
 
BCRP and/or PGP transporters are known to transport xenobiotics as well as 
endogenous substrates. Lack of function polymorphisms of these transporters are also 
known to impact the disposition of their substrates in humans, as well as associated with 
pathological abnormalities. Although efforts are being taken to develop inhibitors of 
these transporters to overcome therapeutic resistance, studies are lacking towards a 
systemic understanding of the biological/endogenous role of these transporters. An 
understanding of the endogenous role of these transporters would be extremely helpful 
for identification of the effect of long-term inhibition of these transporters on the 
biological pathways. Therefore, the purpose of the current study was to elucidate the 




physiological function in rats, towards developing a novel understanding of the effect of 
Bcrp and/or Pgp transporters on their endogenous, xenobiotic and dietary substrates.   
 
 
Specific aim 1 
 
The first aim of the current studies was to determine the role of Bcrp and Pgp 
efflux drug transporters on the systemic metabolome in rats. We hypothesized that 
untargeted metabolomics combined with transcriptomic analysis can help understand the 
endogenous function of these transporters.  
 
 
Specific aim 2 
 
The second aim of the current studies was to understand the effect of Bcrp and 
Pgp on ketamine, used as the animal anesthetic and identified as a putative dual substrate 
of these transporters in Aim 1 analysis. We hypothesized that Bcrp and/or Pgp can affect 
the pharmacokinetics (PK) and pharmacodynamics (PD) of ketamine in mice. 
 
 
Specific aim 3 
 
The third aim of the current studies was to utilize pheophorbide A (PhA), a 
dietary substrate of Bcrp, also identified in Aim 1 analysis, as an in vivo marker of Bcrp 
function. We hypothesized that PhA can be utilized for identification of oral drug-drug 






CHAPTER 2.    ELUCIDATION OF ENDOGENOUS FUNCTION OF BCRP AND 





 Drug transporters play an important physiological role by regulating the 
disposition of important endogenous metabolites. Efflux transporter multi-drug resistant 
protein 4 (Mrp4; Abcc4) is known to transport Prostaglandin E2 [60] and cAMP [201], 
while uptake transporters such as organic cation transporter (Octn2; Slc22a5) transports 
carnitine [202] and dopamine [203] and organic anion transporters (Oats) are known to 
transport uremic toxins [142]. P-glycoprotein (Pgp; Abcb1) and breast cancer resistant 
protein (Bcrp; Abcg2) are multi-drug efflux transporters that are ubiquitously present in 
different tissues and cell types in human and other mammals [46, 104]. The major 
function of Bcrp and Pgp is to control absorption of their substrates into blood from 
intestine, or increase their clearance at liver, kidney and other tissues, thereby regulating 
tissue exposure of their substrates. Thus, absence or inhibition of these transporters may 
lead to accumulation of their substrates, leading to toxicity or altered efficacy of their 
substrate drugs. These properties make Bcrp and Pgp among the most important FDA-
regulated efflux transporters for drug-approval processes [31]. 
 
 Bcrp and Pgp are broad chemical specificity efflux transporters, with a substantial 
overlap in their substrates and inhibitors [102, 204] and a similar tissue distribution [205]. 
In addition, these transporters have been associated with the transport of important 
endogenous metabolites. For example, Bcrp is known to transport riboflavin (Vitamin 
B2) [9], uric acid [54] and folic acid [124], while Pgp-mediated transport has been 
reported for cortisol, aldosterone [57], phospholipids [161], bilirubin [160] and 
endogenous opioid peptides [58]. Both Bcrp and Pgp are well-conserved in the 
eukaryotic system and alteration in expression or association of these transporters has 
been reported in different disease conditions [54, 150, 173, 206, 207], implying their 
important physiological function. In addition, we have previously reported that apart 
from its expression on the apical surface of choroid plexus (CP) in mice [208], Bcrp is 
present on both apical and basolateral side at the arachnoid barrier (AB) epithelial cells, 
thus facing both blood and CSF [135]. Thus, role of Bcrp in CSF disposition of its 
substrates is complicated by the two opposing factors: (i) Bcrp reduces permeability of its 
substrates at BBB to brain and thus eventually in CSF and (ii) Bcrp increases efflux of its 
substrates from BCSFB into CSF. It also raises the possibility that Bcrp might have some 
important endogenous function at the BCSFB. 
 
 Metabolomic analysis is widely utilized to understand altered biological function 
in disease states [209], identification of biomarkers for disease [210] and drug treatment, 
[211] as well as for elucidation of endogenous functions or biomarkers for enzymes and 
transporters [198]. While untargeted metabolomics can lead to a broad systemic 
understanding, targeted metabolomics can answer questions related to specific 
metabolites in certain biological pathways [141, 179, 212]. Recently, untargeted 




and OAT transporters [140, 142, 198]. An understanding of the transporter effect on 
metabolome can help elucidate pharmacometabolomics of drugs (that are transporter 
substrates or inhibitors), which might be useful to analyze pharmacokinetic variabilities, 
pharmacokinetic-pharmacodynamic relationships and toxicities or side effects associated 
with the drug treatment [213, 214]. Several marketed drugs are known inhibitors of Bcrp 
and Pgp transporters, of which many are used for chronic therapy. Thus, a systems level 
understanding of the metabolomic impact and altered biological function thereof, due to 
lack of function of Bcrp and Pgp transporters, can lead to better understanding of the 
desired/ undesired effects of such therapy.  
 
 Therefore, to understand the effect of Bcrp/Abcg2 and Pgp/Abcb1a absence on 
the systemic metabolome, we performed an untargeted metabolomics study of plasma 
and CSF, as well as tissue transcriptomics of kidney, liver and brain (frontal cortex) from 
Bcrp-Pgp double knockout (dKO) and wild type (WT) rats. We chose to compare WT vs 
dKO male rat CSF and plasma because (a) BCRP shows significant sexual dimorphism 
(Male >Female) in many tissues [215], hence male dKO would be expected to show the 
largest difference in substrate concentration; (b) CSF volume would be significantly 
higher in rats vs. mice; (c) dKO animals show a significantly higher concentration of dual 
Pgp/Bcrp substrates compared to single Pgp or Bcrp KO animals [94]; and (d) the 
CSF/brain concentration of Pgp or Bcrp KO mice is routinely different from WT while 
the plasma concentration does not always vary [144] hence sampling only the plasma 
would miss identifying some Pgp or Bcrp substrates. 
 
 Our results demonstrate a significant effect of Bcrp and Pgp transporters on 
plasma as well as CSF metabolome of rats, including a distinct impact in plasma vs. CSF 
compartment metabolomes. Utilizing the transcriptomic analysis and biological pathway 
information, our results also indicated important biological functions of Bcrp and Pgp 
efflux transporters. We also utilized an in silico Bcrp and Pgp-interaction prediction 
model to further identify metabolites that could be putative substrates of Bcrp and/or Pgp. 
To our knowledge, this is the first effort for complete systemic understanding of the 
endogenous biological function of efflux transporters. 
 
 
Materials and Methods 
 
 
Chemicals and reagents 
 
 Ketamine (JHP Pharmaceuticals, Rochester, MI, USA), Xylazine (LLOYD 
Laboratories, Shenandoah, Iowa, USA), scalp vein set (27G X ¾” T.W.) for CSF 
collection (Exelint International,Co., LA, CA, USA), RNAlaterTM, TrizolTM and 
Affymetrix Rat 2.0 St Array (ThermoFisher Scientific, Little Rock, AR, USA) were 







Animal experiments and sample collection 
 
 24 male wild-type (WT) and Bcrp – Pgp double knockout (dKO) Sprague-Dawley 
rats (n=12 each group), 10 weeks of age, obtained from SAGE Laboratories (Saint Louis, 
MO, USA), were used for the study. All animals were provided water and food ad 
libitum. All experimental procedures were approved by the Institutional Animal Care and 
Use Committee at St. Jude Children’s Research Hospital. 
 
 Rats were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 
mg/kg) and fixed on a stereotaxic apparatus. CSF was collected via the cisterna magna 
using a scalp vein set and a 100 µL Hamilton syringe (Reno, Nevada, USA). CSF was 
immediately kept on dry ice, and later stored at -80°C. Immediately after CSF collection, 
blood was collected by cardiac puncture in EDTA-coated tubes, centrifuged at 5000g for 
5 minutes at 4°C, and plasma collected and stored at -80°C. Kidney, liver and brain 
frontal cortex were also isolated from each rat. The liver was frozen at -80°C and brain 
frontal cortex and kidney were kept in RNAlaterTM following the manufacturer’s 
instructions.  
 
 CSF and plasma samples were sent to Metabolon® for untargeted metabolomic 
analysis, and kidney, liver and brain frontal cortex tissues were utilized for 
transcriptomics analysis. A brief outline of the study design is illustrated in Figure 2-1. 
 
 
Metabolomic analysis  
 
 Untargeted metabolomics of CSF and plasma samples from WT and dKO rats 
(n=8 each genotype) was performed by UPLC-MS/MS and GC-MS based methods at 
Metabolon® (Durham, NC, USA) [186]. Metabolon® maintains a metabolite library 
consisting of retention index (RI), mass/charge (m/z) and chromatographic data of 
authenticated standard metabolites including the MS/MS spectral information. Named 
metabolites in the sample were identified by comparing the mass (± 0.005 amu), RI and 
spectral data of the sample peaks with the library standards, the area under the peak 
quantified, median normalized and then compared between the WT and dKO groups 
using the two-sample t-test with Welch’s correction. An estimate of false discovery rate 
(q-value) was also calculated because of multiple comparisons and q < 0.1 was 
considered to have higher confidence in the data. Significant metabolites were identified 
based on p< 0.05 and highlighted dark red for increase or dark green for decrease in CSF 
of dKO compared to WT rats. Trending significant is considered when 0.1>p>0.05 and 
highlighted light red for increase or light green for decrease in CSF and plasma of dKO 
compared to WT rats. Principal component analysis was used to identify the data pattern 
[216] in the samples (WT vs dKO plasma and WT vs dKO CSF). Results were further 
analyzed by Random Forest Analysis to identify important metabolic features that 
contribute the most towards the group separation. The final output of fold change and 
associated p and q values were log2-transformed and volcano plots created on Tibco® 
Spotfire® 7.5 for better visualization and identification of the significant metabolites. 












samples were assumed to be contaminated with plasma and this information was used to 
calculate ‘no contamination’ fold change and p-values for the CSF samples, and is listed 
along with the uncorrected result for all CSF metabolite results generated by 
Metabolon®. The non-normalized raw data from Metabolon® was used to calculate the 
ratio of the signal intensity of metabolites that were detected both in CSF and plasma 
(CSF/plasma ratio). CSF/plasma ratio of the metabolites were analyzed by two sample t-
test considering unequal variance to identify metabolites that have significant alterations 
in CSF abundance in the dKO rats compared to WT rats. Fold change of (CSF/plasma) 
_dKO/ (CSF/plasma) _WT were log2-transformed and plotted against log2 (t values) on 
Tibco® Spotfire® 7.5 for further identification and better visualization of metabolites 
with significantly altered CSF abundance in the dKO rats.  
 
 
Metabolomic analysis using MetaboAnalyst 3.0  
 
 Raw metabolite intensity data from Metabolon® was further analyzed separately 
using the MetaboAnalyst software. Briefly, raw data was first screened for missing values 
and any metabolite with more than 50% missing values was omitted from further 
analysis. Due to a low number of features (<2000), the data filtration step was skipped. 
Data was further median-normalized and log-transformed to obtain a Gaussian data 
distribution for further statistical analysis. Significant metabolites were identified based 
on ≥1.5- fold increase or decrease in median intensity in dKO compared to WT CSF or 
plasma, and a p-value less than 0.05. Partial least square discriminant analysis and 
hierarchical clustering analysis was performed to assess the group separation (WT vs. 
dKO). The list of significant metabolites was compared with the Metabolon® data to 
assess the reproducibility of the significant features.  
 
 
RNA extraction and microarray analysis  
 
 Brain, kidney and liver tissues were weighed, diluted 10 times with TriazolTM, 
homogenized and RNA isolated according to the manufacturer’s instructions. RNA 
samples were analyzed for quality and integrity on the Agilent 2100 Bioanalyzer and the 
concentration of RNA was determined using NanoDropTM 8000 spectrophotometer. A 
hundred nanograms (100 ng) of total RNA was processed for use on the microarray using 
the Ambion WT kit and the Affymetrix Terminal labeling kit according to the 
manufacturer’s instructions. The resultant single-stranded cDNA was labeled, fragmented 
and then hybridized to the Rat Gene 2.0 ST array for sixteen hours at 45 at 60 rpm. The 
arrays were then washed, stained, and scanned using the Affymetrix Model 450 Fluidics 
Station and Affymetrix Model 3000 7G scanner using the manufacturer's recommended 
protocols. 
 
 Affymetrix Rat 2.0 ST array was used to perform the gene expression level 
analysis using Affymetrix Expression Console software and results saved as RMA 
(Robust Multiarray Averaging) level signal. The RMA signal file was uploaded into 




the biological pathway information for the Affymetrix Rat Gene 2.0 ST Array, pooled 
based on intensity, corrected for multiple test comparisons at q < 0.05 and fold change 
≥1.2, to identify the significantly altered genes and biological pathways.  
 
 
In silico prediction of BCRP and/or PGP putative substrates or inhibitors 
 
 Metabolites identified by the Metabolon® as significant (p< 0.05) or trending 
significant (0.05<p< 0.1) were analyzed for their interaction with BCRP and/or PGP by a 
predictive Bayesian Machine learning model implemented in Assay Central at 
Collaborations Pharmaceuticals according to the previously published methods [217, 
218]. Models were generated for human PGP using 1217 molecules and human BCRP 
with 392 molecules.  A five-fold cross-validation was performed to assess the receiver 
operator characteristic (ROC). The metabolites were then scored with these models to 
output a score. Further, physicochemical descriptors, e.g. AlogP, molecular polar surface 
area, hydrogen bond acceptor and donor counts, molecular weight, for the metabolites 
were obtained from the public database. Regression analysis employing standard least 
square method was used to predict observed fold changes (dKO/WT) in the plasma and 
CSF for each metabolite using the molecular descriptors, along with the ABCG2 or PGP 
Bayesian model score to determine a structure-property relationship and understand if the 







Bcrp and Pgp gene deletion in rats results in altered metabolome of CSF and plasma 
 
The following four sections describe the overall findings of the metabolomic 
analysis: 
 
1. Metabolomics analysis identified differentially expressed metabolites between 
WT and dKO rats, in both CSF and plasma. To identify the effect of Bcrp and Pgp gene 
deletion on metabolite expression, we performed untargeted metabolomics analysis in 
CSF and plasma of WT and Bcrp-Pgp dKO rats. A total of 564 named metabolites were 
identified in both WT and dKO rats, with 306 metabolites uniquely identified in plasma, 
25 metabolites identified only in CSF and 233 metabolites identified in both CSF and 
plasma (Figure 2-2A). Data analysis for significant metabolite changes was performed 
independently at Metabolon® and in-house using the MetaboAnalyst software 3.0. 
Principal component analysis (PCA) (Figure 2-3A and B) and Partial Least Square 
Discriminant Analysis (PLS-DA) (Figure 2-2B and C) identified distinctly different 
patterns for the metabolites expressed by WT and dKO rats in both CSF and plasma. In 
addition, hierarchical clustering analysis performed at Metabolon® (Figure 2-3C and D), 
and on MetaboAnalyst (Figure 2-2D and E) demonstrated that majority of the samples 




Notes: Venn-diagram showing number distribution of detected named metabolites in CSF 
and plasma samples (A). PLS-DA analysis 2D-scores plot performed on MetaboAnalyst 
3.0, showing clear group separation between WT and dKO in CSF (B) and plasma (C). 
Hierarchical clustering of the normalized metabolomic data clusters each of WT and dKO 




Figure 2-2. Metabolites in CSF and plasma are differentially expressed between 





Notes: Principal Component Analysis of median normalized named metabolites in CSF 
(A) and plasma (B) identified significant pattern separation between WT and dKO rats. 
Hierarchical clustering analysis of the fold change (dKO/WT) data in CSF (C) and 




Figure 2-3. Metabolites in CSF and plasma are differentially expressed between 





2. Significantly altered metabolites in CSF and plasma of dKO rats (compared to 
WT) displayed unique signatures. A total of 169 metabolites were found to be 
significantly altered together in the CSF and plasma of dKO rats compared to WT rats. 
Of these, 79 metabolites were significantly altered only in the plasma, 71 only in the CSF 
and 19 metabolites were altered in both CSF and plasma of dKO rats, compared to WT 
rats (Figure 2-4A). The features of the metabolites altered in CSF and plasma were found 
to be strikingly different. While majority of the metabolites altered in CSF were amino 
acid-related metabolites (57%) (Figure 2-4B), lipids comprised the major metabolites 
(49%) significantly altered in the plasma of dKO rats, compared to WT rats (Figure 
2-4C).  
 
 Volcano plots (log10(q) vs log2(fold change)) of the metabolome data revealed 
those metabolites that were significantly increased vs. decreased (Figure 2-5 and  
Figure 2-6). In addition, we found that most of the metabolites in CSF were increased in 
dKO rats, compared to WT (Figure 2-5), while an equal number of metabolites were 
increased as were decreased in the dKO plasma (Figure 2-6). The metabolites with the 
highest fold-change increases in dKO rats were O-methyl catechol sulfate in CSF (5.5-
fold) and 4-hydroxychlorothalonil (3.6-fold) in plasma. Only one metabolite, indolin-2-
one, was found to be significantly decreased (0.29-fold) in the CSF of dKO rats while 
many lipid metabolites were significantly decreased in dKO plasma. 
  
 Random Forest Analysis (RFA) was performed to identify the metabolites with 
the greatest effect on group separation (WT and dKO) in CSF and plasma. RFA 
identified group separation with 100% prediction accuracy and results were plotted based 
on effect of each metabolite on mean decrease accuracy, displaying 30 metabolites with 
increasing order of their importance to group separation from bottom to top (Figure 2-7 
and Figure 2-8). Among the metabolites with a significant effect on group separation, 
RFA identified known Bcrp substrates riboflavin and urate in the CSF metabolome and 
riboflavin and pheophorbide A in the plasma metabolome. RFA also confirmed our 
previous results that CSF and plasma maintain unique metabolomic signatures with 
significant metabolites being related to amino acids in the CSF and lipids in the plasma.  
 
 Analysis of the data with MetaboAnalyst using a more stringent data filtering 
protocol identified 29 metabolites altered significantly in the CSF (Figure 2-9) and 47 
metabolites in the plasma (fold change ≥ 1.5) (Figure 2-10) of dKO rats compared to WT 
rats, with metabolites listed in increasing order of significance from top to bottom. A list 
of metabolites which were significantly altered in CSF (Supplement_Chapter 
2_Metabolites.Table S1A) and plasma (Supplement_Chapter 2_Metabolites Table 
S1B) of dKO vs WT rats when analyzed by both Metabolon® and MetaboAnalyst is 
provided, identifying a common list of altered metabolites, thereby incorporating 
robustness in our data analysis.  
 
 As expected, known endogenous and dietary substrates of Bcrp were increased in 
both CSF and plasma of dKO rats, compared to WT rats (Figure 2-11). While riboflavin, 
a known Bcrp substrate, was found to be increased in both CSF and plasma of dKO rats, 




Notes: Venn-diagram showing distribution of significant (p< 0.05) metabolites in CSF 
and plasma of dKO vs. WT rats (A). Pi-chart showing distribution of percentage of 
significant (p<0.05) metabolites in different metabolite classes as designated by the 
colors in CSF (B) and plasma (C) of dKO vs. WT rats. 
  
 
Figure 2-4. Significantly altered metabolites in CSF and plasma of dKO rats 





Notes: Volcano plot of CSF metabolites identified by pathway information (color of 
markers) and their significance (p-value) (size of marker). Data is plotted as log2 
(dKO/WT metabolite raw signal intensity) on X-axis vs. negative log (Q-value of 
metabolite comparison dKO vs WT) on Y-axis. Horizontal purple and red lines designate 
p < 0.05 and q < 0.05 respectively. Significant metabolites (p< 0.05) are identified above 
the purple line. Similarly metabolites with 1.5-fold increase or decrease are identified 
with vertical red and green lines respectively. Metabolites on the right side of red line or 
on the left side of green line and above the horizontal purple line are significantly 
increased (>1.5 fold) or decreased (<1.5 fold) in CSF. 
  
 
Figure 2-5. Significantly altered metabolites in CSF of dKO rats (compared to 





Notes: Volcano plot of plasma metabolites identified by pathway information (color of 
markers) and their significance (p-value) (size of marker). Data is plotted as log2 
(dKO/WT metabolite raw signal intensity) on X-axis vs. negative log (Q-value of 
metabolite comparison dKO vs WT) on Y-axis. Horizontal purple and red lines designate 
p < 0.05 and q < 0.05 respectively. Significant metabolites (p< 0.05) are identified above 
the purple line. Similarly, metabolites with 1.5-fold increase or decrease are identified 
with vertical red and green lines respectively. Metabolites on the right side of red line or 
on the left side of green line and above the horizontal purple line are significantly 
increased (>1.5 fold) or decreased (<1.5 fold) in plasma.  
  
 
Figure 2-6. Significantly altered metabolites in plasma of dKO rats (compared to 





Notes: Random forest analysis (RFA) was used to calculate group separation and identify 
metabolites with highest importance for group separation. RFA identified two groups 
(WT and dKO) with 100% accuracy in CSF. Metabolites were plotted against their Mean 
Decrease in Accuracy, calculated by RFA. Metabolites have higher importance on group 
separation as we move up along the Y-axis and they are also color coded to identify 
which pathway the metabolites belong to. 
  
 
Figure 2-7. Random forest analysis identifies metabolites that significantly 





Notes: Random forest analysis (RFA) was used to calculate group separation and identify 
metabolites with highest importance for group separation. RFA identified two groups 
(WT and dKO) with 100% accuracy in plasma. Metabolites were plotted against their 
Mean Decrease in Accuracy, calculated by RFA. Metabolites have higher importance on 
group separation as we move up along the Y-axis and they are also color coded to 
identify which pathway the metabolites belong to.  
 
Figure 2-8. Random forest analysis identifies metabolites that significantly 





Note: Raw data from Metabolon were reanalyzed using MetaboAnalyst 3.0. Significant 
metabolites were identified based on p < 0.05 and fold change > 1.5. Fold change of all 
significant metabolites were plotted against their p-value. The red arrow indicates known 
substrates of Bcrp and/or Pgp. 
  
 
Figure 2-9. Independent analysis of metabolome data with MetaboAnalyst 





Notes: Raw data from Metabolon were reanalyzed using MetaboAnalyst 3.0. Significant 
metabolites were identified based on p < 0.05 and fold change > 1.5. Fold change of all 
significant metabolites were plotted against their p-value. The red arrow indicates known 
substrates of Bcrp and/or Pgp. 
  
 
Figure 2-10. Independent analysis of metabolome data with MetaboAnalyst 





Note: Raw LCMS median signal intensities are plotted for each genotype (n=8), with 
significance calculated at p < 0.05 by Mann-Whitney test.  
  
 
Figure 2-11. Known endogenous substrates of Bcrp were increased in abundance 





The dietary Bcrp substrate pheophorbide A [92] signal was detected only in the plasma of 
dKO, but not WT, rats. Another dietary Bcrp substrate the soy isoflavone daidzein (2.05-
fold) and its metabolite daidzein sulfate (2.41-fold) were also significantly increased in 
the plasma of dKO compared to WT rats.  
 
 One interesting observation was alteration of few xenobiotics in the dKO rat 
plasma (Supplement_Chapter 2_Metabolites Table S5). Among many xenobiotic 
metabolites ketamine, the anesthetic drug, was found 1.74-fold high in dKO plasma and 
1.93-fold high in dKO CSF. Also, a 3.6-fold higher level of 4-hydroxychlorothalonil, a 
metabolite of pesticide chlorothalonil [219], was found in the plasma of dKO rats 
compared to WT (Supplement_Chapter 2_Metabolites Table S5).  
 
 3. CSF/plasma intensity ratio identified metabolites with greater CSF 
accumulation in dKO rats, compared to WT. Bcrp and Pgp are known to have a 
significant impact on the brain permeability of their substrates [167] and many Bcrp and 
Pgp substrates show accumulation in CSF or brain over plasma in the absence or 
inhibition of these transporters [130, 144, 165]. Therefore, we calculated and compared 
the CSF/plasma ratio of the raw LC-MS/MS signal intensity of metabolites identified in 
WT and dKO rats. Assuming no significant difference in plasma protein binding between 
WT and dKO rats, the above-mentioned ratio of CSF/plasma can be utilized to identify 
metabolites that have significantly accumulated in the CSF of dKO rats, compared to WT 
rats. Figure 2-12 shows all metabolites with significantly increased (50 metabolites) 
(dark red) or decreased (3 metabolites) (dark green) CSF/plasma ratio in dKO vs WT 
rats. While urate, a known Bcrp substrate, was found to have significantly higher 
CSF/plasma ratio (3.23 fold) in dKO compared to WT rats (Figure 2-13), riboflavin, 
another known substrate of Bcrp, while significantly increased in both plasma and CSF of 
dKO rats compared to WT, and had a similar CSF/plasma ratio between WT and dKO 
rats (1.11-fold dKO/WT) (Figure 2-14). Other interesting metabolites with greater 
accumulation in CSF were catechol sulfate, O-methyl catechol sulfate, methionine 
sulfoxide, isovalerylcarntine and pyridoxate (Figure 2-13). A list of metabolites with 
significantly altered CSF/plasma ratios between WT and dKO rats, along with their 
biological pathway information are provided in Supplement_Chapter 
2_Metabolites_Table S2. 60% of these metabolites were related to amino acids. Phenol 
sulfate, a known gut microbiome contributed tyrosine metabolite and isovalerate 
metabolites, which could be contributed by the gut microbiome, were also altered. 13% 
of the metabolites were xenobiotic in nature, which may be either contributed by dietary 
metabolites, or could also be metabolites of dietary fiber metabolism by gut microbiota. 
Furthermore, metabolites such as catechol sulfate (pyrocatechol sulfate) and O-methyl 
catechol sulfate maybe of interest as putative Bcrp substrates with 2.13- and 13-fold 
higher CSF/plasma ratio in the dKO rats, compared to WT, respectively. Pyrocatechol 
sulfate is a known uremic toxin, supporting a role of Bcrp and Pgp transporters in 
controlling toxin exposure in the brain. Interestingly, while 11-dehydrocorticosterone was 
unchanged in the CSF and in the plasma of dKO compared to WT rats, a CSF/plasma 
ratio of 1.4 indicated an increase in CSF abundance of this steroid metabolite in the dKO 
rats. Since glucocorticoids are known Pgp substrates [57], 11-dehydrocorticosterone is 




Notes: Fold change is calculated by dividing CSF/plasma ratio of metabolite raw signal 
intensity in dKO with that of WT rats. Log2 (Fold change) is plotted on X-axis and log 
10 (t-value of CSF/plasma dKO vs CSF/plasma WT metabolite ratio) is plotted on Y-
axis. Metabolites that are significantly higher (p< 0.05) in CSF of dKO over WT rats are 
identified by dark red marker and metabolites that are significantly decreased (p<0.05) in 
CSF of dKO over WT rats are identified with dark green marker. Metabolites in dark red, 
with > 1.5-fold (red vertical line) significant increase in CSF/plasma ratio in dKO 
compared to WT signifies metabolites with significant accumulation in dKO CSF. 
  
 
Figure 2-12. Identification of metabolites with significant accumulation in CSF of 





Notes: Box plots of metabolites with significantly higher CSF/plasma ratio in the dKO 
rats, similar to urate, is plotted as median value ± range and significance is calculated by 




Figure 2-13. Identification of metabolites with significant accumulation in CSF of 





Notes: Box plot of median ± range of riboflavin intensity in plasma and CSF of dKO and 
WT are significantly different, but median ± range CSF/plasma ratio is not different 










4. Metabolites related to specific metabolic pathways were altered in the CSF and 
plasma of dKO rats, compared to WT. Apart from significant changes in many 
metabolites, the following three significantly altered metabolic pathways were of 
particular interest: 
 
 (a) dKO rats show a significantly altered plasma lipid metabolome: Significant 
alteration in fatty acid metabolites was observed particularly in the plasma metabolome 
of dKO rats, compared to WT (Table 2-1). While Bcrp or Pgp substrates are expected to 
increase in abundance in dKO rat plasma, we observed a significant decrease in medium 
and long chain fatty acids, unsaturated fatty acids, dicarboxylate, and monohydroxy fatty 
acids, amide and amino fatty acids in the plasma of dKO rats, indicating a significant 
alteration in the fatty acid metabolism pathway. 
 
 Unlike the fatty acid metabolites, there was a significant increase in the lysolipid 
metabolites in the plasma (Table 2-2). Similarly, few fatty acid metabolites were also 
found to increase in abundance in the dKO rat CSF, e.g. butyrylcarnitine showed a > 3.5-
fold increase in CSF abundance in the dKO rats (Table 2-3). The significant increase in 
few fatty acid metabolites in CSF could be related to Bcrp and/or Pgp mediated transport, 
as well as possible compensatory transporter expression or metabolic pathway changes. 
 
 (b) dKO rats show significant exposure of microbiome, xenobiotic and sulfated 
metabolites in CSF and plasma: Absence of the Bcrp and Pgp efflux transporters in the 
intestinal epithelial cells is expected to increase absorption of dietary metabolites as well 
as gut microbiota metabolites. The metabolomic analysis clearly showed significant 
alteration of gut microbiota metabolites in both CSF and plasma (Table 2-4). Of 
particular interest, gut microbiota metabolites of the amino acid tyrosine, p-cresol sulfate 
and phenol sulfate decreased 0.45-fold and increases 1.93-fold, respectively, in the CSF 
of dKO rats. In addition, sulfated metabolites, many of which are contributed by the gut 
microbiota, were also altered (Table 2-5 and Table 2-6). Among these metabolites, p-
cresol sulfate, equol sulfate (daidzein metabolite) and daidzein sulfate are known Bcrp 
substrates [170, 220]. Due to high affinity of Bcrp for sulfated metabolites, these 
metabolites may be of particular interest as putative Bcrp substrates. 
 
 (c) Altered purine and pyrimidine biosynthesis pathway metabolites: The purine 
catabolites xanthosine, urate, allantoin, and allantoic acid, as well as, the pyrimidine 
degradation products uracil, pseudouridine, and N-acetyl-beta-alanine accumulated in the 
CSF and plasma of dKO rats (Supplement_Chapter 2_Metabolites _Table S5 and S6). 
The pyrimidine metabolites orotate and orotidine were also higher in dKO CSF and to 
less of an extent in plasma compared to WT rats (Supplement_Chapter 2_Metabolites 
_Table S5 and S6). Bcrp transporter shows affinity towards purine analogues [221] and 
thus the alteration in purine pathway metabolites could be the direct result of a lack of 
Bcrp function. Accumulation of the pyrimidine analogues in the CSF could also indicate 






Table 2-1. Decrease in fatty acids in dKO rat plasma 
 





Medium Chain Fatty Acid heptanoate (7:0) 0.79 0.08 
Medium Chain Fatty Acid 10-undecenoate (11:1n1) 0.44 0.05 
Medium Chain Fatty Acid 5-dodecenoate (12:1n7) 0.56 0.04 
Long Chain Fatty Acid myristoleate (14:1n5) 0.64 0.06 
Long Chain Fatty Acid eicosenoate (20:1n9 or 11) 0.52 0.01 
Long Chain Fatty Acid erucate (22:1n9) 0.61 0.00 
Polyunsaturated Fatty Acid (n3 and n6) docosahexaenoate (DHA; 22:6n3) 0.59 0.01 
Polyunsaturated Fatty Acid (n3 and n6) docosatrienoate (22:3n3) 0.64 0.07 
Polyunsaturated Fatty Acid (n3 and n6) arachidonate (20:4n6) 0.75 0.07 
Polyunsaturated Fatty Acid (n3 and n6) adrenate (22:4n6) 0.52 0.01 
Polyunsaturated Fatty Acid (n3 and n6) docosapentaenoate (n6 DPA; 
22:5n6) 
0.42 0.00 
Polyunsaturated Fatty Acid (n3 and n6) mead acid (20:3n9) 0.51 0.02 
Fatty Acid, Branched isocaproate 0.45 0.07 
Fatty Acid, Branched 15-methylpalmitate  0.76 0.06 
Fatty Acid, Dicarboxylate azelate (nonanedioate) 0.76 0.08 
Fatty Acid, Dicarboxylate tetradecanedioate 0.6 0.07 
Fatty Acid, Dicarboxylate hexadecanedioate 0.6 0.02 
Fatty Acid, Dicarboxylate octadecanedioate 0.66 0.01 
Fatty Acid, Dicarboxylate eicosanodioate 0.6 0.01 
Fatty Acid, Dicarboxylate docosadioate 0.68 0.01 
Fatty Acid, Amide stearamide 0.31 0.00 
Fatty Acid, Amide erucamide 0.25 0.01 
Fatty Acid, Amino 2-aminoheptanoate 0.58 0.00 
Fatty Acid, Amino 2-aminooctanoate 0.65 0.01 
Fatty Acid Metabolism(Acyl Glycine) N-palmitoyl glycine 0.54 0.01 
Fatty Acid Metabolism(Acyl Carnitine) myristoleoylcarnitine* 0.71 0.05 
Carnitine Metabolism carnitine 1.14 0.03 
Fatty Acid, Monohydroxy 2-hydroxyoctanoate 0.39 0.00 
Fatty Acid, Monohydroxy 2-hydroxydecanoate 0.45 0.00 
Fatty Acid, Monohydroxy 5-hydroxyhexanoate 0.67 0.02 
Fatty Acid, Monohydroxy 16-hydroxypalmitate 0.7 0.02 
Fatty Acid, Monohydroxy 13-HODE + 9-HODE 0.69 0.09 
Fatty Acid, Dihydroxy 12,13-DiHOME 0.65 0.09 
Endocannabinoid oleic ethanolamide 0.85 0.07 
Inositol Metabolism pinitol 1.67 0.01 
Phospholipid Metabolism glycerophosphorylcholine (GPC) 1.61 0.01 
Phospholipid Metabolism glycerophosphoethanolamine 2.00 0.09 
Monoacylglycerol 1-oleoylglycerol (1-monoolein) 0.52 0.04 
Sphingolipid Metabolism palmitoyl sphingomyelin 1.49 0.00 
Sterol 7-Hoca 0.57 0.00 
Sterol campesterol 1.38 0.00 
Steroid corticosterone 0.64 0.00 
Steroid 11-dehydrocorticosterone 0.8 0.07 
Primary Bile Acid Metabolism chenodeoxycholate 0.51 0.10 
Primary Bile Acid Metabolism glycochenodeoxycholate 0.11 0.09 
Secondary Bile Acid Metabolism deoxycholate 0.55 0.06 
Secondary Bile Acid Metabolism glycodeoxycholate 0.1 0.03 
Secondary Bile Acid Metabolism taurodeoxycholate 0.57 0.06 
Secondary Bile Acid Metabolism tauroursodeoxycholate 0.58 0.08 




Table 2-1.  Continued 
 
Note: Raw signal intensity of the metabolites was used to compute the fold change (dKO/ 
WT) and p-value was calculated using Welch’s two sample t-test to identify metabolites 
as significant (p<0.05) (in dark green & red) or trending significant (0.1>p>0.05) (light 





Table 2-2. Increase in lysolipids in dKO rat plasma 
 
Sub Pathway Biochemical Name Fold Change p-Value 
Lysolipid 1-stearoylglycerophosphocholine (18:0) 0.77 0.03 
Lysolipid 2-stearoylglycerophosphocholine 0.63 0.06 
Lysolipid 1-linoleoylglycerophosphocholine (18:2n6) 1.09 0.00 
Lysolipid 1-arachidonoylglycerophosphocholine (20:4n6) 0.91 0.08 
Lysolipid 1-oleoylglycerophosphoethanolamine 1.39 0.00 
Lysolipid 1-linoleoylglycerophosphoethanolamine 1.37 0.01 
Lysolipid 1-palmitoylglycerophosphoinositol 2.09 0.01 
Lysolipid 1-linoleoylglycerophosphoinositol 2.17 0.01 
Lysolipid oleoyl-linoleoyl-glycerophosphoinositol (1) 1.43 0.00 
Lysolipid palmitoyl-linoleoyl-glycerophosphocholine (1) 1.34 0.00 
Lysolipid palmitoyl-linoleoyl-glycerophosphocholine (2) 1.33 0.00 
Lysolipid palmitoyl-linoleoyl-glycerophosphoinositol (1) 1.7 0.00 
Lysolipid palmitoyl-oleoyl-glycerophosphocholine (1) 1.24 0.01 
Lysolipid stearoyl-arachidonoyl-glycerophosphocholine (2) 0.68 0.00 
Lysolipid oleoyl-linoleoyl-glycerophosphocholine (1) 1.18 0.01 
Lysolipid oleoyl-linoleoyl-glycerophosphocholine (2) 1.39 0.04 
Lysolipid stearoyl-arachidonoyl-glycerophosphoethanolamine (1) 1.68 0.00 
Lysolipid stearoyl-linoleoyl-glycerophosphoethanolamine (1) 2.18 0.00 
Lysolipid 2-behenoylglycerophosphocholine 0.24 0.02 
Lysolipid stearoyl-arachidonoyl-glycerophosphoinositol (2) 0.87 0.01 
 
Note: Fold change (dKO/ WT) was computed from raw signal intensity of metabolites 
and Welch’s two sample t-test was used to identify metabolites as significant (p<0.05) (in 





Table 2-3. Increase in fatty acids in dKO rat CSF 
 

















 1.36 1.42  0.03 0.05 
Fatty Acid Synthesis malonylcarnitine  1.24 1.33  0.02 0.01 
Fatty Acid Synthesis 2-methylmalonyl 
carnitine 




butyrylcarnitine  3.77 3.84  0.00 0.00 
Carnitine Metabolism deoxycarnitine  1.42 1.41  0.00 0.00 
Carnitine Metabolism carnitine  1.18 1.14  0.09 0.18 
Ketone Bodies 3-hydroxybutyrate 
(BHBA) 
 0.80 0.75  0.04 0.02 









 0.56 0.69  0.05 0.18 
 
Notes: Fold change (dKO/ WT) was computed from raw signal intensity of metabolites 
and Welch’s two sample t-test was used to identify metabolites as significant (p<0.05) (in 
dark green & red) or trending significant (0.1>p>0.05) (light green & red). CSF samples 
were analyzed without contamination compensation or with contamination compensation 





Table 2-4. Gut microbiota metabolites identified altered in the plasma or CSF of 
dKO rats 
 














riboflavin (Vitamin B2) 2.64 0.0002  3.09 2.00E-
07 
 26283345  
creatine 0.7 0.0016  0.95 0.35  26283345  
4-hydroxycinnamate 0.53 0.0023     26861391  
taurocholenate sulfate 1.99 0.009     26283345 Y 
p-cresol sulfate 0.45 0.0091     26283345 Y 
phenyllactate (PLA) 1.72 0.0117  1.56 0.0004  27505423  
daidzein 2.05 0.0181       
indolelactate 1.45 0.0201     26283345 Y 
phenylacetylglutamine 0.46 0.0215     26283345 Y 
glycodeoxycholate 0.1 0.0309     26283345 Y 
3-(2-hydroxyphenyl) 
propionate 
0.62 0.0314     27505423  
phenylacetate 0.44 0.0338       
indoleacetate 0.75 0.0539  1.53 0.14  26283345 Y 
deoxycholate 0.55 0.0607       
indole-3-carboxylic 
acid 
0.64 0.0742       
tauroursodeoxycholate 0.58 0.0769     26283345 Y 
phenol sulfate 1.27 0.1189  1.93 0.0078  26283345 Y 
Isovalerate 0.86 0.3158  1.25 0.0084  26283345 N 
creatinine 1.07 0.4987  1.21 0.0005    
 
Notes: Metabolites of gut microbiota origin were identified based on previously 
published papers as well as microbiome metabolite list maintained at Metabolon ®. Only 
significant (p<0.05) and trending significant (0.1>p>0.05) metabolites are listed from 
both plasma and CSF. Fold change is the ratio of dKO/WT metabolite signal intensity 





Table 2-5. Sulfated metabolites significantly altered in the plasma of dKO rats 
 
Sub Pathway Biochemical Name 
Fold 
Change p-Value 
Phenylalanine and Tyrosine Metabolism p-cresol sulfate 0.45 0.01 
Secondary Bile Acid Metabolism taurocholenate sulfate 1.99 0.01 
Benzoate Metabolism catechol sulfate 1.4 0.08 
Food Component/Plant equol sulfate 1.57 0.02 
Food Component/Plant 4-vinylguaiacol sulfate 0.41 0.04 
Food Component/Plant daidzein sulfate (2) 2.41 0.00 
Drug 4-acetylphenol sulfate 2.29 0.00 
Chemical sulfate* 0.87 0.07 
Chemical 2-aminophenol sulfate 1.44 0.05 
Chemical 3-hydroxypyridine sulfate 2.53 0.00 
 
Notes: Sulfated metabolites of different pathway origin that were significantly increased 
or decreased in dKO rat plasma are listed. Welch’s two sample t-test was used to identify 
metabolites as significant (p<0.05) (in dark green & red) or trending significant 





Table 2-6. Sulfated metabolites significantly altered in the CSF of dKO rats 
 



















Dipeptide prolylglycine  1.17 1.15  0.02 0.06 
















Notes: Sulfated metabolites of different pathway origin that were significantly increased 
or decreased in dKO rat CSF are listed. Welch’s two sample t-test was used to identify 
metabolites as significant (p<0.05) (in dark green & red) or trending significant 





Bcrp and Pgp gene deletion in rats results in altered transcriptome of brain, kidney 
and liver 
 
To understand the effect of compensatory pathways on metabolomic signatures, 
we performed a microarray analysis comparing gene expression in the brain (frontal 
cortex), kidney and liver of WT and dKO rats. A total of 435 genes in kidney, 398 genes 
in liver and 240 genes in brain frontal cortex was found to be significantly different 
(Figure 2-15A). 75 genes were common between kidney and liver, 45 genes between 
kidney and brain and 40 genes between brain and liver. Hierarchical clustering analysis 
revealed striking differences in gene expression in all tissues between the WT and dKO 
rats (Figure 2-15B). A list of significantly altered genes in all tissues, along with their 
associated p-values, identified by both Nexus expression analysis and GSEA analysis 
method are provided in the supplement (Supplement_Chapter 2_Genes. S7 and S8) 
Gene expression analysis exhibited significant changes in gene expression of few 
Cytochrome P450 enzymes (Table 2-7), few ABC efflux transporters, mainly the Abcg 
group of transporters (Table 2-8) and few solute carrier (SLC) uptake transporters (Table 
2-9), but none of the major renal drug efflux or uptake transporters. A significant increase 
(2.93-fold) in Cyp2b1 gene expression was observed in the liver of dKO rats, compared 
to WT rats. Many SLC uptake transporters in kidney and liver were also found to have 
altered expression (Table 2-9), e.g. Slc22a5 or OCTN2 is a carnitine transporter, 
significantly decreased in the kidney of dKO rats. Similarly, an alteration in the Abcg 
group of transporters in kidney (Abcg1, 1.5-fold) and liver (Abcg3, 0.5-fold and Abcg1, 
1.5-fold) indicates compensatory alteration of these transporters due to absence of Abcg2 
or Bcrp. Upregulation of Abcg1, sterol and choline phospholipid transporter [14], might 
have an impact on steroid and sterol metabolism thus impacting the lipid metabolome. 
Cholesterol and steroid metabolic pathway was also found to be altered in the kidney and 
liver of dKO rats, respectively (Table 2-10). Table 2-10 lists the significantly altered top 
20 common biological pathways between brain, liver and kidney of, dKO rats, compared 
to WT rats. Of particular interest among altered pathways were urate biosynthetic process 
and response to lipopolysaccharide in brain, oxidation-reduction process and response to 
oxidative stress in kidney and circadian rhythm in liver, a majority of which were found 
to be altered in all three tissues (Table 2-11). These altered pathway information, in 
conjunction with the metabolomic signatures, indicated a possible impact of Bcrp and 
Pgp transporters at the physiological level.  
 
 
Use of gene expression and known substrate knowledge for understanding 
metabolomic features 
  
 Significantly altered biological pathways and the associated gene expression 
changes indicated that a part of the observed metabolomic changes was due to either 
direct effect of compensatory pathways or indirect effect of many metabolites. Figure 
2-16, Figure 2-17 and Figure 2-18 show few proposed models of possible gene-
metabolite interactions and impact of Bcrp and/or Pgp on biological pathway, 
respectively, derived from a knowledge-based integration of metabolite-gene expression-




Notes: Venn diagram showing the number of significant (p<0.05) genes in kidney (blue), 
liver (red) and brain frontal cortex (green) of the dKO compared to the WT rats (A). 
Hierarchical clustering heatmap shows significant expression in gene expression between 
WT and dKO rat kidney, liver and brain frontal cortex tissues (B) 
  
 
Figure 2-15. Gene expression in brain, kidney and liver of the dKO is significantly 





Table 2-7. Significantly changed Cytochrome P450 (CYP) enzymes in dKO rats 
 









Cyp4v3 UP     1.33 0.02  1.24 0.01 
Cyp4a8 DOWN  0.71 0.00       
Cyp4a3 UP        1.50 0.00 
Cyp3a85-ps DOWN  0.58 0.00       
Cyp3a73 DOWN  0.67 0.00       
Cyp2j4 UP  1.34 0.01     1.61 0.00 
Cyp2g1 DOWN     0.72 0.04    
Cyp2d5 DOWN  0.54 0.00     0.33 0.00 
Cyp2d2 DOWN        0.75 0.00 
Cyp2d1 DOWN        0.71 0.00 
Cyp2c12 DOWN  0.56 0.00       
Cyp2c11 UP        1.77 0.00 
Cyp2b2 UP  1.24 0.04       
Cyp2b1 UP  2.66 0.00       
Cyp26a1 UP  1.39 0.01       
Cyp24a1 UP        1.79 0.00 
Cyp1a1 UP        1.76 0.00 
 
Note: List of significantly (p< 0.05) increased (red) or decreased (green) CYP enzymes’ 





Table 2-8. Significantly changed ATP-binding Cassette (ABC) transporters in 
dKO rats 
  
   Liver  Brain  Kidney 
Gene 
Symbol Regulation  
Fold 
Change p-Value  
Fold 
Change p-Value  
Fold 
Change p-Value 
















 1.48 0.00 








 0.76 0.02 





Note: List of significantly (p< 0.05) increased (red) or decreased (green) ABC 





Table 2-9. Significantly changed SLC transporters in dKO rats 
 



















Slco1c1 OATP1C1 UP  
  
 1.22 0.02  
  
 T4, T3 




 1.26 0.01   









 0.69 0.00  Short chain 
fatty acid 




 1.28 0.02  Myoinositol 




 0.80 0.04  Mannose, 
fructose, 
glucose 
Slc4a7  UP  
  
 1.29 0.00  
  
  




 1.33 0.00   





Slc39a12  UP  
  
 1.61 0.00  
  
  




 1.24 0.00   





Slc35f1  DOWN  
  
 0.83 0.04  0.65 0.00   









 0.82 0.04   









 0.63 0.00   









 0.82 0.05  Fe2+ 




 1.52 0.00   




 0.82 0.00  ATP, AMP, 
ADP, Pi 










Slc16a6 MCT7 UP  
  
 1.28 0.01  0.71 0.00  Orphan 




 0.83 0.02  T2, T3,T4 




 0.59 0.00  di- and tri-
peptides 








Note: List of significantly (p< 0.05) increased (red) or decreased (green) SLC 





Table 2-10. Significantly altered top biological pathways based on gene expression changes in dKO compared to WT rats 
 
Notes: Top 20 most significant biological pathways were identified by enrichment of significantly altered genes in the dKO rat brain frontal 
cortex, kidney and liver at p < 0.05. 
Brain  Kidney  Liver 
Enrichment Term p-Value  Enrichment Term p-Value  Enrichment Term p-Value 
retina development in camera-type eye 5.43E-05  response to drug 1.72E-11  aging 3.33E-07 
bronchus development 1.43E-04 
 response to organic cyclic 
compound 9.79E-09 
 
response to drug 3.06E-06 
urate biosynthetic process 1.43E-04  oxidation-reduction process 2.80E-07  wound healing 4.24E-05 
response to glucocorticoid stimulus 1.56E-04 
 
Aging 3.26E-07 
 antigen processing and presentation of 
exogenous peptide antigen via MHC class II 8.17E-05 
angiogenesis 2.48E-04 
 positive regulation of 
apoptotic process 5.23E-07 
 
steroid metabolic process 1.17E-04 
retinal cell programmed cell death 4.25E-04 
 response to organic 
substance 3.69E-06 
 
glucose 6-phosphate metabolic process 2.29E-04 
negative regulation of cell volume 4.25E-04 
 response to mechanical 
stimulus 5.86E-06 
 
negative regulation of signal transduction 2.56E-04 
trachea formation 4.25E-04  response to food 7.14E-06  response to organic cyclic compound 2.77E-04 
vocalization behavior 8.42E-04 
 
response to oxidative stress 8.53E-06 
 positive regulation of fatty acid beta-
oxidation 3.60E-04 
negative regulation of actin filament bundle 
assembly 8.42E-04 
 
response to nutrient 1.31E-05 
 leukocyte migration involved in 
inflammatory response 3.60E-04 
glomerular visceral epithelial cell development 0.001393  response to cytokine stimulus 1.44E-05  urate metabolic process 3.60E-04 
homeostasis of number of cells within a tissue 0.001424  response to glucose stimulus 1.77E-05  maintenance of protein location in cell 3.64E-04 
positive regulation of endothelial cell migration 0.001424  Ossification 2.63E-05  cellular protein complex disassembly 3.64E-04 
embryonic digit morphogenesis 0.001712  cellular response to cAMP 3.70E-05  response to estrogen stimulus 4.08E-04 
response to hypoxia 0.001923 
 positive regulation of 
cholesterol efflux 4.02E-05 
 positive regulation of transcription from 
RNA polymerase II promoter 5.28E-04 
activation of cysteine-type endopeptidase 
activity involved in apoptotic process by 
cytochrome c 0.002073 
 
embryo implantation 4.50E-05 
 
circadian rhythm 6.14E-04 
visual perception 0.00231  cholesterol homeostasis 5.31E-05  drug metabolic process 7.29E-04 
response to lipopolysaccharide 0.002551 
 negative regulation of ERK1 
and ERK2 cascade 5.38E-05 
 
response to glucocorticoid stimulus 7.96E-04 
cellular response to interferon-gamma 0.002845  response to vitamin D 6.94E-05  glutathione biosynthetic process 0.001018 
glial cell apoptotic process 0.002879 
 
cholesterol metabolic process 9.20E-05 





Table 2-11. Significantly altered common biological pathways between all the tissues 
 
 
Note: Top 22 common biological pathways that were identified by enrichment of significantly altered genes in the dKO rat brain 
frontal cortex, kidney and liver at p < 0.05. 
 
 p-Value 
Common Biological Pathways Brain Liver Kidney 
urate biosynthetic process 1.43E-04 0.037835 0.042625 
response to glucocorticoid stimulus 1.56E-04 0.000796 0.000459 
Angiogenesis 2.48E-04 0.047942 0.002913 
response to lipopolysaccharide 0.002551 0.013290 0.003599 
circadian rhythm 0.004231 0.000614 0.000171 
drug transport 0.004859 0.011985 0.015081 
antigen processing and presentation 0.005943 0.020920 0.028569 
drug transmembrane transport 0.006026 0.014794 0.018585 
antigen processing and presentation of exogenous peptide antigen via MHC class II 0.010200 8.17E-05 0.000130 
protein localization in mitochondrion 0.011969 0.019100 0.021544 
cellular response to type I interferon 0.011969 0.019100 0.021544 
negative regulation of helicase activity 0.011969 0.019100 0.021544 
positive regulation of angiogenesis 0.013703 0.003538 0.001348 
male gonad development 0.020563 0.006432 0.039839 
mitochondrial electron transport; cytochrome c to oxygen 0.023795 0.037835 0.042625 
nucleotide-binding oligomerization domain containing 1 signaling pathway 0.023795 0.037835 0.042625 
hypoxanthine biosynthetic process 0.023795 0.037835 0.042625 
regulation of mitochondrial fission 0.023795 0.037835 0.042625 
negative regulation of apoptotic process 0.039936 0.001377 0.001713 
brown fat cell differentiation 0.046865 0.017487 0.000351 
response to peptide hormone stimulus 0.046952 0.001474 0.000167 




Notes: Metabolomic analysis showed a significant decrease in corticosterone in dKO rat 
plasma (A). Transcriptomic analysis showed a significant increase in CYP2B gene 
expression in the liver of dKO rats, possibly by glucocorticoid mediated pathway 
activated by corticosterone. 
  
 
Figure 2-16. Possible explanation of observed decrease in corticosterone, a Pgp 





Notes: Bcrp substrate daidzein and also its metabolites were significantly increased in the 
plasma of dKO rats. Isoflavonoid and Bcrp substrates daidzein and genistein are known 
activator of PPARα as well as PPARγ pathways. Gene expression analysis also observed 
gene expression changes possibly related to PPAR activation pathway, thus leading to 
alteration in fatty acid metabolic pathways. 
  
 
Figure 2-17. Possible explanation of activation of peroxisome proliferator-









Figure 2-18. Possible biological pathways altered in the absence of Bcrp and Pgp 





In silico prediction of BCRP and PGP substrate-like properties for the significantly 
altered metabolites in CSF and plasma of dKO rats 
 
Screening of all 169 metabolites significantly altered in CSF and plasma of dKO 
rats for their interaction with Bcrp and /or Pgp may not be a feasible option. Also, it is 
unlikely that all observed metabolic changes were due to the direct effect of Bcrp and/or 
Pgp transport deficiency. Therefore, we used an in silico prediction-based approach to 
identify metabolites that are more likely to be substrates of Bcrp and/or Pgp. A Bayesian 
machine learning model, built with compounds known to interact with Bcrp and Pgp, was 
used to score the metabolites based on their level of interaction (high score for higher 
interaction). Compared to the xenobiotics, many of these metabolites are smaller 
molecules, and might also have weaker interaction with the transporters, which is also 
reflected by their low interaction score. As described in the methods, Bcrp or Pgp 
Bayesian interaction score for each metabolite along with their molecular descriptors 
(molecular weight, molecular polar surface area, AlogP etc.) were used to predict the 
observed log2(fold change) of the metabolites in CSF and plasma. Metabolites in the 
plasma, irrespective of their significance and direction of fold change, did not correlate 
well with either the Abcg2 or Pgp score along with other descriptors (data not shown). A 
significant correlation was observed for the metabolites that are significantly altered in 
the CSF of dKO compared WT rats (Figure 2-19A). In particular, metabolites that 
significantly increased by > 1.5-fold in the CSF of dKO rats, correlated strongly with the 
ABCG2 score, logP and molecular polar surface area of the metabolites (Figure 2-19B). 
Raw data for the significantly altered CSF metabolites that are used for this analysis is 





 The goal of the current study is to understand the effect of Bcrp and Pgp efflux 
transporters on the rat metabolome, and elucidate their biological functions. A systemic 
level understanding of the impact of these transporters on metabolomic and 
transcriptomic profiles could be useful to identify their overall endogenous function, 
leading to a better understanding of long-term inhibition of these transporters by 
xenobiotics or dietary inhibitors, as well as elucidate effects of the well-known BCRP 
polymorphism [111] on population physiology and drug treatment outcome.  
 
 Bcrp and Pgp are abundant at the blood brain barrier (BBB), blood CSF barrier 
(BCSFB) and on enterocytes of small intestine, where they restrict brain permeability and 
oral absorption, respectively, of many known drugs and toxic chemicals [46, 149]. 
Absence of these transporters is expected to increase the concentration of their substrates 
in both blood and brain / CSF. Therefore, by comparing the CSF and plasma 
metabolomic profiles between WT and Bcrp-Pgp KO (dKO) rats, we aimed to identify 







Notes: ABCG2 or BCRP interaction score from a Bayesian model, molecular weight, 
molecular polar surface area and AlogP of each significantly altered metabolites (A) or 
only >1.5-fold significantly increased metabolites (B) in CSF were used in a predictive 
regression model to predict their fold change (dKO/WT) in CSF. Log2 (Fold change) 
actual vs. Log2 (Fold change) predicted compared using a standard least square method. 
Significance of the correlation computed at p < 0.05. 
  
 
Figure 2-19. Metabolites with significantly higher abundance in dKO CSF 





 We observed a significant difference in abundance of metabolites in CSF and 
plasma between WT and dKO rats. While 90% of the significant metabolites in CSF 
increased in dKO rats compared to WT, the plasma metabolome demonstrated 50% 
abundance of both increased and decreased metabolites. The majority of the altered 
plasma metabolomic signature was represented by the lipid metabolites. Specifically, 
long and medium chain fatty acids, dicarboxylate and polyunsaturated fatty acids were 
found to be significantly decreased in the plasma of dKO compared to WT rats. Similar 
to our observations, in a metabolomic study in mice after treatment with PPARγ agonist 
rosiglitazone, the authors reported a decrease in polyunsaturated fatty acids such as mead 
acid, oleic acid, phosphatidylethanolamine and phosphatidylcholine [197]. In addition, 
our transcriptomic analysis revealed significant alteration of genes related to the PPARγ 
pathway [197] such as uncoupling protein 1 (Ucp1, 1.4-fold increase in dKO kidney), 
fatty acid binding protein 4 (Fabp4, 2-fold increase in dKO kidney), leptin (Lep, 1.4-fold 
increase in dKO kidney) and lipoprotein lipase (lpl, 1.5-fold increase in dKO liver and 
1.3-fold increase in dKO kidney). Of particular interest, we observed a 1.5-fold increase 
in PPARγ gene expression in both kidney and liver of dKO rats.  
 
 In a separate study, treatment with PPARα agonist fenofibrate was reported to 
increase the acylcarnitine metabolites including propionyl-, isobutyryl-, 2-methylbutyryl- 
and isovalerylcarnitine in the urine of healthy volunteers [222]. A significant increase in 
these carnitine analogs was also observed in our dKO rat CSF metabolome signature 
(Table 2-3 and Supplement_Chapter 2_Metabolites _ S1B). Interestingly, another 
PPARα activity biomarker in mice, nicotinamide [222], was found to be significantly 
decreased in the CSF of the dKO rats. Furthermore, we observed a 0.56-fold decrease in 
gene expression of carnitine palmitoyl transferase 1a (CPT1a) which is known to be 
altered due to PPARα activity [222], in the liver of dKO rats. Alteration in amino acid 
and carnitine metabolites in CSF and plasma has been reported by another group of 
researchers in rats treated with pan-PPAR agonist tetradecylthioacetic acid [223]. In 
addition, a 5-fold increase in 2, 8-quinolinediol in the dKO rat plasma (Figure 2-4), is 
commensurate with previous findings in mice, where treatment of mice with PPARα 
ligand Wy-14,643 significantly decreased urinary 2, 8-dihydroxyquinoline [224]. 
Therefore, taken together, our metabolomic and transcriptomic results suggest a possible 
induction of the PPARα and PPARγ pathways in rats lacking Bcrp and Pgp transporters, 
possibly leading to the observed changes in fatty acid and amino acid metabolites (Table 
2-1, Table 2-2, Table 2-3, Supplement_Chapter 2_Metabolites _Table S5 and S6). 
This implies that in the absence/inhibition of Bcrp and Pgp in enterocytes, substrates of 
these transporters, which are also PPARα/γ agonists, such as dietary isoflavones genistein 
[225-229] and daidzein [230, 231] (was increased 2 fold in our dKO rat plasma, Figure 
2-11), may be absorbed more, leading to higher PPARα/γ activity in the system (Figure 
2-17).  
 
 Another striking effect on the plasma lipid metabolome was the overall increase 
in lysolipids (Table 2-2). In a recently published report on identification of early 
biomarkers of lipopolysaccharide (LPS)-induced sepsis in rats, the authors reported an 
alteration in palmitoyl carnitine, acetyl-L-carnitine, propionyl-L-carnitine, branched 




methionine sulfoxide and lysolipids [232]. Our metabolomic data demonstrated an 
increase in methionine, N-acetyl methionine and methionine sulfoxide in CSF 
(Supplement_Chapter 2_Metabolites _Table S1B) and lysolipids in plasma (Table 
2-2) of the dKO rats. In addition, transcriptomic analysis found ‘response to 
lipopolysaccharide’ as one of the top 10 significantly altered biological pathways in liver, 
kidney and brain of dKO rats (Table 2-11). LPS is a complex large glycolipid found on 
the outer membrane of Gram (-) bacteria and can act as an endotoxin. Gut microbiota can 
utilize LPS to cause low grade inflammation in the host and thereby associate with 
different pathogenesis of the host, such as obesity and cardiovascular risk [233]. 
Therefore, our findings strongly suggest that the absence of Pgp/Bcrp has affected the gut 
microbiota, and the altered microbiota, in turn, is influencing both the plasma and CSF 
metabolome in dKO rats. The decrease in the secondary bile acid metabolites, such as 
deoxycholate (0.55-fold, 0.1>p>0.05), glycodeoxycholate (0.1 fold, p<0.01), 
taurodeoxycholate (0.57 fold, 0.1>p>0.05) and tauroursodexycholate (0.58 fold, 
0.1>p>0.05), which are majorly derived by the gut microbiota, in the plasma of dKO rats 
(Table 2-1), also indicates a possible change in the gut microbiome in the absence of 
Bcrp and Pgp transporters.  
 
 Additional evidence of altered gut microbiome, in the absence of Bcrp and Pgp, 
comes from the signatures of cresol sulfate and phenol sulfate metabolites. Both are 
tyrosine metabolite products of the gut microbiota [234]. While cresol sulfate was 
significantly decreased in plasma, phenol sulfate was increased in the CSF of dKO rats 
(Table 2-4). Phenol sulfate is produced by E. Coli species of bacteria, which have been 
reported to increase in abundance in mice lacking Mdr1a (Pgp) [162, 235]. Thus, a 
dysregulation in bacterial abundance in the dKO rats, leading to altered production of 
metabolites, might have led to some of these observed metabolomic changes. Our results 
also show alteration in other known gut microbiota metabolites in the plasma of dKO 
rats, such as the tryptophan metabolite indolelactate (1.5-fold increase) and phenylalanine 
and the tyrosine metabolite phenylacetyleglutamine (0.46-fold increase) (Table 2-4). 
Some of these metabolites were also found to be significantly increased in the CSF of 
dKO rats (Table 2-4). While our findings indicate an alteration in gut microbiome 
metabolites in the absence of Bcrp and Pgp transporters in rats, it remains to be 
understood which altered microbiome metabolites are due to exclusive alteration in the 
gut microbiome itself, and/or due to a change in the efflux transporters for these 
metabolites.  
 
 Sulfated metabolites, many of which are of gut microbiota origin, were 
significantly increased in the CSF and plasma of dKO vs. WT rats (Table 2-5 and Table 
2-6). Bcrp is known to be a broad-specificity phytoestrogen sulfate transporter [127]. 
Dietary isoflavones such as genistein and daidzein, as well as their sulfated metabolites 
are also known substrates of Bcrp [93, 225]. Although cresol sulfate has been shown to 
be a Bcrp substrate [83], a decrease in plasma abundance of cresol sulfate, which is a gut 
microbiota-generated metabolite, indicated a possible alteration in the gut microbiome, as 
discussed before. Many sulfated metabolites of gut microbiota origin are also uremic 
toxins [212] and are known to interact with Bcrp as well as MRP4 and OAT, e.g., indoxyl 




or uptake transporters, in the absence of Bcrp function, in dKO rat enterocytes, leading to 
alterations in sulfated metabolites. Accordingly, in CSF and plasma of dKO rats, we 
observed significant changes in p-cresol sulfate (0.5-fold, decrease, plasma), 
pyrocatechol sulfate (catechol sulfate, 3.3-fold increase, CSF) and equol sulfate (1.6-fold 
increase, plasma), which are known to be gut microbiota-derived uremic toxins [212]. 
Among them, p-cresol sulfate and equol sulfate are already known Bcrp substrates [83, 
127]. We also observed a 2.14-fold higher CSF/plasma ratio of pyrocatechol sulfate in 
the dKO rats compared to WT, implying a significant accumulation of this uremic toxin 
in the CSF of dKO rats. Hence, due to known affinity of Bcrp towards sulfated 
metabolites [121], we think pyrocatechol sulfate may be a putative endogenous Bcrp 
substrate. Another such metabolite, 2-aminophenol sulfate, was found to be 3-fold higher 
only in the CSF of dKO rats (Table 2-6). In addition, the CSF/plasma ratio of 2-
aminophenol sulfate was 1.9-fold higher in dKO vs WT rats (Supplement_Chapter 
2_Metabolites _Table S2). Known as a uremic toxin [142], this metabolite could also be 
of interest as a putative Bcrp substrate. 
 
 As discussed before, these uremic toxins and sulfated metabolites can be 
substrates of multiple transporters and be part of the Remote Sensing and Signaling [142] 
mechanism. In a recently published report, comparing the plasma metabolomics of Oat3 
knockout and WT mice, Bush K et.al observed a significant increase in catechol sulfate, 
O-methyl catechol sulfate and 2-aminophenol sulfate among many other metabolites in 
the plasma of Oat3 knockout mice [140]. Interestingly, we also observed a 3 fold increase 
in catechol sulfate and 2-aminophenol sulfate and a 5-fold increase in O-methyl catechol 
sulfate in the CSF of dKO compared to WT rats (Table 2-6), but no change in the 
expression level of OAT1/3 transporters in any tissue (Table 2-9). In addition, the 
CSF/plasma ratio was 2-fold higher for catechol and 2-aminophenol sulfate and 13-fold 
higher for O-methyl catechol sulfate in dKO vs WT rats (Supplement_Chapter 
2_Metabolites _Table S2). While the increased concentration of catechol and 2-
aminophenol sulfate in the dKO rat plasma could be explained by inhibition of renal Oat3 
or Oat1 transporters, their accumulation in the CSF of Bcrp and Pgp dKO rats cannot be 
solely explained by these primarily kidney transporters, raising the possibility that these 
metabolites are also substrates of Bcrp and/or Pgp. A recent observation that the 
association of methotrexate clearance variability with the liver transporter OATP1B1 
polymorphism was primarily related to inhibition of renal methotrexate transporter 
OAT1/3 by endogenous metabolites of OATP1B1 [213], further strengthens the Remote 
Sensing and Signaling hypothesis. 
 
 Similar to previously published findings in single Pgp or Bcrp knockout rats [91], 
our transcriptomic analysis did not reveal a drastic compensatory effect in gene 
expression of uptake (Table 2-9) or efflux transporters (Table 2-8) in the dKO rats. 
However, the Remote Sensing and Signaling hypothesis, discussed above, can lead to 
alteration of many transporter activities. One significant observation was the reduction in 
Slc22a5 or the Octn2 transporter in kidney, a known carnitine transporter [202], which 
might contribute to the observed alterations in carnitine metabolites. Glucocorticoids are 
known substrates of Pgp [57]. However, a significant increase (2 fold) in Cyp2b1 gene 




the liver of dKO rats, might further explain the decrease in corticosterone levels in the 
plasma of dKO rats (Figure 2-16). 
 
 Due to the significant impact of Bcrp and Pgp transporters on the brain 
penetration of their substrates [50, 237], we think CSF might be a better matrix to 
identify putative Bcrp and/or Pgp endogenous substrates than plasma. When we used in 
silico Pgp and Bcrp scores, along with molecular descriptors (AlogP, molecular weight, 
polar surface area) to predict the log2(fold change) of metabolites observed in plasma and 
CSF, only significantly altered metabolites in CSF, and not plasma (data not shown), 
displayed a better correlation between predicted and observed data (Figure 2-19). 
Correlation was also found to be better with only significantly increased metabolites in 
the CSF of dKO rats (Figure 2-19B), thus implying that these metabolites in dKO rats 
possessed Bcrp substrate-like properties. In addition, Random Forest Analysis identified 
metabolites based on their importance in group separation in the CSF of dKO compared 
to WT rats (Figure 2-7), which included known Bcrp substrates riboflavin and urate in 
the CSF and only riboflavin in the plasma. Of note, our metabolomic analysis identified 
ketamine, the drug used for anesthetizing the rats, increased 2-fold in both CSF and 
plasma of dKO rats compared to WT. Further investigation revealed that ketamine oral 
bioavailability and ketamine-induced loss of righting reflex pharmacodynamic activity 
was significantly higher in Bcrp-Pgp dKO and Pgp KO mice, indicating ketamine is a 
dual substrate of Bcrp and Pgp [95]. In addition, Kaiser et al. recently reported that 
ketamine is a substrate of Pgp in vitro [98], further validating our hypothesis that 
metabolomic analysis could identify novel substrates of Bcrp and Pgp. Our observation 
that pesticide chlorothalonil metabolites 4-hydroxychlorothalonil was increased in the 
plasma of dKO rats, indicates possible risk of exposure to the pesticide in people lacking 
BCRP and/or PGP function. Lack of 4-hydroxychlorothalonil in CSF also indicates the 
involvement of other efflux mechanism at the BBB that prevents this metabolite from 
getting into CSF. 
 
 Among the known Bcrp substrates, urate’s signature in the CSF was of particular 
interest. Urate was found to be significantly increased only in the CSF of dKO rats 
(Figure 2-11). In addition, the CSF/plasma ratio of urate was found to be 3-fold higher in 
the dKO compared to WT rats. While elevated serum urate is known to be positively 
correlated to gout, cardiovascular and renal diseases, it has been shown to be negatively 
correlated to Alzheimer’s and Parkinson’s diseases [238]. Bcrp is a low affinity and high 
capacity transporter of uric acid [54] and has also been associated with Alzheimer’s 
disease [207]. Thus, altered uric acid in CSF of dKO rats may have varied physiological 
consequences. In addition, uric acid has been reported to be both antioxidant as well as 
causing oxidative stress [239, 240]. It has also been associated with causing endoplasmic 
reticulum stress leading to changes is fatty acid metabolism [241]. Similar findings were 
observed in our metabolomic analysis with a significant increase in methionine sulfoxide, 
a possible biomarker of oxidative stress [242] along with ‘oxidative stress’ as a 
significantly altered biological pathway in the transcriptomic analysis. Furthermore, uric 
acid is known to inhibit UMP synthase [243] that can reduce orotidine metabolism, which 
might explain the observed increase in orotidine in the CSF and plasma of dKO rats. 




adenine containing- and guanine containing- purine metabolites were found to be 
significantly increased in the CSF of the dKO rats (Supplement_Chapter 2_Metabolites 
_ S6). Similarly, pyrimidine, specifically orotate and uracil containing, metabolites also 
significantly increased in the CSF of dKO rats. In an unpublished previous study in the 
lab, comparing the CSF of WT and Bcrp KO female rats (n=12), we also observed 
increased xanthine along with urate and allantoin in the CSF of Bcrp KO compared to 
WT female rats. Thus, alteration in purine metabolite pathway might be related to the 
absence of Bcrp transporter. Bcrp is also known to have affinity for purine ring 
containing chemicals [221], raising the possibility that some of the purine pathway 
metabolites apart from urate could be putative Bcrp substrates. 
 
 Comparison of gene expression between WT and dKO rat tissues by microarray 
also identified ‘circadian rhythm’ pathway as a significantly altered biological pathway. 
This is particularly interesting since Bcrp substrate protoporphyrin IX is a porphyrin 
metabolite, and may influence the circadian rhythm pathway. Indeed, cobalt and zinc 
conjugated protoporphyrin IX (PPIX) have been shown to be a ligand activator of REV-
ERBα / NR1D1, important for the circadian rhythm pathway [244]. In a previous 
experiment in our lab, we observed a 6-fold higher PPIX in the red blood cells (RBCs) of 
Bcrp KO female compared to WT female rats (data not shown). Thus, it is possible, PPIX 
is mediating the changes in the circadian pathway that we observed in our experiment. 
Evidence for this comes from the microarray analysis of the dKO vs WT kidney and liver 
that showed changes in expression of Rorα, Per2 and Nr1d1 and ATF3, and the mouse 
phenome database showing abnormal sleep behavior in Bcrp knockout mice 
(http://www.mousephenotype.org/data/genes/ MGI:1347061#section-associations). Bcrp 
gene expression in the mouse intestine was recently reported to be under the control of 
circadian clock-activating transcription factor 4 (ATF4) pathway, and authors showed a 
clear difference in sulfasalazine absorption when administered orally at Zeitgeber time 2 
(ZT2) compared to 14 (ZT14) [245]. 
 
 While our results indicate an effect of both Bcrp and Pgp transporters on the 
endogenous metabolome and biological pathways, further studies are required to dissect 
out the effect of the individual transporters. Due to lack of an exhaustive database and 
useful analytical methods for our dataset, we have used a knowledge-based integration of 
transcriptomic and metabolomic data. Our study design falls under a source-matched 
study design for metabolomic and transcriptomic studies [194] usually performed in 
animals, and the difficulty of analyzing the data lies in the integration of metabolomic 
and transcriptomic information originating from different matrices. In particular, the 
plasma metabolome can reflect the overall change from almost all highly perfused 
tissues. In this regard, while our data demonstrates an effect of Bcrp and/or Pgp 
transporters on the gut microbiome, further studies are needed for better understanding of 
this effect. Although our metabolomics comparison identified known Bcrp substrates, 
urate, pheophorbide A, riboflavin in the dKO rat CSF and/or plasma, the metabolomic 
analysis did not identify PPIX in the rat plasma/CSF. PPIX is a high affinity substrate of 
Bcrp, that is otherwise trapped in RBCs [246], suggesting that we could miss some 





 In conclusion, our results demonstrate a significant impact of the two efflux 
transporters Pgp and Bcrp on the systemic metabolome in rats and have increased our 
understanding of the endogenous function of these transporters. To our knowledge, this is 
the first study towards understanding the systemic level impact of efflux transporters. We 
have also shown that CSF and plasma metabolome can be independent from each other 
and the effect of Bcrp and/or Pgp transporters in these two compartments can be very 
different. Finally, our results demonstrate the importance for considering the Remote 
Sensing and Signaling hypothesis for chronic use of transporter inhibitors, and might 
throw some light on pharmacokinetic/ pharmacodynamic variability of many drugs that 








CHAPTER 3.    KETAMINE PHARMACOKINETICS AND 
PHARMACODYNAMICS ARE ALTERED BY PGP AND BCRP EFFLUX 





 Ketamine is a clinically useful anesthetic that is used either alone or in 
combination with other drugs in different surgeries [247]. It is also useful for the 
management of neuropathic and postoperative pain [248, 249]. It has been reported 
recently that ketamine has long-lasting antidepressant activity at sub-anesthetic doses 
[250]. But clinical utility of ketamine is affected by its recreational abuse, which often 
reported to cause kidney pathology, ulcerative cystitis [251] and bladder toxicity [252] in 
chronic ketamine abusers. 
 
 Pharmacologically, ketamine is a N-methyl-D-aspartate (NMDA) receptor 
antagonist that binds to the phencyclidine binding pocket of the receptor [253] to elicit 
anesthesia. However, ketamine is also known to interact with other pharmacological 
targets [247]. For example, ketamine was shown to have rapid onset antidepressant 
activity following metabolism to (2R, 6R)-hydroxynorketamine that activates α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs) [274]. 
 
 Ketamine pharmacokinetics (PK) in humans are well-described by a two or three 
compartment PK model [254, 255] with a high volume of distribution, high clearance and 
low plasma protein binding [253]. Ketamine is metabolized primarily by CYP2B6 and 
CYP3A4 to form norketamine, which is further metabolized to hydroxynorketamine and 
its glucuronide [256]. Ketamine has a low oral bioavailability that can be partially 
explained by its high metabolism observed by the oral route compared to intravenous or 
intramuscular routes [255, 257]. In addition, modifications in ketamine metabolism have 
been reported to cause potential drug-drug interactions [79]. 
 
Breast cancer resistant protein (Bcrp/Abcg2) and P-glycoprotein (Pgp/Abcb1a) 
are membrane-bound efflux transporters that are present in a wide variety of tissues such 
as blood-brain barrier and blood-cerebrospinal fluid barrier in the brain, intestinal 
epithelial cells, and bile canalicular membrane and kidney tubules. These transporters 
recognize a wide variety of chemicals as their substrates and reduce substrate systemic 
exposure by decreasing absorption (intestine) and increasing elimination (liver and 
kidney). Pgp and BCRP expression at the BBB and BCSFB decreases substrate 
movement from blood to brain and to CSF, respectively. Thus, inhibition of Bcrp and / or  
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Pgp can lead to systemic overexposure of their substrates and cause toxicity. A wide 
variety of drugs as well as chemicals from food or drinks are known to inhibit these 
transporters, and can therefore lead to potential drug-drug or drug-food interactions [71, 
258, 259]. Moreover, the BCRP Q141K inactivating allele is common in some 
populations with as many as 6% of Asians homozygous for this loss of function allele 
[111]. 
 
 Screening drugs in development for Bcrp and Pgp transport and inhibition 
capability is one of the FDA required drug approval criteria [31, 71] because of the large 
number of Bcrp and Pgp substrates and inhibitors, and the potential for some chemicals 
to be dual substrates for both transporters.  Some in vivo studies in rodents as well as in 
humans have suggested a potential interaction of ketamine with Bcrp and/or Pgp [260, 
261]. Given the clinical and recreational use of ketamine, and the significant interest in 
ketamine as an effective anti-depressant, we sought to identify if ketamine is a substrate 
of Bcrp and/or Pgp. Using mice with and without these two transporters, we report for the 
first time that ketamine is an apparent dual Pgp/Bcrp substrate whose pharmacokinetic 
and pharmacodynamic properties are affected by both Pgp and Bcrp. 
 
 
Materials and Methods 
 
 
Drugs and chemicals 
 
 Ketamine hydrochloride injection USP (100 mg/ml) was purchased from JHP 
Pharmaceuticals (Rochester, MI), elacridar was purchased from Astatech Inc. (Bristol, 
PA), Hydroxypropylmethylcellulose (HPMC) and Tween 80 were purchased from 
Sigma-Aldrich (St Louis, MO), Promega Reporter Lysis buffer (5X), PierceTM BCA 
protein assay reagent (A and B), bupropion, acetonitrile, formic acid and ammonium 
hydroxide were purchased from Fisher Scientific (Pittsburgh, PA). 3H-ketamine was 
obtained from American Radiolabeled Chemicals (St.Louis, MO).  
 
 
Animals and cell lines  
 
 Wild-type (WT) and Bcrp/Pgp (Abcg2-Abcb1a) double-knockout (dKO) male 
Sprague-Dawley rats, weighing 200 – 250 g, were obtained from SAGE® Labs (Horizon 
Discovery – St Louis, MO). Male Bcrp (Abcg2) KO, Pgp (Abcb1a/b) KO, Pgp/Bcrp 
(Abcb1a/1b/ Abcg2) double KO (dKO), and Wild-type Friend virus B (FVB) mice were 
obtained from Taconic farms (Germantown, NY). Rats used in the experiments were 12 
weeks old and mice were 10-16 weeks old. All animals were provided water and food ad 
libitum. Ketamine hydrochloride stock solution (100 mg/ml) was diluted with filtered 
autoclaved water to the appropriate dilution for dosing. Elacridar (10mg/ml) was 
formulated by suspending elacridar in a solution of 0.5 % Hydroxypropylmethylcellulose 
(HPMC) with 1% Tween 80. A 1.5 inch 20 GA feeding needle (Fisher Scientific Co., 




Committee of St. Jude Children’s Research Hospital in accordance with the U.S. National 
Institutes of Health guidelines approved all experimental procedures. 
 
 MDCKII parental cells and derivative cells stably overexpressing both human 
PGP and BCRP were kindly provided by Dr. Alfred H. Schinkel’s lab (The Netherlands 
Cancer Institute, Amsterdam) and cultured as described [262].  
 
 
Drug formulations for animal experiments  
 
 Ketamine hydrochloride stock solution (100 mg/ml) was diluted with filtered 
autoclaved water to appropriate dilution for oral (PO) or intraperitoneal (IP) dosing. 
Elacridar (solution) formulation was prepared by suspending the appropriate amount of 
elacridar in 0.5 % Hydroxypropylmethylcellulose (HPMC) with 1% Tween 80 solution to 
achieve a final concentration of 10 mg/ml.  
 
 
Estimation of ketamine exposure in rat CSF and plasma  
 
 Male WT and Pgp/Bcrp dKO rats (n= 8 per group) were anesthetized with 
intraperitoneal ketamine (100 mg/kg) and xylazine (10 mg/kg) formulated in water, at a 
dose volume of 10 ml/ kg of body weight. Cerebrospinal fluid (CSF) was collected from 
the cisterna magna immediately after the anesthesia was achieved (~7 minutes), followed 
by blood collection by cardiac puncture. Blood samples were centrifuged and plasma 
separated from the blood. Both plasma and CSF samples were immediately frozen on dry 
ice, stored at -80 0C, and shipped to Metabolon® (Research Triangle Park, NC) for 
metabolomic analysis. LC-MS/MS sample analysis, data normalization and analysis were 
performed at Metabolon® as described in other reports [186]. Normalized ketamine peak 




Pharmacokinetic study of ketamine in WT, Bcrp KO, Pgp KO and dKO mice after 
oral and intraperitoneal dosing at 100 mg/kg 
 
 A serum pharmacokinetic study was conducted following ketamine 
intraperitoneal and oral dosing (IP and PO PK) of WT, Bcrp KO, Pgp KO and dKO mice 
at 100 mg/kg dose of ketamine. For IP PK, six mice from each genotype were divided 
into two groups of three mice each. After the animals were dosed IP, blood was collected 
from one group of mice at 2, 10 and 40 minutes, and from another group of mice at 5, 20 
and 60 minutes. At each time point, 50 µL blood was withdrawn from each mouse from 
the saphenous vein into microvette capillary blood collection tubes (Sarstedt, obtained 
from Fisher Scientific, Pittsburgh, PA). Samples were kept at room temperature and were 
centrifuged at 10,000 rpm for 5 minutes to obtain serum, which was immediately 
separated and stored at -80°C until further analysis. For the PO PK study, six mice from 




dosing blood samples were collected at alternative time points from each group similar to 
the IP study. After a two-week washout period, the same oral study was repeated by 
altering the groups and time points such that all time-points were collected from each 
mouse. The two PO PK data sets were first analyzed separately and compared to identify 
any significant inter-day variation, and, after confirming no inter-day difference in PK 
profile, the data from the two collection dates were merged to obtain complete PK 
profiles for each mouse. 
 
 
Determination of ketamine concentration in mouse serum by HPLC/UV  
 
 Serum samples from the intraperitoneal ketamine PK studies in mice were treated 
with chilled acetonitrile (1:5); samples were vortexed and centrifuged for 15 minutes at 
4000 rpm to precipitate the protein and extract ketamine. After centrifugation, the 
supernatant was collected and further centrifuged for sample cleaning. The resultant final 
supernatant was then diluted 1:1 with water: acetonitrile (1:1) and a 10 µL sample was 
injected onto the HPLC for further analysis. For PO PK, a 1:2.5 initial dilution with 
chilled acetonitrile was used, followed by centrifugation and protein precipitation and re-
centrifugation of the supernatant for sample cleaning. The final supernatant was injected 
onto the HPLC system (Shimadzu Prominence, Kyoto, Japan) consisting of a LC-20AD 
binary high pressure gradient pump, SIL-20ACHT auto sampler, and SPD-20AV UV- 
detector. Bupropion (100 µg/mL) was added as an internal standard to all the samples 
prior to extraction and was extracted along with ketamine. Chromatographic separation of 
ketamine along with the internal standard was achieved using Hypersil ODS C18 column 
(150X4 mm; 5 µm particle size) fitted with Hypersil ODS (C18) Javelin Guard Column 
(10X4 mm; 5 µm particle size) and a gradient elution method with a run time of 10 
minutes. The mobile phase for elution was 60:40 ammonium formate buffer (20 mM): 
acetonitrile [263] and the gradient used was: 0 to 3 minutes 40% acetonitrile, 3 to 8 
minutes 60% acetonitrile, 8 to 9 minutes 40% acetonitrile, and the run stopped at 10 
minutes. Retention times for ketamine and bupropion were 5.2 and 7.1 minutes, 
respectively. The ketamine peak was identified and absorbance was measured at 210 nm 
[264]. Analyte/IS height ratio was used for preparation of calibration and measurement of 
unknown concentrations. Extraction efficiency was >90% throughout the analysis. The 
calibration range for IP PK and PO PK analysis were 0.39 µg/ml-200 µg/ml and 0.19 
µg/ml-100 µg/ml, respectively.  
 
 
Measurement of ketamine brain/serum ratio following IP ketamine  
 
 Male FVB WT, Pgp KO and Pgp/Bcrp dKO mice were dosed with IP ketamine 
(100 mg/kg) + 1 µCi 3H-ketamine tracer 1 hr before and again 15 min before sacrifice.  
Mice were euthanized by CO2 inhalation, blood was collected and serum separated, and 
brain tissue was weighed and mixed with an equivalent volume of phosphate buffer 
saline (PBS) and homogenized.  Brain homogenate and serum were mixed with 




3H-ketamine brain-to-serum ratio is dpm/gram brain tissue homogenate divided by 
dpm/ml of serum. 
 
 In another similar study, FVB male mice (WT, Pgp KO and Pgp/Bcrp dKO) were 
sacrificed 15 minutes after dosing 100 mg/kg ketamine intraperitoneally. Brain and blood 
were collected from each mouse after sacrifice. Brain tissues were weighed, 
homogenized with 20 mM ammonium formate buffer, and 9 µL brain tissue homogenate 
+ 1 µL IS was extracted using chilled acetonitrile. Supernate from the extracted samples 
were mixed with equal volume of acetonitrile/water (1:1) and injected in HPLC-UV for 
measurement of ketamine against standards prepared similarly from untreated mouse 
brain homogenate. Serum was separated from blood samples and ketamine concentration 
was measured by HPLC-UV based method as described previously. Brain/ serum ratio 
was obtained by dividing weight normalized brain tissue concentration with the serum 
concentration of ketamine. 
 
 
Pharmacokinetic data analysis and interpretation 
 
Non-compartment analysis. Initial analysis of both IP and PO PK study data 
was performed by a non-compartment approach using PK package on R statistical 
software [265] to determine whether there were significant differences in ketamine serum 
exposure between WT and Bcrp KO, Pgp KO and dKO mice. A serial sacrifice design 
was assumed to compute the area under time – concentration curve extrapolated to 
infinity (AUCinf) and the associated variability as described [265].  
 
Nonlinear mixed effect modeling. Upon identification of significant exposure 
difference between genotypes in the PO PK study by non-compartment analysis, the PO 
and IP PK data were combined and analyzed with nonlinear mixed effect modeling 
implemented in Monolix 4.3.3 (Lixoft, France) using a stochastic approximation 
expectation maximization algorithm [266] combined with a Markov chain Monte Carlo 
procedure. Population analysis of our PK data did not find any difference in ketamine 
serum PK between WT and Bcrp KO mice and thus, these two genotypes were combined 
in the final model. Out of 144 data points in the PO PK study, there were four 
concentrations that were below the lowest calibration standard concentration (0.19 
µg/mL) and these were removed from the analysis. One- and two-compartment models 
were evaluated. The goodness-of-fit-criteria and minimization of Akaike information 
criterion were used to select the base model. The effect of over-parameterization was also 
assessed using the condition number and Bayesian information criterion. Covariate 
analysis included the effect of genotype as a categorical covariate following an 
exponential model. The effect of genotype on individual parameters was determined by a 
forward addition process with a decrease in OFV ≥ 3.84 considered significant at p = 
0.05 for one degree of freedom, based on x2 (chi-square) distribution. Variability in 
observed data from the model predicted population mean data is considered to be due to 
between-subject variability (BSV) and residual unexplained variability (RUV). The 





 Pi = θpop x exp (ηpop) 
 
where, Pi ¬= PK parameter of the ith individual; θpop = population mean for P; η = 
normally distributed between-subject random effect with a mean of zero and variance of 
ω2. Constant, proportional and combined constant and proportional error models were 
tested for RUV, and the final model used the proportional error model that follows the 
following equation,  
 
 Yij = Ŷij + Yij *ε 
 
where Yij = observed concentration of ith individual at time j; Ŷij = individual predicted 
concentration and ε is the proportional error that is normally distributed with a mean of 
zero and variance of σ2. 
 
 Diagnostic plots were used for the final assessment of the model. Correlation 
between the observed and model predicted concentrations were evaluated and used as 
screening criteria for model selection.  Population weighted residuals or individual 
weighted residuals were plotted against time and population or individual predicted 
ketamine concentration. Normalized prediction distribution error plotted against time and 
population predicted ketamine concentration was also evaluated for model 
misspecification assessment. Apart from the diagnostic plots, final model selection also 




Comparison of ketamine-induced duration of Loss of Righting Reflex (dLORR) 
between WT, Bcrp KO, Pgp KO and dKO mice 
 
 Ketamine-induced dLORR was studied as described [267]. Briefly, animals were 
administered ketamine (50, 100 or 200 mg/kg) intraperitoneally or by oral gavage, and 
after four minutes waiting time (to reduce manual stimulation), mice were placed on their 
back.  Loss of righting reflex was defined to have taken place when the mouse could not 
right itself for at least 20 seconds. The dLORR was then measured until the mouse woke 
up spontaneously and the dLORR was compared between WT, Bcrp KO, Pgp KO and 
dKO mice. In a separate study, WT mice were orally administered elacridar (ECD) (100 
mg/kg) or vehicle 1.5 hours prior to IP administration of 50 or 100 mg/kg ketamine and 
dLORR was measured as described above.  
 
 
Intracellular uptake of radiolabeled ketamine in MDCKII cells overexpressing 
human PGP and BCRP 
 
 Madine-Darby canine kidney II (MDCKII) cells +/- BCRP and PGP were plated 
at 0.2*106 cells/ well in a 24 well plate. The next day media was removed and cells were 
incubated with 3H-ketamine at 37°C. At the selected time points, cells were washed with 




concentration of 3H-ketamine and protein concentration determined. Protein 
concentration was determined in the lysate by BCA protein assay. Results were expressed 
as pmole of ketamine per milligram of protein lysate. First, we determined the time to 
reach an equilibrium of intracellular uptake by incubating both WT and transfected cells 
with 0.5 µM 3H-ketamine for one hour and measuring the intracellular radioactivity at 2, 
5, 15, 30 and 45 minutes. In a separate assay, the concentration-dependent uptake of 3H-
ketamine up to the time of equilibrium was determined in MDCKII and BCRP-PGP-
MDCKII cells by incubating the cells with different concentrations of 3H-ketamine until 
they reached equilibrium and then measuring intracellular concentration of 3H-ketamine. 
The intracellular ketamine concentration was calculated and compared between the 
MDCKII and BCRP-PGP-MDCKII cells. 
 
 
Statistical analysis  
 
 GraphPad QuickCalcs was used to perform Grubb’s outlier test to remove outlier 
data from the analysis. Statistical analysis of significance for CSF and plasma ketamine 
exposure data in rats, all pharmacodynamic (dLORR) data, in vitro cell uptake study data, 
and non-compartment analysis were performed in GraphPad Prism software version 5.02. 
Ketamine’s CSF and plasma peak intensity in the dKO rats and WT rats was compared 
using the unpaired t-test with Welch’s correction. All dLORR study data was analyzed 
using Mann-Whitney U test. Intracellular uptake study results were analyzed using an 
unpaired t-test. The non-compartment-determined AUCinf was analyzed using a one-way 
ANOVA with Newman-Keuls Multiple Comparison Test. Significance for all analyses 






Deletion of both Bcrp and Pgp results in greater ketamine exposure in the CSF and 
plasma of dKO rats 
 
 We performed a metabolomic comparison analysis of the CSF and plasma from 
WT and Bcrp-Pgp dKO rats anesthetized with a cocktail of ketamine-xylazine. A full 
report of the metabolomics results will be published elsewhere. Ketamine levels 
(measured by LC-MS/MS) were found to be significantly higher in the CSF (1.74 times) 
and plasma (1.93 times) of dKO compared to WT rats (Figure 3-1). These results 
suggested that ketamine might be a substrate of Bcrp and/or Pgp. The metabolomic 
analysis did not identify the presence of xylazine in either the rat CSF or plasma from 







Notes: Ketamine levels in male Sprague Dawley rats after IP administration of 100 
mg/kg ketamine.  Data is plotted as median LC-MS/MS peak intensity ± range 
(n=8/genotype). The plasma and CSF median peak intensity in dKO rats was compared 
to the corresponding median peak intensity from WT rats using the unpaired t-test with 










Ketamine oral (PO) serum exposure is higher in mice lacking Bcrp and Pgp 
 
 To determine if Bcrp and Pgp can affect the PK of ketamine, we collected serum 
following a 100 mg/ kg IP dosing to WT, Bcrp KO, Pgp KO, and dKO mice. Serum 
concentrations of ketamine at the selected time points were found to be similar 
betweenall four genotypes (Figure 3-2A). Ketamine serum exposure, as measured by 
area under time – concentration curve (AUCinf) by a non-compartment analysis (NCA), 
was also found to be similar between all the genotypes (Figure 3-2B). 
 
 Since Bcrp and Pgp have a higher impact on their substrates serum/ plasma 
exposure after oral compared to IP dosing [268], we collected serum following a 100 
mg/kg oral dose of ketamine in WT, Bcrp KO, Pgp KO and dKO mice. Ketamine serum 
concentrations were significantly higher in the dKO mice compared to the WT mice 
(Figure 3-2C). Ketamine serum exposures (AUCinf), calculated by the non-compartment 
analysis method, were found to be significantly higher in dKO (1.96-fold) and Pgp KO 
(1.52-fold) mice and slightly higher in Bcrp KO (1.20-fold) mice compared to the WT 
mice (Figure 3-2D). Ketamine serum concentration at the 60 minute time point could be 
detected in only two out of six WT mice, but in all of the Bcrp KO, Pgp KO and dKO 
mice. Thus, the last time point for observed concentration is different between WT and 
other knockout mice. Hence, AUCinf was used to compare the exposure between all 
genotypes. Both Pgp KO as well as Bcrp KO showed higher concentrations of ketamine 
than WT mice at earlier time points, indicating a possible alteration in absorption, and 
possibly driving the observed difference in AUCinf with the WT mice. Detailed non-
compartment analysis parameters for both IP and PO PK studies are listed in Table 3-1. 
While the non-compartment analysis allowed comparison of concentration-time curve 
properties, there was no assumption of the compartment, and no information about which 
PK parameters could be causing the difference in AUCinf, although there was the 
suggestion of an alteration in bioavailability because dividing the oral AUCinf by the IP 
AUCinf gave an (F) for the mice that was greatest in the dKO (~27%) > Pgp KO (~24%) 
> Bcrp KO (~17%) ~= WT (~14%). 
 
 
Population pharmacokinetic analysis demonstrates an increase in ketamine oral 
bioavailability in Pgp/Bcrp dKO and Pgp KO mice compared to WT and Bcrp KO 
mice 
 
To better understand the impact of Bcrp and Pgp mediated efflux on PK 
properties of ketamine, we combined both PO and IP PK data in a simultaneous model 
using a population pharmacokinetic approach. This model also assumed that 
bioavailability after IP dosing was equal to one. The final model was a one-compartment 
distribution with zero order absorption for PO and first-order absorption for the IP dosing 
and first-order elimination from the central compartment (Figure 3-3). The one 
compartment model was sufficient to describe these data (Figure 3-4, Figure 3-5 and 
Figure 3-6). The final parameters of population analysis are shown in Table 3-2. 
Transporter genotypes had no effect on clearance or volume of distribution. The small 




Notes: (A) & (C): Mean ketamine plasma concentrations ± SE over time curves after IP 
(n = 3/genotype) and oral (n=6/genotype) ketamine dosing, respectively of FVB WT, Pgp 
KO, Bcrp KO and dKO mice. (B) & (D): Ketamine plasma AUCinf ± SE following IP and 
oral dosing of FVB WT, Pgp KO, Bcrp KO and dKO mice. The AUC was calculated by 
non-compartment analysis using the PK package on R. One way ANOVA with Newman-
Keuls Multiple Comparison Test was used to compare AUCinf.. * p< 0.05, ** p< 0.01, 
*** p< 0.001. 
  
 
Figure 3-2. Ketamine serum exposure in Pgp/Bcrp dKO mice is significantly 





Table 3-1. Noncompartment analysis (NCA) parameters for ketamine IP and PO 













 22.93 ± 
2.33 
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Notes: All pharmacokinetic parameters were calculated by noncompartment analysis 
using PK package in R, with variability calculated using bootstrap t method.  
AUCs are compared by one way ANOVA with Newman-Keuls multiple comparison test 
to compare all the groups. The results in the table show the comparison between each 
transporter genotype vs. WT. * p< 0.05, *** p<0.001. 





Note: Ketamine one-compartmental distribution with zero order absorption for PO and 










Notes: Observed ketamine concentration versus population predicted (A) and (B) 
individual predicted ketamine concentration for the final ketamine population PK model. 
The solid line represents the line of identity and the gray line represent the spline of the 
model. The plots show that the spline is very close to the line of identity, which implies 
that the final model was able to successfully predict the observed ketamine 
concentrations in serum. 
  
 






Notes: (A) & (B) – population weighted residual (PWRES) vs. time and predicted 
ketamine concentration, respectively. (C) & (D) – Individual weighted residual (IWRES) 
vs. time and predicted concentration, respectively.  The solid line represents the reference 
line at zero and the gray line represents the spline of the model. The plots show there was 
no systematic bias in the model over time or concentration range. Majority of the 
population residuals were equally distributed around zero and within ± 2, which indicates 
that the predicted data is within an acceptable range to the observed data. 
  
 





Notes: (A) NPDE vs. time and predicted ketamine concentration, respectively. (B) NPDE 
vs. time and predicted concentration, respectively. The solid line represents the reference 
line at zero and the gray line represents the spline of the model. The plots show a lack of 
model misspecification for the final model. 
  
 










Estimates S.E. p-Value 
F_pop 0.175 0.0072  
θ_Pgp KO  0.227 0.062 0.00028 
θ_dKO 0.514 0.062 < 1e-10 
Tk0_pop (1/hr)  0.104 0.0092  
F2_pop 1 Fixed N.E.  
ka_pop (1/hr)  19.1 1.6  
V1_pop (L/Kg)  9.32 0.35  
CL_pop (L/hr/Kg)  20.2 0.72  
    
ω_BSV     
F 0.0276 0.077  
Tk0 0.32 0.077  
F2 N.E. N.E.  
ka   0.091 0.14  
V1 0.0857 0.061  
CL   0.0781 0.056  
    
σ - RUV    
Proportional 0.341 0.022  
    
F_ (WT and Bcrp 
KO)  
0.175 0.0072  
F_ (Pgp KO)  0.22 0.011  
F_ (dKO)  0.293 0.015  
 
Notes: F – oral bioavailability; F_pop – Population mean oral bioavailability; θ_Pgp KO 
and θ_dKO – estimated coefficient of the effect of categorical covariate Pgp KO and 
dKO on the oral bioavailability; Tk0_pop – population mean oral zero order absorption 
rate constant; F2_pop – population mean intraperitoneal bioavailability which was 
assumed to be 1; ka_pop – population mean first order absorption rate constant for i.p 
route; V1_pop – population mean volume of distribution; CL_pop – population mean 
clearance; ω_BSV – between subject variability; σ - RUV – residual unexplained 





compartment analysis was not observed with the population approach likely due to 
variability in the result. However, both Pgp KO and dKO genotypes had a significant 
impact on population bioavailability (p<0.001). Oral bioavailability (F) for the WT 
population was 17.5%, which significantly increases to 22% in the Pgp KO mice, and 
increases further to 29% in the dKO mice. Hence, altered ketamine PK were observed 
following oral administration to mice lacking Pgp singly or in combination with Bcrp.  




Ketamine-induced duration of loss of righting reflex (dLORR) was significantly 
increased in mice lacking Bcrp and Pgp  
 
 The difference in PO PK between WT and Bcrp and/or Pgp knockout mice, and 
higher plasma and CSF abundance of ketamine in the dKO compared to WT rats led us to 
investigate if ketamine pharmacodynamics are also affected by Bcrp and Pgp. We used 
the ketamine-induced loss of righting reflex (LORR) model in the mouse to study the 
effect of Bcrp and Pgp on ketamine pharmacodynamics. Following itraperitoneal 
ketamine, the median dLORR in the dKO mice was longer than in WT (2.6-fold), Bcrp 
KO (2.1-fold), and Pgp KO (1.3-fold) mice (Figure 3-7A and Table 3-3). In addition, the 
median dLORR was 2-fold longer in the Pgp KO compared to the WT mice. These 
results indicate that both Pgp and Bcrp influence ketamine pharmacodynamics as 
measured by ketamine-induced dLORR. 
 
 To determine whether ketamine brain concentrations were different in the 
transporter KO vs. WT mice we first administered IP ketamine and measured brain and 
serum concentrations at 15 minutes after dosing (n=3 in each genotype group). Our 
HPLC-UV analysis shows a median brain/serum ratio of 1.32 in all genotypes and there 
is no significant difference in brain/serum ketamine concentration between genotypes ( 
Figure 3-8). To understand if the total concentration of ketamine and its metabolites are 
higher in the knockout mice compared to WT mice, we performed a whole brain 
homogenate 3H-ketamine radioactivity study. We administered IP the standard anesthetic 
dose of ketamine (100 mg/kg) spiked with 3H-ketamine and measured the 3H-ketamine 
brain/serum ratio at 1.25 hr. Brain/serum 3H-ketamine radioactivity ratio was not 
significantly different between genotypes with a median ratio of 1.45 in all mice. This 
result is similar to what we observed with the HPLC-UV analysis. Although there was a 
measurable increase in the level of 3H-ketamine in the brains of Pgp and Pgp/Bcrp dKO 
mice, the difference between genotypes did not reach statistical significance ( 
Figure 3-8), despite the remarkable impact of the transporters on ketamine’s 
pharmacodynamic effect (Figure 3-7A), and the significant increase in CSF ketamine 
(measured by LC-MS/MS) in Pgp/Bcrp dKO rats (Figure 3-1). Although Pgp KO vs 
dKO brain 3H- ketamine radioactivity difference reached statistical significance, the 
median dKO/ Pgp KO radioactivity ratio is 0.85, which could be due to differences in 
metabolite concentration between these two genotypes or even variability associated with 





Notes: (A) Comparison of the duration of ketamine (100 mg/kg body weight, IP) induced 
dLORR in WT, Bcrp KO, Pgp KO and dKO FVB mice. (B) The duration of ketamine 
(50, 100 and 200 mg/kg body weight, intraperitoneal) induced LORR in WT mice with or 
without 1.5 hr pretreatment with elacridar (ECD) (100 mg/ kg body weight). Results are 
expressed as median dLORR ± range. Significance is calculated using Mann-Whitney 




Figure 3-7. The duration of IP ketamine induced loss of righting reflex (dLORR) 





Table 3-3. Descriptive statistics of ketamine induced dLORR in male FVB mice 






Bcrp KO  
(n=12) 




Minimum  0.0 0.0 0.0 13.0 
25% Percentile 0.75 3.5 8.0 14.0 
Median 6.0 7.5 12.0*       16.0*** 
75% Percentile 11.5 12.75 17.25 19.0 
Maximum 15.0 17.0 20.0 22.0 
Mean 6.5 8.0 11.58 16.73 
Std. Deviation 5.45 5.69 6.20 3.13 
Std. Error 1.57 1.64 1.79 0.94 
Lower 95% CI of mean 3.04 4.38 7.64 14.62 
Upper 95% CI of mean 9.96 11.61 15.52 18.83 
 
Note: Significance is calculated using Mann-Whitney test by comparing the median 
dLORR in each genotype with the median dLORR in the WT mice. * p < 0.05, *** p< 





Note: Brain ketamine in mice after IP dosing with ketamine (100 mg/kg) + 1 µCi 
ketamine tracer. Results are expressed as median radioactivity (A, B) or brain/serum 
radioactivity ratio ± range (C). Brain/serum concentration ratio (D) was measured by 
HPLC-UV based method after single intraperitoneal dose of ketamine (100 mg/kg). 
Significance is calculated using Mann-Whitney test. * p < 0.05, ** p< 0.01, *** p< 0.001 
  
 






Pharmacological inhibition of Bcrp and Pgp by elacridar increased IP ketamine-
induced dLORR in WT mice 
 
Since we observed altered PK and PD of ketamine in mice with genetic deletion 
of Bcrp and/or Pgp, we investigated whether ketamine PD were also altered by 
pharmacological inhibition of these efflux transporters by using elacridar as a dual 
inhibitor of Bcrp and Pgp. Elacridar dosing and time schedules for pretreatment were 
based on previous reports that clearly demonstrated loss of Bcrp and Pgp function at the 
dose selected [269-271]. Wild-type mice were pretreated with vehicle or 100 mg/kg 
elacridar and 1.5 hrs later ketamine was dosed IP at 50, 100 and 200 mg/kg (n=6 per dose 
group) and duration of LORR measured. The results in WT mice of ketamine treatment 
alone (Figure 3-7B, Table 3-4) demonstrated a dose-proportional increase in drug-
induced dLORR from 50 to 100 mg/kg, but a disproportionately longer increase in 
dLORR at 200 mg/kg. Pretreatment with elacridar significantly increased dLORR in the 
WT mice treated with either 50 or 100 mg/kg ketamine. Based on the exceedingly long 
dLORR with 200 mg/kg ketamine alone, co-treatment at this dose with elacridar was not 
attempted to avoid toxicity. These results show that inhibition of Bcrp and Pgp with the 
dual inhibitor elacridar significantly increased ketamine-mediated dLORR in WT mice.  
 
 
Ketamine-induced dLORR was significantly longer in dKO vs. WT mice after oral 
dosing of 200 mg/kg ketamine 
 
Because ketamine can be taken orally, we compared the effect of the drug 
transporters on its pharmacodynamic effect following oral administration. Oral ketamine 
(100 mg/kg) dosing was insufficient to cause a LORR in any of the mice (data not 
shown) likely because the ketamine serum concentration was lower following oral vs. IP 
dosing (four-fold lower in dKO mice and seven-fold lower in WT mice) (Table 3-1). 
Following oral ketamine (200 mg/kg) treatment, WT mice were all awake within 4 
minutes, while one of the dKO mice died and the others needed to be warmed to wake 
them after 30 minutes, preventing further analysis of this dose (not shown).   
 
 
Ketamine accumulation is lower in MDCKII cells transfected with human BCRP 
and Pgp compared to WT MDCKII cells  
 
The time course of 3H-ketamine cellular uptake was first compared between 
MDCKII cells and MDCKII-PGP-BCRP cells stably expressing the human transporters 
[262]. The 3H-ketamine cellular concentration was significantly greater in MDCKII 
parental cells compared to cells expressing BCRP and PGP at all time points, but uptake 
reached equilibrium by 20 minutes (Figure 3-9A). Likewise, the 3H-ketamine 
intracellular concentration measured at 20 minutes was higher in the parental MDCKII 
cells compared to the dual BCRP/Pgp expressing cells between 0.1 to 5 µM 
concentrations but not at 10 µM concentration (Figure 3-9B). The data also indicated 
that the magnitude of difference in intracellular 3H-ketamine was greater at lower 




Table 3-4. Descriptive statistics of ketamine induced loss of righting reflex 
(LORR) in male WT FVB mice with or without 100 mg/kg oral elacridar 1.5 hours 
before intraperitoneal ketamine dosing 
 

















Minimum 0.00 1.00 6.00 11.00 33.00 
25% Percentile 0.00 2.50 6.00 12.50 33.00 
Median 0.00   3.50* 6.00   14.00* 34.00 
75% Percentile 2.00 4.50 7.50 17.00 42.50 
Maximum 2.00 6.00 8.00 18.00 44.00 
Mean 0.67 3.50 6.60 14.60 37.00 
Std. Deviation 1.03 1.64 0.89 2.61 5.15 
Std. Error 0.42 0.67 0.40 1.17 2.30 
Lower 95% CI of mean -0.42 1.78 5.49 11.36 30.61 
Upper 95% CI of mean 1.75 5.22 7.71 17.84 43.39 
 
Note: Significance is calculated using the Mann-Whitney test by comparing each ECD 







Figure 3-9. 3H-ketamine uptake is lower in the MDCKII BCRP-PGP cells 
compared to MDCKII WT cells 
 
Notes: (A) Time dependent uptake of 3H-ketamine in WT and BCRP-PGP transfected 
MDCKII cells. Ketamine’s intracellular concentration at each time point was compared 
between the WT and BCRP-PGP cells using an unpaired t-test, ** p< 0.01. (B) 3H-
ketamine uptake in WT and BCRP-PGP transfected MDCKII cells at different ketamine 
concentrations. The intracellular concentration of 3H-ketamine at each treatment was 
compared between the WT and BCRP-PGP cells using an unpaired t-test, * p< 0.05, ** 







drug transporters. In support of these findings, Keiser et al (2018) recently published 






Following the unexpected finding that the concentration of the anesthetic 
ketamine was elevated in the CSF and plasma of Pgp-Bcrp dKO compared to wild-type 
rats, this study was performed in mice to determine whether PK and PD of ketamine is 
affected by these transporters, and thus, if ketamine is a possible dual substrate of these 
transporters. We observed ketamine oral exposre increased in the following order: WT < 
Bcrp KO < Pgp KO < dKO (Figure 3-2). Likewise, ketamine-induced dLORR was 
significantly longer in the dKO > Pgp KO > Bcrp KO > WT mice (Figure 3-7). In 
summary, absence of Pgp/Bcrp decreased IP ketamine-induced dLORR (Figure 3-7), 
increased ketamine oral clearance (Figure 3-2D, Table 3-2), and inhibition of these 
transporters by elacridar increased IP ketamine induced-dLORR in wild-type mice 
(Figure 3-7B), demonstrating ketamine is an apparent substrate for both transporters, and 
also indicating a possible drug-drug interaction of ketamine with clinical Bcrp-Pgp 
inhibitors, such as elacridar. 
 
There is mixed evidence in the literature that ketamine might interact with Pgp or 
Bcrp. Ketamine was previously screened for inhibitory activity against BCRP and PGP 
[272] using MDCKII cells stably transfected with human BCRP or MDR1 (PGP) and 
found to not inhibit either transporter. However, high concentrations of cyclosporine 
increased the dLORR in mice [261], which could be due cyclosporine’s ability to inhibit 
ketamine metabolizing Cyps as well as Pgp and Bcrp. The finding that female vs. male 
rats show a longer ketamine induced dLORR [273] might also reflect the fact that there is 
significant sexual dimorphism in rodent Bcrp expression with males vs. females having 
significantly higher levels of Bcrp in liver, intestine and kidney [215]. Co-administration 
of morphine (a Pgp substrate) and ketamine increased ketamine’s brain concentration 
[260], which would be consistent with the ketamine competing with morphine for Pgp 
transport. 
 
We used dLORR to compare the ketamine-induced anesthetic/hypnotic effect in 
mice with different transporter genotypes as dLORR can be used to assign dose-
dependent pharmacodynamic effects [267]. Although we observed a significantly 
increased IP ketamine induced dLORR in the dKO mice compared to WT, Bcrp KO and 
Pgp KO mice (Figure 3-7A), we did not find a significant increase in serum PK after IP 
ketamine dosing (Figure 3-2.A) in the transporter single and dKO mice. However, it is 
not unprecedented for some Pgp substrates to not show systemic PK differences between 
WT and Pgp KO mice following IP dosing (e.g., dasatinib) [268]. Although ketamine 
levels were significantly higher in the plasma of Pgp/Bcrp dKO rats ~ 7 min after IP 
dosing (Figure 3-1), we were unable to detect a significant difference in ketamine PK 
following IP dosing of WT or single transporter KO mice (Figure 3-2A). This might 




metabolism/transport and the difference in blood collection time after ketamine between 
the two studies. PK parameters of ketamine in mice are not extensively reported in the 
literature. From the concentration–time data reported [267] after a 200 mg/kg IP dose, 
and [274] after a 10 mg/kg IP dose in mice, ketamine’s plasma half-life (t1/2) is 
approximately 25 minutes, which is similar to the results obtained in our study (Table 
3-2). The Cmax after IP dosing of 10 mg/kg ketamine was reported between 0.55 µg/ml 
and 1 µg/ml [274, 275], while we observed a Cmax of 7.88 ± 1.38 µg/ml (Table 3-1) after 
100 mg/kg IP dose of ketamine, which is within the dose linear range of the reported 
data. Whereas, Sato et al., after 200 mg/kg IP ketamine dosing in C57Bl/6 mice, reported 
a highest concentration of approximately 30 µg/mL at 10 minutes [267], indicating a 
possible more than dose proportional increase in ketamine exposure beyond 100 mg/kg 
dose. Although ketamine bioavailability in humans after oral dosing has been reported to 
be between 7 and 20% [79, 255, 257], bioavailability after oral dosing in mice is not well 
established. Assuming 100% bioavailability after IP dosing, bioavailability after oral 
dosing in WT mice falls into the same range (F_Pop, Table S1) in our study to that 
observed in humans. 
 
We did not find a significant difference in ketamine brain/ plasma ratio between 
the mice with different transporter genotypes (Figure 3-8), and the increase of CSF 
concentrations in Pgp/Bcrp KO vs. WT rats can largely be explained by the increase in 
plasma concentrations (Figure 3-1).  These data suggest blood brain barrier Pgp/Bcrp do 
not (or may not) impair ketamine brain concentration.  So why are the effects of 
Pgp/Bcrp on ketamine’s pharmacodynamics consistent following either IP or oral dosing, 
mirrored by their dual inhibitor elacridar, and consistent with oral ketamine PK, but 
inconsistent with ketamine’s brain concentration? There are several alternative reasons 
for not finding a measurable effect of the transporters on ketamine brain concentration at 
15 minutes (HPLC-UV) and 1.25 hr (radioactivity). First, most studies that have shown a 
significant effect of Pgp/Bcrp on substrate brain concentrations in vivo have measured 
drug brain levels 4-24 hrs after drug administration to allow brain accumulation and 
hence maximize the difference in brain substrate concentration in the KO vs. WT mice. 
However, because of ketamine’s rapid clearance rate (estimated t1/2= 25 min) (Table 
3-1), brain concentrations would not be measureable hours after dosing. Second, 
ketamine is a high permeability rapid clearance drug and the magnitude of effect of Pgp 
and Bcrp is typically greater for substrates with poor apparent permeability coefficients 
[31], so the magnitude of transporter effect on this type of substrate would be assumed to 
be small. Indeed, terfenadine, another drug with high passive permeability that is a Pgp 
substrate, showed no difference in brain uptake clearance, measured by in situ brain 
perfusion, between WT and Pgp-KO mice [97]. Third, it was previously shown that i.v 
administered ketamine shows significant regional differences in brain exposure (that are 
thought to be pertinent to its effect on anesthesia) during loss of righting reflex in rats, 
and the difference minimizes as the rats regained righting reflex [276], which might 
explain its PD effect, but which would not be captured by measuring ketamine in total 
brain homogenate (as we did in this study). Hence, it is possible that regional 
concentration difference of ketamine could be driving its dLORR effect, and ketamine 
plasma and total brain concentration may not be a good predictor of its PK/PD 




mixture but it is entirely possible that the S- and R-ketamine enantiomers (that have 
enantiomer specific pharmacology) might interact differently with the transporters 
(beyond the scope of this paper). Finally, we think the striking effect of transporter 
genotype on ketamine PD, but not systemic or total brain distribution, for brain acting 
drugs like ketamine that have high passive permeability may, in fact point to the potential 
for missing a Pgp or Bcrp effect if only the PK is measured and used to predict whether 
these transporters would influence the drug’s CNS pharmacodynamic activity.  
 
A population PK model was used for simultaneous analysis of IP and PO PK data 
to enable estimation of fixed parameters and sources of variability. Assuming a 100% 
bioavailability after IP dosing (F2 = 1, Table 3-2), population PO bioavailability in the 
current study was estimated to be 17.5%, which is in accordance to the published reports 
of ketamine bioavailability in humans after oral dosing.  Population analysis of IP and PO 
data together identified a change in oral bioavailability in the Pgp and dKO groups. The 
mean population clearance for ketamine was found to be 20.2 L/hr/kg and volume of 
distribution 9.32 L/kg, suggesting ketamine has very high clearance and volume of 
distribution, which is in accordance with previously published results [253]. 
 
While our in vivo data clearly shows Pgp and Bcrp alter the POPK and dLORR of 
ketamine, we wanted to know if the same is observed in vitro. Previously published 
results show ketamine does not have any interaction with PGP, as substrate or inhibitor. 
However, our data clearly indicates, in a dual BCRP and PGP transfected MDCKII cell 
line, these transporters can effectively reduce ketamine uptake in MDCKII cells at low 
ketamine concentration. We think both the selection of ketamine concentration and also 
time of in vitro assay will have significant effect on the outcome. Also, our in vitro data 
suggests that effect of these transporters will be significant at ketamine exposure lower 
than 10 µM or 2.4 µg/ml. A higher clinical ketamine concentration is required for 
anesthetic effect of ketamine, whereas, lower concentrations are useful for antidepressant 
effect and also often achieved in the ketamine abusers. Thus, our data warrants a possible 
drug-drug or food-drug interaction for antidepressant use of ketamine and in ketamine 
abusers.  
 
The finding that ketamine appears to be a dual Pgp/Bcrp substrate has a number 
of important clinical implications. Ketamine is an anesthetic widely used in animal 
studies as well as human pediatric settings where a short-acting rapid-onset anesthesia is 
needed.  Importantly, it was recently recognized that ketamine can elicit rapid-onset long-
acting anti-depressant activity. However, ketamine is also a significant drug of abuse, 
particularly in Asian countries. Notably, reports have also appeared in the past few years 
that chronic ketamine abusers develop serious lower urinary tract symptoms, voiding 
problems, ulcerative cystitis, and significant damage to the urinary tract [252], although 
there may be individual differences in vulnerability.  Both Pgp and Bcrp are expressed in 
human kidney at the proximal tubule epithelium where they move substrates into the 
urine, and both transporters may be expressed in bladder urothelium [277] at the apical 
epithelium. Given our findings that ketamine is an apparent Pgp/Bcrp substrate it is 
tempting to speculate that BCRP genetic variation, particularly the BCRP Q141K allele 




populations [111] may influence susceptibility to ketamine-induced urinary tract damage. 
Equally important is the potential for co-administered Pgp/Bcrp substrates or inhibitors to 
affect both ketamine bioavailability and urinary tract damage. Indeed, our studies with 
the dual Pgp/Bcrp inhibitor elacridar demonstrated that pharmacological inhibition of the 
transporters can affect ketamine PK. Further, cyclosporine, a known Pgp/Bcrp as well as 
Cyp inhibitor has similarly been shown to affect ketamine dLORR in mice [261]. Many 
therapeutically used drugs and chemicals present in food are inhibitors of Bcrp and Pgp 
[259]. Thus, our results suggest a potential interaction of ketamine with these Bcrp-Pgp 
inhibitors. Moreover, the proposed use of ketamine as an antidepressant may require 
dosing with other antidepressant drugs, some of which are known inhibitors of these 
transporters [278].  
 
We conclude that Bcrp and Pgp can affect the PK and PD of ketamine in mice. 
Using a pharmacological inhibitor of Bcrp and Pgp function our data clearly demonstrate 
DDI potential of ketamine with inhibitors of Bcrp and Pgp. Further studies should be 
carried out to understand the impact of these transporters on ketamine PK, PD and DDI 
potential in humans and whether persons with polymorphic Bcrp taking Pgp inhibitors 








CHAPTER 4.    PHEOPHORBIDE A: IN VIVO BCRP SUBSTRATE TO 





The xenobiotic efflux transporter, breast cancer resistance protein (BCRP), 
encoded by the ABCG2 gene, is an ATP-binding cassette (ABC) sub-family G member 2 
half transporter that is well characterized for its effect on pharmacokinetics and 
pharmacodynamics of multiple drugs [6]. BCRP was originally discovered and named by 
Doyle et al. in breast cancer cell line (MCF7) conferring resistance to anthracycline 
anticancer drugs [62]. Though originally named for its expression on breast cancer cells, 
BCRP is expressed almost ubiquitously on the apical membrane of endothelial and/or 
epithelial cells, where it limits tissue or organ permeability of its substrates [103, 104], as 
well as on stem cells, where BCRP can provide some survival advantages [109, 129]. 
Expression of BCRP is now well-established in liver, kidney, intestine and blood-brain 
and blood-CSF barriers [135, 279]. It has a significant effect on the bioavailability of its 
substrates, administered orally, [177] as well as their brain permeability in mice lacking 
Bcrp or in presence of Bcrp inhibitors [94]. Bcrp is also known to efflux its substrates 
into milk at the mammary gland in rodents [280] and confer protection to the fetus at 
placenta [281]. A wide variety of drugs such as antivirals, antibiotics, calcium channel 
blockers and statins, as well as endogenous and dietary metabolites such as riboflavin, 
folic acid, uric acid, protoporphyrin IX, pheophorbide A and estrone-3-sulfate are 
substrates of Bcrp [6, 9, 54, 101, 124, 129]. Moreover, multiple clinically used drugs, 
such as tyrosine kinase inhibitor lapatinib, HIV protease inhibitor ritonavir, calcium 
channel blockers, immunosuppressant etc., are known inhibitors of this transporter [121]. 
  
Due to its wide range of substrate and inhibitor recognition, as well as significant 
effect on the systemic distribution of its substrates, Bcrp is recognized by the FDA and 
International Transporter Consortium (ITC) as an important transporter which is prone to 
potential clinical drug-drug interactions (DDI) [1, 25, 31, 80, 208]. Except for 
biopharmaceutical classification system class I (BCS class I, high solubility and high 
permeability) compounds, BCRP substrates (victim) are prone to BCRP inhibitor 
(perpetrator)-mediated DDI when they are dosed concomitantly, through the oral route 
[1, 71]. It has also been recognized by FDA that the DDI liability related to BCRP needs 
to be especially considered if the victim drug has potential toxicity concerns in 
distributing tissues [1, 80]. Therefore, a better understanding of systemic inhibition of 
BCRP is also required for substrates whose tissue distribution (such as in brain, kidney, 
etc.) is controlled by the BCRP transporter.  
 
While ITC and FDA have detailed the decision tree and guidelines for 
determination of BCRP substrates, inhibitors and the possibility of clinical DDI [1, 25], it 
has also been recognized that clinically used probe-substrates such as rosuvastatin and 
sulfasalazine are not specific to BCRP [282-284]. Hence, multiple factors, such as 
enzyme inhibition or inhibition of other transporters such as OATP1B1, can lead to 




thereby requiring careful consideration for better understanding of the results [71]. 
Moreover, due to lack of specificity of the clinical inhibitors of BCRP [71], as well as 
expression of multiple transporters in the cell lines used for identification of BCRP 
substrates and inhibitors [279, 285, 286], translation of in vitro observations to in vivo is 
often challenging. In vivo assessment of Bcrp substrates have utilized transporter 
knockout models or imaging techniques such as positron emission tomography (PET) and 
gamma-scintigraphy which are known to have their own caveats [25]. Therefore, a 
suitable assay for Bcrp activity, utilizing a specific and, if possible, same probe, both in 
vitro and in vivo, that is also more economical and with potential high-throughput 
capabilities, will be of immense value.  
 
Pheophorbide A (PhA) is a breakdown product (catabolite) of chlorophyll and is a 
specific dietary substrate of Bcrp [92, 287, 288], with an efflux ratio of 3.15 in cell lines 
overexpressing Bcrp [289]. It is a low solubility, low permeability compound with no 
reported metabolic instabilities. Therefore, PhA might be a potentially suitable candidate 
as an in vitro as well as in vivo probe for investigating Bcrp function according to the 
FDA and ITC guidelines [25] [1]. PhA is also a colored compound with absorption 
maxima between 670 nm and 680 nm, and fluorescence emission maxima between 675 
and 720 nm [290], with typical fluorescence spectra for in vitro studies being 400 nm 
(excitation) and 670 nm (emission). However, a higher excitation (654 nm) and emission 
(750 nm) has also been reported for PhA [291], indicating that PhA fluorescence can be 
detected at the near infrared (NIR) region, thereby making it a suitable candidate for in 
vivo fluorescence measurement in whole animals [292]. 
 
We therefore hypothesized that PhA can be utilized as an in vivo probe for 
assessment of DDI associated with the inhibition of Bcrp at the gastro-intestinal tract 
(GIT) in mice. We utilized a live animal fluorescence imaging technique, using PhA, to 
screen for orally administrated BCRP inhibitors and predict intestinal BCRP-mediated 
DDIs. Our results demonstrate that in vivo fluorescence imaging utilizing PhA can be 




Materials and Methods 
 
 
Chemicals and reagents  
 
 The following chemicals and reagents were purchased: Pheophorbide A (Frontier 
Scientific, Newark, DE, USA), lapatinib and curcumin (Cayman Chemicals, Ann Arbor, 
MI, USA), elacridar (Astatech Inc., Bristol, PA, USA), pantoprazole (Santa Cruz 
Biotech, Dallas, TX, USA), sorafenib and dasatinib (Chemietek, Indianapolis, IN, USA), 









 Wild type (WT) and Bcrp KO Friend Virus B (FVB) male mice (n = 4 each 
group, 10 weeks old) were purchased from Taconic Biosciences, Inc. (Hudson, NY) for 
the knockout mice study. For all other Bcrp inhibitor studies, control mice of FVB 
background (n = 4 for control and each inhibitor treatment group) were purchased from 
The Jackson Laboratory (Bar Harbor, ME, USA). All mice were fed either regular diet 
(Purina catalog# 5013, Largo, FL) or alfalfa-free (AFF) diet (Purina, catalog# AIN-93G, 
Largo, FL) for at least three days to reduce background auto-fluorescence, and they were 
provided water ad libitum. All experimental procedures were approved by the 
Institutional Animal Care and Use Committee of St. Jude Children’s Research Hospital in 
accordance with the U.S. National Institutes of Health guidelines. 
 
 
Cell lines  
 
 Madin-Darby Canine Kidney (MDCKII) cells overexpressing human full length 
wild type BCRP and the parenteral cell lines were kindly provided by Dr. Alfred 
Schinkel and were cultured as described [293]. 
 
 
Determination of Pheophorbide A concentration in rodent food pellet  
 
 Six food pellets each from regular diet and AFF diet were weighed and soaked 
with half parts of water. After 30 minutes, one gram of food pellet was mixed with 5 mL 
methanol and stirred overnight for PhA extraction. The following day, samples were 
centrifuged at 15000 g for 15 minutes and the supernatant collected. The supernatant was 
further centrifuged, filtered and used for measurement of PhA using a modified HPLC-
Fluorescence Detector (HPLC-RF)-based method published previously [294]. 40 µL of 
the final supernatant was injected onto the HPLC system (Shimadzu Prominence, Kyoto, 
Japan) consisting of a LC-20AB quaternary high pressure gradient pump, SIL-20ACHT 
auto sampler and RF-10 AXL fluorescence-detector. Chromatographic separation of PhA 
was achieved using Hypersil ODS C18 column (150X4 mm; 5 µm particle size) fitted 
with Hypersil ODS (C18) Javelin Guard Column (10X4 mm; 5 µm particle size) and a 
gradient elution method with a run time of 10 minutes. The mobile phase for elution was 
80% methanol in 0.5M ammonium acetate (Phase A) and 100% methanol (Phase B) with 
a gradient of: 0 to 2 minutes 60 to 95% methanol, 2 to 8 minutes 95% methanol, 8 to 9 
minutes 95 to 60% methanol, and the run stopped at 10 minutes. Retention time for PhA 
was 3.5 minutes. The PhA peak was identified and fluorescence was measured at 400 
(Ex) and 670 (Em) nm. Analyte area was used for calibration and measurement of 
unknown concentrations against a known PhA concentration prepared in mobile phase A. 










 Mice were kept on AFF diet for at least three days to reduce the background 
autofluorescence. WT and Bcrp KO mice (10 weeks, n = 4/group) were administrated 
PhA (10 mg/kg) by oral gavage, and imaging or blood collection was performed at 
appropriate time points up to 6 hrs after dosing.  For the inhibitor study, oral doses of the 
inhibitors were selected based on clinical relevance or previously demonstrated effects 
(Table 1) and formulated for oral dosing by suspending an appropriate amount of the 
compound in 0.5% hydroxypropyl-methyl- cellulose (HPMC) and 1% Tween 80 (Sigma, 
St. Louis, MO). Bcrp inhibitors elacridar (ECD) (100 mg/kg), lapatinib (LPB) (90 
mg/kg), dasatinib (DSB) (10 mg/kg), sorafenib (SFB) (40 mg/kg), curcumin (CCM) (300 
mg/kg) and pantoprazole (PPZ) (40 mg/kg) were administrated orally, one hour prior to 
oral dosing of PhA. Imaging and blood collection was performed at appropriate times up 
to 6 hours after PhA dosing. All animals were fasted up to 6 hours after PhA dosing. 
 
 
In vivo fluorescence imaging  
 
 Mice were anesthetized by isoflurane anesthesia (2%, inhalation) and placed 
ventrally in the chamber of Xenogen IVIS 200 (PerkinElmer, USA) imaging system. 
Fluorescence images were obtained under anesthesia with a fixed exposure time of one 
second and NIR filter setting of 675 nm excitation and 840 nm emission. Mice were 
repetitively imaged at 0, 1, 2, 3, 4 and 6 hours after PhA administration. Images were 
scaled to a maximum intensity of 1 × 108 photons/s/cm2/sr for visualization. All images 
were analyzed with Living Image® v4.5 (PerkinElmer, USA) to obtain the fluorescence 
intensity in the selected region of interest (ROI) of fluorescence (flux/sec), which was 
selected as a fixed rectangular area around each mouse. For the control and inhibitor 
treatment groups, ROI (flux/sec) for each mouse was normalized by its flux measured at 
0 hr. For the WT and Bcrp KO mice, ROI of the WT mice at 0 hour was used for 
normalizing all fluorescence (ROI) data. Normalized ROI data was used for calculation 
of AUCFL 0-6hr¬ in GraphPad Prism v 5.02. 
 
 
Pharmacokinetic study of PhA 
 
 Immediately after the imaging, as mice came out of anesthesia, 50 µL of blood 
samples were collected by saphenous vein into a microvette capillary blood collection 
tubes (Sarstedt, obtained from Fisher Scientific, Pittsburgh, PA) and serum was separated 
by centrifuging the samples at 5000 rpm for 10 min. Blood samples were collected at 1, 
2, 4 and 6 hrs for measurement of PhA concentration in serum.  
 
 
Measurement of PhA concentration in whole serum  
 
 A fluorescence-based method was used to measure PhA concentration in whole 




concentrations prepared in DMSO into 24 µL of blank serum, collected from mice on 
AFF diet. 25 µL of standard serum concentrations and serum samples collected for the 
study were diluted to 100 µL with distilled water in a 96 well clear bottom black 
polystyrene plate (Cat# 3603, Corning, NY, USA). PhA fluorescence was measured at 
400 nm (Ex) and 670 nm (Em) on a Synergy H4 Hybrid Reader (BioTek, Winooski, VT, 
USA). All fluorescence values were blank-corrected and unknown sample PhA 
concentrations were interpolated from a freshly prepared PhA standard curve (0.02 µM to 
10 µM) and the PhA concentration for each mouse was used to measure AUCSerum 0-6hr¬ 
in GraphPad Prism v 5.02. 
 
 
Ex vivo fluorescence imaging of mouse intestine  
 
 After in vivo imaging, mice were immediately euthanized and blood was collected 
by cardiac puncture. The small intestine was dissected out and fluorescence (675 nm 
excitation and 840 nm emission) images were obtained before and after flushing out of 
intestinal contents with PBS (5 ml, three times). Fluorescence images were obtained 
using one second exposure with a filter setting for near infrared. Images were scaled to a 
maximum intensity of 1 × 108 photons/s/cm2/sr.  
 
 
Fluorescence microscopy of intestinal sections  
 
 Intestinal segments of WT and Bcrp KO mice on a regular diet were washed with 
cold PBS and filled with warm 3% agarose. Paraffin blocks were prepared from agarose 
filled intestines, which were precision-cut for preparing slides for fluorescence 
microscope imaging (Nikon ECLIPSE Ti) 
 
 
In vitro assay for measuring IC50 of Bcrp inhibitors  
 
 A 96 well plate-based assay utilizing control and BCRP overexpressing Madin-
Derby Canine Kidney (MDCKII) cells [295], was used for measuring the IC50 of 
selected BCRP inhibitor drugs using PhA as a probe BCRP substrate [288]. Briefly, 
1*10^4 cells/ well were plated in a 96 well plate and incubated at 37°C till the cells were 
at least 80 - 90% confluent. On the day of the experiment, media was removed, cells were 
washed with PBS and incubated for 30 min with or without BCRP inhibitors prepared in 
100 µL of modified Krebs Ringer buffer (115 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 
1.2 mM NaH2PO4, 2.5 mM CaCl2, 2.5 mM NaHCO3 and 10 mM Glucose) [296]. After 
incubation with inhibitors, media was removed and cells were incubated with 1 µM PhA 
with or without the inhibitor prepared in 100 µL Krebs-Ringer buffer for 2 hrs. 
Fumitremorgin C (FTC) at a concentration of 5 µM was used as a standard BCRP 
inhibitor. After 2 hrs, cells were washed with chilled Dulbecco’s phosphate buffer saline 
(DPBS) twice, 100 µL DPBS added, and fluorescence measured on Synergy H4 Hybrid 
Reader at 400 nm (Ex) and 670 nm (Em). Immediately after fluorescence measurement, 




added to each well, incubated at 37°C for 5 minutes, and luminescence measured. To 
calculate the cell number/well 120000 MDCKII control and BCRP overexpressing cells 
were plated per well and diluted with cell culture media 1:1 up to 937 cells/well (n=6 
each dilution each cell type), incubated at 37°C for 6 hours for the cells to attach. After 6 
hrs, cells are washed with chilled DPBS, after which 100 µL DPBS and CellTiter-Glo ® 
reagent at room temperature was added to the cells, incubated for 5 min at 37°C and 
luminescence measured. First, the results were background-corrected, normalized with 
cell number in each well to calculate PhA fluorescence/ 10^3 cells/ well. Fold change of 
PhA accumulation in MDCKII cells in presence of BCRP was calculated by dividing 
MDCKII-BCRP fluorescence/cell with that of MDCKII. The % inhibition by BCRP 
inhibitors was calculated by the following equation: 
 
% Inhibition = 
(Fluorescence Inhibitor – Fluorescence no inhibitor)
(Fluorescence FTC – Fluorescence no inhibitor)
*100 
 
 IC50 values of the inhibitors were calculated using GraphPad prism v5.02. All 
assays were run at least three times with n = 6 wells per inhibitor or standard inhibitor 
concentration in each assay. Results of all experiments were combined (n=18) to 
calculate final parameters. 
 
 
Statistical analysis  
 
 All serum PhA concentration–time data were plotted as mean PhA concentration 
± SEM and similarly, the whole-body fluorescence data over zero-hour of each individual 
mouse (for the inhibitor study), or over WT mice zero-hour fluorescence (for Bcrp KO 
study), were plotted as mean ratio ± SEM. GraphPad Prism v5.02 was used to calculate 
the area under the concentration – time or fluorescence (flux/sec) ratio – time curve for 
individual mice up to 6 hours (AUCSerum 0-6h or AUCFL 0-6h). Mean AUC±SEM are plotted 
and compared with the control or WT using the unpaired t-test, significance is calculated 






Bcrp KO mice on a regular diet have higher whole-body fluorescence, arising from 
PhA, than WT mice 
 
 It has been previously reported that whole body autofluorescence during live mice 
imaging can be reduced by feeding the mice alfalfa free (AFF) diet, and also by choosing 
an excitation wavelength at the near infrared region (NIR, 700 nm to 1 mm) of light [297, 
298]. To determine differences in autofluorescence, we imaged both WT and Bcrp KO 
mice and found a higher whole-body autofluorescence in the Bcrp KO compared to the 
WT mice, when the mice were fed a regular diet (Figure 4-1A). Alfalfa is known to be a 
source of chlorophyll, and its catabolite pheophorbide A (PhA), which is a known BCRP 




Note: Comparison of fluorescence (Ex675/Em840) in WT and Bcrp KO mice fed a 
regular diet or AFF diet at least for three days (A). Comparison of fluorescence 
(Ex675/Em840) in a regular and AFF diet (B). Fluorescence comparison of known 
concentrations of chlorophyll a (CLPa), PhA and a prototypical Bcrp substrate 
protoporphyrin IX (PPIX) fluorescence with filter setting (Ex675/Em840) (C). 
  
 
Figure 4-1. Autofluorescence derived from dietary PhA is higher in the Bcrp KO 





determine the contribution of PhA to the observed autofluorescence, we imaged both WT 
and Bcrp KO mice after feeding them an alfalfa free (AFF) diet. We observed a total loss 
of whole-body autofluorescence in both WT and Bcrp KO mice (Figure 4-1A). To 
confirm if diet was the source of the observed fluorescence, using the same imaging 
parameters, we compared the regular and AFF diet pellets and observed fluorescence 
only from the regular food pellets (Figure 4-1B). To further confirm the source of 
fluorescence as dietary PhA, we compared PhA, chlorophyll a (CLPa) and another 
fluorescent Bcrp endogenous substrate protoporphyrin IX (PPIX) at a concentration range 
of 0.31 to 10 μM, at the same fluorescence setting (excitation at 670 nm and emission at 
840 nm). We found that only PhA can be detected at 0.31μM, which is almost 10-fold 
lower than the lowest detectable concentration of CLPa (2.5 μM), and that PhA had a 
higher fluorescent intensity then CLPa at each concentration (Figure 4-1C).  
 
 
Pheophorbide A is present in regular mouse diet, but not in AFF diet 
 
 To further verify that the source of fluorescence from regular diet is PhA, and that 
its absence reduces whole-body fluorescence in mice, we analyzed the amount of PhA in 
mouse food pellets using an HPLC-RF- based method (Figure 4-2). We observed that 
PhA is present only in the standard (Figure 4-2A) and the regular food pellet extract 
(Figure 4-2B), but not in the AFF pellet extract (Figure 4-2C). Using a calibration of 
known concentrations of PhA, we found the PhA concentration in the regular diet to be 
1.71 µg/gm of food pellet. Assuming daily food intake for a 30 gm mouse is 6 gms, it can 
be estimated that a mouse on a regular diet consumes 343 µg PhA/kg body weight daily.  
 
 
Bcrp gene deletion leads to higher absorption of PhA in mouse enterocytes  
 
 During in vivo live animal imaging, we observed the maximum fluorescence in 
the intestinal region of Bcrp KO mice (Figure 4-1A). This was unanticipated since we 
expected a higher level of PhA absorbance in the Bcrp KO mice. Therefore, to determine 
if this fluorescence was due to trapping of PhA in the intestinal enterocytes we analyzed 
the localization of fluorescence in WT and Bcrp KO mice fed a regular diet, by ex vivo 
imaging of isolated intestine (Figure 4-3A) and fluorescence microscopy of intestinal 
sections (Figure 4-3B). A high fluorescence intensity was observed in the upper 
intestinal segment of both WT and Bcrp KO mice (data not shown). But after washing 
and removal of food contents, the upper intestinal segment of Bcrp KO mice displayed 
considerably higher fluorescence, compared to that in WT mice (Figure 4-3A). 
Fluorescence microscopy of transverse sections of a paraffin fixed intestinal segment 
showed higher fluorescence in the enterocytes of the Bcrp KO mice, compared to the WT 
(Figure 4-3B), confirming that the absence of Bcrp at the enterocytes may lead to higher 





Notes: Representative HPLC-RF run profile of 2.5 μM known concentration of PhA (A), 
methanol extract from regular rodent diet (B), and the alfalfa free (AFF) defined diet (C). 
PhA peak or peak position is indicated in each graph.   
  
 





Notes: Ex vivo image comparison of intestinal segments of WT and Bcrp KO mice on a 
regular diet, after flushing out the gut contents with saline (A). Microscopic examination 
of cross-sectional images of upper intestine from WT and Bcrp KO mice on regular diet; 
blue is Dapi stain for nuclear localization) and red is Pheophorbide A using the Cyanine5 
Ex/Em wavelengths (B). 
  
 





Oral absorption of PhA is greater in Bcrp KO mice treated with exogenous PhA  
 
 To eliminate background fluorescence and increase the uniformity and amount of 
PhA exposure, WT and Bcrp KO mice were fed an AFF diet for 3 days, then 
administered PhA orally at a dose of 10 mg/kg and fasted for 6 hrs. Representative 
images at 2 hrs after PhA dosing displayed significantly greater whole-body fluorescence 
in the Bcrp KO compared to WT mice, as shown in Figure 4-4A. The whole-body 
fluorescence at different time-points, normalized to the fluorescence in WT mice at 
baseline, when plotted against time after dosing, exhibited significantly higher 
fluorescence in Bcrp KO mice across all observed time points (1, 2, 4 and 6 hrs) (Figure 
4-4B). Quantification of the area under fluorescence ratio time curve up to 6 hrs (AUCFL 
0-6h) showed a significant increase (3.5-fold) in fluorescence in the Bcrp KO compared to 
WT mice (Figure 4-4C). We also measured the serum concentration of PhA in the same 
experiment at 1, 2, 4 and 6 hrs. The serum concentration of PhA in the Bcrp KO mice 
was also found to be significantly higher across all observed time points compared to WT 
mice (Figure 4-4D) with a 50 fold increase in area under concentration-time curve 
calculated up to 6 hrs (AUCSerum 0-6h) (Figure 4-4E). These results, showing a 
significantly higher fold increase of PhA fluorescence, both whole-body and serum, in 
Bcrp KO mice compared to WT, suggest that orally administered PhA can be utilized to 
capture a range of inhibition by Bcrp inhibitors, and thereby identify Bcrp-mediated 
drug-drug interactions (DDIs) in mice. 
 
 
Selected Bcrp inhibitors exhibited comparable in vitro IC50 values with PhA as 
reported previously 
 
 To further test our hypothesis that PhA can be used as an in vivo probe for 
identification of intestinal Bcrp-mediated DDIs, we selected known Bcrp inhibitors as per 
FDA guidance based on their [(Clinical dose/250 ml)/IC50 or Igut/IC50] (Table 4-1), 
where Igut is the maximum human dose in the apparent human gut fluid volume of 250 
ml. While IC50 values of the selected inhibitors (except dasatinib) were reported in the 
literature, a wide variety of Bcrp probe substrates as well as cell lines were used for these 
IC50 measurements. Using PhA as a BCRP probe substrate, we used MDCKII-BCRP 
cell-based assays to determine the IC50 of the selected BCRP inhibitors (Figure 4-5). 
Lapatinib (LPB) was found to be the strongest BCRP inhibitor with a measured IC50 of 
40 nM, followed by elacridar (ECD) (0.21 µM), sorafenib (SFB) (2.18 µM), curcumin 
(CCM) (2.58 µM), pantoprazole (PPZ) (11.19 µM) and dasatinib (DSB) (22.76 µM). The 
IC50 of these inhibitors were found to be similar to those reported in the literature using 
different BCRP probe substrates (Table 4-1), except for PPZ, for which the observed 
IC50 was 2-fold higher than the reported IC50 (5.5 µM). Assuming a 0.8 mL mouse 
stomach volume, Cgut/IC50 was ≥ 10 for all the inhibitors (Table 4-1), indicating a 
possible drug-drug interaction observation with orally dosed BCRP substrates in mice, 






Notes: Representative image comparing of PhA fluorescence (Ex675/Em840) in WT and 
Bcrp KO mice, 2 hrs after oral administration of 10 mg/kg PhA (A).  Fluorescence 
intensity over zero- hour WT fluorescence-time profile up to 6 hours following 10 mg/kg 
of PhA oral administration in Bcrp WT and KO mice (n=3) (B). Comparison of Area 
under the fluorescence ratio time curve up to 6 hrs (AUCFL 0-6h) in Figure B calculated 
using GraphPad Prism v5.02 (C). Comparison of PhA serum concentration at 1, 2,4 and 6 
hrs from the WT and Bcrp KO mice dosed 10 mg/kg PhA (D) and the associated 
AUCSerum 0-6h (E). Results are presented as means ± SEM; and significance is calculated at 
p < 0.05 by comparing the means with unpaired t-test. *** P < 0.001. 
 
 





Table 4-1. Results of all in vitro, in vivo experiments and literature data-based 
comparisons 
 





Mol. Wt. (gm/mol) 488.01 464.83 383.37 563.65 368.38 581.06 
Pred. Sol. (µM) 
(DrugBank) 
26.23 3.68 1291.18 4.99 15.61 38.38 
Pred. logP 
(DrugBank) 
2.77 4.12 2.11 6.81 3.62 5.18 
Reported IC50 (µM)  3.11 5.52 0.313 1.64 0.0255 
        
Clinical 
information 










Cmax (µM)  6.45 7 6.5 6 0.327 6  4.2 6 
Igut/IC50  1110 67 6 9200 6 14000 6 210000 6 
Cmax/IC50  2.08 1.2 6 1.1 6  170 6 
Possible DDI No Yes Yes Yes Yes Yes 
        
PK information 
from mice 
Dose (mg/kg) 10 40 40 100 300 90 
Cmax (µM) ~ 0.7 10 21 1  0.78 8 ~0.06 12 ~ 10 11 
Tmax (Hr) 0.25- 2 1 9  8 1.5 0.5-1 
t1/2 (Hr)    20 12 3 
       
Prediction of 
possible outcome 
in mouse based on 
selected dose and 
observed IC50 
Observed IC50 (µM) 22.76 2.18 11.19 0.21 2.52 0.04 
Cmax/ IC50 0.03 9.63  3.71 0.02 250 
Oral Dose for mice 
study (mg/kg) 
10 40 40 100 300 90 
Cgut (µM) 639 2689 3260 5544 25449 4840 
Cgut/ IC50 28 1233 291 26400 10098 121000 
Cgut_soluble/ IC50  1.2 1.7 115.4 23.7 6.2 959.5 
Expected Oral DDI No May be Possible Yes Yes Yes 
        

















Fold Change over 
control 
1.24 1.45 2.02 5.17 7.79 13.78 
Observed DDI? No May be Yes Yes Yes Yes 
















Fold Change over 
control 
1.2 1.44 0.84 2.17 2.31 2.4 
Observed DDI? No May be No Yes Yes Yes 
 
Notes: Mol. Wt. = molecular weight; Pred. Sol = Predicted aqueous solubility; Igut = Clinical 
dose / 250 mL; Cgut = mouse dose / 0.8 mL (mouse gut fluid volume); Cgut_soluble = Pred. 
Solubility 
 






Notes: Mean % increase in Pheophorbide A accumulation ± SEM in the MDCKII cells 
overexpressing BCRP in presence of selected Bcrp inhibitors was plotted against log 
transformed inhibitor concentration. IC50 was determined using GraphPad Prism v5.02. 
  
 






Bcrp inhibitors increase whole body and serum fluorescence of PhA 
 
 Based on reported literature, the selected drugs were expected to cause drug-drug 
interactions with Bcrp substrates when administered concomitantly, via an oral route, and 
increase systemic exposure (blood/ plasma / serum AUC) of the substrate. Therefore, we 
dosed the inhibitors orally, along with the Bcrp probe substrate PhA, and measured whole 
body fluorescence and serum PhA concentrations. Whole-body fluorescence imaging in 
mice treated with the Bcrp inhibitors LPB, ECD and CCM displayed higher fluorescence 
compared to the control-treated mice (Figure 4-6). After quantification of fluorescence 
flux/second and normalization with baseline fluorescence from the same mice, these 
values were plotted against time after dosing (Figure 4-7A and B), and AUCFL 0-6h was 
calculated for all the inhibitor-treated and control mice. LPB exhibited the maximum fold 
increase (2.4-fold) of AUCFL 0-6h over control mice, followed by CCM (2.3-fold), ECD 
(2.2-fold) and SFB (1.44-fold) (Figure 4-7C). PPZ showed a decrease in AUCFL 0-6h 
compared to control (0.84-fold) and DSB did not significantly increase the AUCFL 0-6h 
over control mice.  
 
 Serum fluorescence spectra of PhA was measured and compared with a standard 
PhA sample to confirm the identity of PhA in each sample. Representative PhA spectra 
of control (CT) mice, curcumin (CCM) and lapatinib (LPB) treated mice are showing 
PhA peak at 670 nm in each sample corresponding to the standard PhA peak (Figure 
4-8). 
 
The PhA serum concentration-time plots after treatment with Bcrp inhibitors 
displayed a similar trend as observed with whole body fluorescence (Figure 4-7D and E), 
with a similar rank order of inhibitor-mediated increase in AUCSerum 0-6h observed as was 
seen for AUCFL 0-6h (Figure 4-7F). LPB treatment had the maximum increase in PhA 
fluorescence (13.8-fold), followed by CCM (7.79-fold), ECD (5.2-fold), PPZ (2.02-fold) 
and SFB (1.45-fold). No significant effect of DSB was found on serum PhA 
concentration consistent with the lack of effect on PhA whole-body fluorescence. PPZ 
showed a significant increase in serum PhA AUCSerum 0-6h, but not AUCFL 0-6h, 
measured by the whole-body fluorescence data. Whereas Cgut/IC50 for all inhibitors were 
≥ 10, Cgut_soluble/IC50 values (Table 4-1) displayed a better correlation with the observed 
fold change by Bcrp inhibitors, where Cgut_soluble is the predicted solubility of the 





 The ATP-binding efflux transporter Bcrp plays a significant role in controlling 
xenobiotic exposure by reducing absorption and increasing elimination of its substrates 
[129]. Drug-drug interactions (DDI) associated with Bcrp have been reported for Bcrp 
substrates such as topotecan [299], sulfasalazine [259] and rosuvastatin [300]. Based on 
the clinical evidence and importance of its transporter effect, Bcrp has been recognized 
by FDA and ITC as having the potential for causing clinical DDI [1, 25, 80]. Due to 




Note: Six hour representative image comparing fluorescence (Ex675/Em840) in control 
mice orally administrated 10 mg/kg of PhA ± Bcrp inhibitors, 1 hr prior to PhA 
administration as indicated in the method. 
  
 
Figure 4-6. Inhibition of BCRP increased whole body fluorescence in control 





Notes: Whole body fluorescence (flux/sec) was normalized to the zero-hour fluorescence 
of the same mice and data plotted as mean fluorescence ratio ± SEM vs. time (hrs), for 
the tyrosine kinase inhibitors (A) and other inhibitors (B). AUCFL 0-6h calculated for each 
mouse and plotted as mean ± SEM (C). PhA serum concentration- time plot for the 
control and tyrosine kinase inhibitors (D) and other inhibitors (E) plotted as mean ±SEM 
and the associated AUCSerum 0-6h calculated using GraphPad Prism v5.02 (F). Significance 
is calculated by comparing the mean AUC after inhibitor treatment with that of control 




Figure 4-7. Inhibition of BCRP increased whole body fluorescence as well as the 





Note: Mean fluorescence ± SD spectrum with excitation at 400nm and emission at 670 
nm for the PhA standard prepared in serum, control serum from PhA (10 mg/kg) dosed 
mice and inhibitor (LPB and CCM) treated mice. 
  
 
Figure 4-8. Fluorescence spectra showing identity of the PhA peak used for 





enzymes, interpretation of clinical DDI studies utilizing probe substrates is often difficult. 
Therefore, a more selective or specific probe-based assay, or utilization of a biomarker 
for elucidation of Bcrp-mediated DDI is highly desirable.  
 
PhA has been documented to be a substrate of human BCRP in cell lines [288] 
and we now show it is a substrate for mouse Bcrp as well (Figure 4-3). Mouse 
Abcg2/Bcrp has 81% sequence homology with human ABCG2/BCRP [55], and there is 
overlapping substrate and inhibitor specificity of human and murine ABCG2 [301]. 
Hence, the substrate and inhibitor profile of BCRP in humans should be comparable to 
that in mice. Bcrp KO mice of FVB background [92] are an established model for 
identification of clinical Bcrp substrates and inhibitors. Therefore, our experimental 
findings of PhA absorption in WT and Bcrp KO mice can likely be extrapolated to 
humans as well.  
 
Using a LC-MS/MS based analytical system to compare the plasma of WT and 
Bcrp-Pgp double knockout (dKO) rats, we detected Pheophorbide A (PhA) only in the 
plasma of the dKO rats, but not in any WT rat plasma (Chapter 2). This observation, 
along with reports that PhA is a selective Bcrp dietary substrate [92, 288], prompted us to 
further investigate the possibility of utilizing PhA as an in vivo probe for identification of 
DDI associated with Bcrp. By utilizing an HPLC-Fluorescence Detector based analytical 
method, we determined PhA content in normal rodent chow to be 1.7 μg/gm of regular 
rodent food pellet (Figure 4-2). PhA is a known catabolite of chlorophyll [287], present 
in regular human diet. For example, chlorophyll content in 1 cup of spinach is 24 mg, ½ 
cup of parsley is 19 mg and 1 cup of sugar snap peas is 24 mg 
(https://draxe.com/chlorophyll-benefits/). It has also been previously reported that the 
plant monooxygenase enzyme can catabolize PhA formation from chlorophyll, thus PhA 
is present in the regular diet in human [302, 303]. Therefore, complete absence of PhA in 
the plasma of WT rats, fed a regular diet, creates the possibility of utilizing PhA as a 
dietary marker of Bcrp transporter function. Also, since PhA is present in regular diet, it 
poses a phototoxicity risk due to unwanted exposure to PhA from food when taken with a 
Bcrp inhibitor, like pantoprazole.  
 
PhA emits fluorescence at the NIR wavelength, thereby creating the exciting 
possibility of utilizing PhA as a probe for in vivo live animal imaging. Whole body 
autofluorescence in rodents has been previously reported to be affected by chlorophyll 
content of food and alfalfa free (AFF) diet [287]. Using whole animal fluorescence 
imaging at 670 nm (Ex) and 840 nm (Em), that corresponded to PhA fluorescence 
(Figure 4-1C), we observed a higher whole-body fluorescence in the Bcrp KO mice, 
compared to the WT mice (Figure 4-1A). Based on lack of background autofluorescence 
when mice are on AFF diet (Figure 4-1A), along with complete absence of PhA in the 
AFF diet (Figure 4-2C), we decided to feed mice an AFF diet for at least three days for 
the majority of our studies to eliminate the effect of background fluorescence. In 
addition, regular food pellet extract, as analyzed by the HPLC-RF based method, 
indicated the presence of an additional peak with similar fluorescence intensity as PhA 
(Figure 4-2B). Therefore, we administered mice fed an AFF diet an oral gavage of 10 




function and for screening Bcrp inhibitors for oral DDI. Pheophorbide A has already been 
reported to be used at a dose of 30 mg/kg intraperitoneally, or 10 mg/kg intravenously, 
for photodynamic therapy of oral squamous cell carcinoma (OSCC) in mice [304]. 
Chlorophyll, the catabolic precursor of PhA, is also present in regular diet in humans, as 
discussed above. Therefore, our current findings utilizing the 10 mg/kg PhA oral dose in 
mice may have a possible significant human translational significance.  
 
We observed a difference in PhA excitation and emission wavelengths in vivo in 
mice (670 nm (Ex) and 840 nm (Em)) vs. in vitro (400-410 nm (Ex) and 670 nm (Em)). 
This is not unexpected because live animal fluorescence is affected by a significant 
amount of absorbance and scattering of light due to the presence of a complex 
environment comprised of plasma proteins and tissue barriers [298]. This is critical since 
selecting the Ex/Em wavelength parameters based on in vitro PhA fluorescence would 
have resulted in overlooking its fluorescence in vivo.  
 
High fluorescence in the intestinal region, but not systemically, in WT mice is due 
to PhA in the luminal contents. PhA is a low solubility and low permeability compound, 
and as a Bcrp substrate is poorly absorbed.  Indeed, PhA has been reported to be mainly 
cleared unabsorbed in feces [287]. Interestingly, ex vivo fluorescence comparison of the 
intestinal segments of WT mice fed a normal PhA-containing diet, after flushing out 
intestinal contents, revealed a lower fluorescence in the duodenum compared to higher 
fluorescence in the jejunum and ileum (i.e., there is lower Bcrp expression in jejunum 
and ileum and hence a small amount of PhA is trapped in the lower small intestine of WT 
mice) (Figure 4-3A) and is consistent with the gradient of Bcrp expression reported in 
rodent intestine (higher in the duodenum than in the ileum), and being the lowest in the 
colon [105]. The increased fluorescence in the intestinal region in Bcrp KO mice (Figure 
4-3A), in spite of increased systemic absorption from the lumen, was due to trapping of 
PhA in the enterocytes in the absence of Bcrp mediated efflux (Figure 4-3B).  
 
We found a higher PhA whole body fluorescence in the Bcrp KO compared to 
WT mice, leading to a significantly higher (3.5-fold) area under the fluorescence ratio – 
time curve up to 6 hrs (AUCFL 0-6h) (Figure 4-4B and C). Comparing the serum PhA 
concentration in the same experiment, we observed a 50-fold increase in PhA area under 
serum concentration – time curve up to 6 hours (AUCSerum 0-6h) in the Bcrp KO compared 
to WT mice (Figure 4-4D and E). The concentration of PhA detectable in the WT mice 
after oral gavage in this study were at the lower limit of quantification (LLOQ), whereas 
in Bcrp KO mice serum, the concentration of PhA was significantly higher than LLOQ. 
This data is in conformation with our previous observation in rats, where PhA could only 
be detected in the Bcrp-Pgp dKO and not in the WT rat plasma, and also reports by 
Jonker et al. that Bcrp KO mice are 100-fold more sensitive to developing phototoxicity 
from PhA [92]. The difference in fold increase between whole body fluorescence (3.5-
fold) and serum concentration (50 fold) could be due to a higher background fluorescence 
in the whole-body fluorescence imaging, especially from unabsorbed PhA remaining in 
the gut, compared to the very low concentration of PhA in serum of WT mice. Thus, 
serum fluorescence of PhA might be a more useful tool than whole body fluorescence for 




using whole body fluorescence of the Bcrp substrate PhA to screen for oral DDI come 
from: (a) the ease and noninvasive nature of its detection, (b) that animals do not need to 
be sacrificed can be used repeatedly, (c) the ability to longitudinally monitor changes in 
Bcrp substrate tissue distribution into other organs in the presence of systemic inhibition 
of Bcrp, and (d) the possibility of transforming it into a better high-throughput method.  
 
The dynamic range of PhA fluorescence, both whole body, and in serum, of WT 
and Bcrp KO mice, allowed us to rapidly examine the effect of Bcrp inhibitors on the 
whole-body fluorescence as well as serum concentration of PhA. For an orally 
administered Bcrp inhibitor drug, if [(dose/250 ml) / IC50 for Bcrp] ≥ 10, or Igut/IC50 ≥ 
10, FDA recommends analysis of possible oral Bcrp inhibition-mediated DDI [1]. Hence, 
we specifically chose drugs that would be predicted to cause a Bcrp-mediated DDI in 
vivo. For pantoprazole- (PPZ), elacridar- (ECD), curcumin- (CCM) and lapatinib (LPB)-
mediated clinical DDI liability, Igut/IC50 was obtained from literature reports, and are 
significantly higher than 10 [71]. For sorafenib (SFB), Igut/IC50 when calculated from 
maximum reported dose of 400 mg BID data [305] and was found to be > 10 (Table 4-1). 
Clinical DDI liability of dasatinib with Bcrp substrates was not reported, and hence was 
selected as a negative control in the experiment.  
 
Based on reported pharmacokinetic (PK) parameters in mice, and associated 
clinically relevant doses and observed IC50 values, we also calculated the Igut/IC50 in 
mice assuming the gut volume in mouse to be 0.8 mL [306]. For the selected inhibitors 
Igut/IC50 values in mice are also ≥ 10 and thus, according to FDA criteria, are expected 
to show preclinical DDI in mice (Table 4-1). Since, only the soluble fraction of the drug 
would be available at the enterocytes to inhibit Bcrp, we also calculated the gut soluble 
concentration of the drug/ IC50 (Cgut_soluble/ IC50), based on the predicted solubility 
values obtained from DrugBank database (https://www.drugbank.ca). Considering these 
Cgut_soluble/ IC50 values, we might potentially rule out DDI for SFB and DSB in mice. 
Cgut_soluble/ IC50 for CCM was also < 10. Kusuhara et al. dosed 300 mg/kg CCM 1 hr 
prior to sulfasalazine oral dosing in mice and observed an 8-fold increase in sulfasalazine 
plasma AUC [259]. We have used the same curcumin dose and thus we expected CCM-
mediated inhibition of gut Bcrp would increase PhA serum AUC.  
 
FDA also indicated that assessment of DDI is not required if there is no safety 
concern for the Bcrp substrate distribution in tissues [1]. Therefore, apart from inhibition 
of Bcrp at the gut, consideration is also required for systemic inhibition of Bcrp. To 
assess systemic Bcrp inhibition, we considered the reported Cmax/IC50 for the Bcrp 
inhibitor drugs [71]. Systemic inhibition for SFB, ECD and LPB were expected based on 
the published Cmax in mice (Table 4-1) and observed IC50 values. But, for SFB, reported 
Cmax is associated with an enabling formulation [166], compared to a suspension 
formulation used in our study. Therefore, we would expect a lower Cmax and thus lack of 
systemic DDI in mice. Of note, based on clinically obtained Cmax of sorafenib [305], 
Cmax/IC50 is 2, suggesting that a systemic Bcrp inhibition by sorafenib may be expected. 
However, for a highly plasma protein bound drug such as sorafenib, unbound fraction in 
plasma (Fu) is 0.3% [307]; unbound concentration in plasma may not be sufficient to 




Physiochemical properties such as logP and solubility values for the selected 
drugs were obtained from DrugBank database (https://www.drugbank.ca) to understand 
the possible disposition characteristic and gut solubility. Among the selected inhibitors, 
LPB, SFB and ECD have high logP or lipid permeability, thus probably have higher 
tissue distribution compared to the other inhibitors. Together with their low IC50 value 
for Bcrp, ECD and LPB might show systemic inhibition of Bcrp. On the other hand, PPZ 
has the highest predicted solubility, thus probably having fast absorption as well as faster 
transit than other selected inhibitors.  
 
Our results with whole body fluorescence imaging (Figure 4-6 and Figure  
4-7A-C) show increased whole-body fluorescence of PhA in mice administered the Bcrp 
inhibitors LPB, ECD and CCM. The AUCFL 0-6h for LPB, CCM and ECD were 2.4, 2.3 
and 2.2-fold significantly higher than the control mice. A similar trend was observed for 
the serum concentration data (Figure 4-7D-F), with LPB having the highest fold change 
(13.8 fold) increase compared to controls, followed by CCM (7.8 fold), ECD (5.17 fold), 
PPZ (2.02 fold) and SFB (1.45 fold). Taken together, the serum concentration and 
imaging data provide evidence that PhA can be used for identification of oral DDIs 
associated with Bcrp. The only exception between these two methods was the observed 
lower AUC FL 0-6h for PPZ. Since PPZ solubility is the highest among all selected 
inhibitors, it is possible that it has a faster GI transit compared to the other drugs, leading 
to short-lasting inhibition of Bcrp at the upper gastro intestinal tract (GIT). Another 
possibility is the effect of altered pH on PhA fluorescence in presence of proton pump 
inhibitor PPZ. When mice were administered CCM with PhA, we observed a 7.79-fold 
increase in serum fluorescence of PhA, while Kusuhara et al. observed an 8-fold increase 
in sulfasalazine plasma exposure in presence of CCM at a dose of 300 to 400 mg/kg 
[259], further corroborating that PhA might be utilized as an in vivo probe for Bcrp 
function. FDA Drug Interactions & Labeling guideline also mentions that a ≥ 1.5-fold 
increase in sulfasalazine AUC when concomitantly dosed with a Bcrp inhibitor should be 
considered an in vivo inhibition of Bcrp. According to these criteria, PPZ, ECD, CCM 
and LPB showed in vivo inhibition of Bcrp-mediated PhA transport in our studies.  
 
Measurement of serum concentration of PhA by fluorescence spectrometry-based 
methods has some advantages of creating a faster and less expensive method for faster 
decision-making processes. However, we recognize that this method might be less 
specific than an HPLC-RF based method. When we used an HPLC-RF based detection of 
PhA for 100 mg/kg oral dose of PhA (data not shown) in WT, Bcrp KO and ECD-
pretreated mice, PhA could be detected at the maximum concentration only in the serum 
of Bcrp KO and ECD-treated WT mice, implying PhA as a source of serum fluorescence. 
For our screening studies, we used a 10 mg/kg PhA dose; thus, the expected PhA 
concentrations would be below the detection limit of our analytical method. Therefore, 
we utilized a whole serum fluorescence spectrometry-based method and confirmed the 
detection of PhA by obtaining similar fluorescence spectra between PhA standard 
concentration, blank serum and inhibitor-treated serum (Figure 4-8) groups, implying 





In our experiments, the Bcrp inhibitors were administered to the mice 1 hr prior to 
PhA dosing. A similar (1-hr prior) dosing schedule was also utilized to investigate CCM-
mediated DDI with sulfasalazine in mice [259]. However, according to the FDA 
guidelines, a concomitant dosing of the two drugs is suggested. Due to fast absorption of 
compounds like dasatinib, with a reported Tmax as early as 15 minutes in mice [308], it is 
possible that in our study we have underestimated the effect of Bcrp inhibition at the GIT. 
Therefore, further investigation and careful observation might be required for 
identification of DDIs of weaker Bcrp inhibitors such as dasatinib.  
 
Further studies are also required to find out if PhA can be used as a probe for 
systemic Bcrp inhibition as well, such as with lapatinib known to exhibit systemic Bcrp 
inhibition. For utilization of this method to its fullest potential, a better understanding of 
PhA pharmacokinetic properties would also be required with more emphasis on its tissue 
distribution and clearance.  
 
To our knowledge, this is the first report that shows a fluorescent Bcrp substrate 
PhA can be utilized for identification of in vivo DDI due to inhibition of Bcrp at the GIT 
and creates an opportunity for a high throughput in vivo Bcrp inhibitor assay. Also, 
utilization of serum fluorescence by simple spectrometry makes this method unique in 
that minimal technical resources are required for identification of Bcrp substrates. 
Furthermore, this method is in conformation with the 3R principal (replacement, 
reduction and refinement), as it would reduce the requirement of invasive studies thus 
significantly reducing the number of lab animals, at the same time creating high quality 
reliable data.  
 
In conclusion, our study shows that dynamic fluorescence imaging in live animals 
utilizing PhA as a Bcrp probe can be used for identification of Bcrp inhibitors and to 
understand the DDI liability of such inhibitors. Further studies are required to determine 
if we can use this compound as a dietary marker of BCRP activity in the clinic, and that 












 The overall goal of this research work was to understand the function of BCRP 
and PGP efflux drug transporters in context of their endogenous, xenobiotic and dietary 
substrates. We found (1) a significant impact of Bcrp and Pgp on the endogenous 
metabolome encompassing dietary, gut microbiome as well as host-derived metabolites, 
(2) a distinct effect of these transporters on the pharmacokinetics and pharmacodynamics 
of the anesthetic/analgesic drug ketamine, and (3) that dietary Bcrp substrate 
Pheophorbide A may be utilized as an in vivo marker for possible identification of Bcrp 
inhibition-mediated drug-drug interactions.  
 
 We compared the CSF and plasma metabolomes as well as gene expression in 
kidney, liver and brain frontal cortex between wild-type (WT) and Bcrp-Pgp double 
knockout (dKO) rats to understand the systemic effect of these transporters in rats 
(Chapter 2). Our results showed a significant difference in both CSF and plasma 
metabolomic signatures between the WT and dKO rats. The most significant feature in 
the plasma metabolome was altered fatty acid metabolites, which was further supported 
by the altered genes and metabolites associated with the peroxisome proliferator activity 
receptor (PPAR) pathway. We also observed changes in gut microbiota-derived 
metabolites in both CSF and plasma of dKO rats, indicating a possible change in the gut 
microbiome, as well as an effect of Bcrp and/or Pgp in regulating the absorption of 
microbiota-derived metabolites in blood, and also their permeability in CSF. 
Transcriptomic analysis further revealed alterations in pathways related to fatty acid 
metabolism, lipopolysaccharide response (again indicating an altered microbiome), 
circadian rhythm as well as oxidative stress response in the dKO rats, when compared to 
WT rats. Analysis of the altered CSF metabolites, utilizing an in silico approach and 
literature-based evidence, identified metabolites which may be putative Bcrp substrates. 
Overall our results identified a significant impact of Bcrp and Pgp drug transporters on 
the endogenous metabolome and biological pathways, without any dramatic 
compensatory changes in transporter or enzyme expression.  
 
 Apart from alteration of known Bcrp endogenous substrates, such as riboflavin 
and urate, we observed a significantly higher abundance of ketamine, an 
anesthetic/analgesic drug used in this study to anesthetize the rats, in the plasma and CSF 
of dKO rats. Thereafter, utilizing mice with genetic deletion of Bcrp, Pgp and both Bcrp-
Pgp, we showed that pharmacokinetics (PK) as well as pharmacodynamics (PD) of 
ketamine were affected by both Bcrp and Pgp transporters (Chapter 3). A recently 
published article also confirmed our finding that ketamine is a substrate of Pgp [98].  
 
 Our plasma metabolomics identified Pheophorbide A (PhA), a catabolite of 
chlorophyll found in regular rodent diet, only in the plasma of dKO rats, but not in WT 
rat plasma. Thereafter, we developed a PhA fluorescence-based in vivo assay using mice 




identify possible oral drug-drug interactions (DDIs) associated with Bcrp inhibition 
(Chapter 4). We observed an increased PhA fluorescence, both whole-body and in serum, 
of Bcrp-knockout mice, and in mice pre-treated with known Bcrp inhibitors, compared to 
WT mice, administered with PhA, suggesting that our assay might identify possible oral 
DDIs due to inhibition of Bcrp at mouse enterocytes.  
 
 
Perspectives and Future Directions 
 
 While drug transporters are important for transporting xenobiotic substrates, and 
thereby involved in therapeutic resistance, drug-drug or food-drug interactions, they are 
also important for transporting endogenous metabolite(s) and involved in many important 
physiological functions [14]. Therefore, a clear understanding of the endogenous function 
of transporters will help better elucidate the effect of loss of function mutation or 
pharmacological inhibition of these transporters, leading to identification of drug-
metabolite-transporter interactions. 
 
 Xenobiotics are often substrates of multiple transporters and/or enzymes. 
Therefore, an altered transport function due to a secondary effect of absence or inhibition 
of other transporter(s) may lead to pharmacokinetic or pharmacodynamic changes of 
transporter substrates and/or DDIs. For example, Martinez et al. recently published that 
association of methotrexate clearance (cleared mainly by urinary excretion) and 
OATP1B1 polymorphism (a transporter of the liver) can be explained by communication 
of OATP1B1 transporter, via its endogenous metabolites, with OAT1/3 transporters 
involved in methotrexate excretion at the kidney [213].  
 
 Several uremic toxins that are substrates/inhibitors of OAT1/3, BCRP and MRP4, 
are also metabolites of the gut microbiota [234] [141] [126]. Several clinically used non-
antibiotic drugs are also known to alter the gut microbiome [313]. Therefore, it can be 
hypothesized that loss-of-function mutation and/or pharmacological inhibition of 
transporter(s) can lead to remote signaling via the gut microbiome metabolites to alter the 
function of other transporter(s), leading to a change in not only metabolite homeostasis, 
but also altered pharmacokinetics of their xenobiotic substrates.  
 
 BCRP and PGP efflux transporters are highly expressed at the enterocytes in 
gastrointestinal tract, regulating the oral absorption of their substrates [11, 115, 177, 258, 
259, 270]. Hence, while considering the effect of gut microbiota on systemic metabolites, 
a special consideration is needed for these efflux transporters that control the oral 
absorption of many different chemical class of compounds.  
 
 The transporters are also highly expressed at the blood brain barrier (BBB) and 
blood CSF barrier (BCSFB), regulating the brain or CSF permeability of their substrates 
[169, 171] [144] [46, 155]. Their effect on brain accumulation of BCRP and PGP 
substrates is so dramatic probably because of (i) lack of efficient metabolic clearance 
from brain, compared to liver that takes care of peripheral blood concentration and (ii) 




of CSF. Specifically, in adult humans, the total CSF volume turnover is about 4 times a 
day, with a CSF synthesis rate of 0.35-0.4 ml/min [314], compared to blood flow rate to 
brain which is about 700 ml/min, and to liver which is 1.4 L/min (http://rmi-
pharmacokinetics.com/Physiological_parameters).  
 
 Therefore, the effect of dietary and microbiome metabolites, that are PGP and/or 
BCRP substrates/inhibitors, might be highly significant in brain as well. To this effect, 
our metabolomic analysis in rats identified abundance of many sulfate metabolites, 
possibly dietary or microbiome-generated, and the known Bcrp substrate urate in the CSF 
of dKO rats, compared to WT rats. Since Bcrp has high affinity for sulfated metabolites 
[127]; our results raise the possibility that BCRP might also be involved in controlling 
gut-brain chemical interactions. A recent finding showed that sulfated steroids, such as 
estradiol sulfate, in female mice urine, can activate vomeronasal sensory neurons (VSNs), 
which are part of accessory olfactory system (AOS), involved in social interaction in 
mice [315]. Therefore, BCRP, which is known to be a transporter of sulfated steroids 
[316], might have a more significant role to play at different tissues including brain, than 
being a mere xenobiotic transporter.  
 
 It is well known that the absence of Pgp in mice leads to an irritable bowel 
syndrome phenotype [51], and possible modification of the gut microbiome in absence of 
Pgp could be the leading cause for this phenotype [162]. Gut microbiome is also reported 
to change in gout patients, who have hyperuricemia [139]. Bcrp is involved in the 
intestinal secretion of uric acid, a decrease of which can lead to hyperuricemia [138] 
[114] and precipitation of gout in humans with BCRP polymorphism [24]. Therefore, 
alteration in the gut microbiome is possible in the absence or chronic inhibition of BCRP 
and/or PGP transporters, leading to an altered metabolome in the host. Gut microbiome 
has also been recently associated with disease conditions related to CNS [317] [318] 
[319]. While Bcrp and/or Pgp knockout mice do not show any obvious phenotype of 
CNS pathology, a behavioral understanding of rodent models of these diseases is not so 
common and more studies need to be done to understand the role of transporters in the 
CNS.  
 
 Recently published reports have highlighted the importance of understanding 
pharmacometabolomics, i.e., the effect of drug treatment on the metabolome, or a 
metabotype of drug action [180, 185]. Lin et al. showed that pharmacometabolomic 
understanding can also help predict population variability in busulfan clearance [214]. 
Studies by Dr. Elizabeth de Lange’s group at Leiden University further showed that 
integrated metabolomics and PK/PD studies can be greatly useful and provide significant 
insight into CNS drug discovery [320, 321]. Therefore, the concept of utilizing 
metabolomics for predicting drug pharmacokinetics and pharmacodynamics may not be a 
far-fetched hypothesis in near future. Knowledge integration of metabolomics of drug 
transporters and associated biomarker information, if possible, could be extremely helpful 
in understanding population variability in PK, drug response as well as toxicity 





 To our knowledge, this is the first study reporting the metabolomic impact of 
Bcrp and Pgp drug transporters in rodents. In a preliminary experiment comparing the gut 
microbiome between WT and Bcrp KO mice by 16S ribosomal RNA sequencing of fecal 
samples, we have observed a significant difference in percentage abundance of gut 
microbial populations, as was suggested by our CSF and plasma metabolomic findings in 
rats (data not shown). Future studies should be directed towards metabolomic analysis of 
fecal, plasma and urine samples from these mice for integration with the microbiome 
abundance data leading to a better understanding of host-microbiome metabolomic 
interactions in absence of Bcrp transporter. Furthermore, metabolomic analyses of 
different models of gene deletion or inhibition of other transporters in a variety of 
matrices would be required for a better understanding of the Remote Sensing and 
Signaling concept [20].  
 
 We unexpectedly found an increase in ketamine abundance in plasma as well as 
CSF of Bcrp-Pgp dKO rats compared to WT rats and later confirmed that 
pharmacokinetics (PK) and pharmacodynamics (PD) of ketamine are affected by these 
transporters in mice [95]. Unlike prototypical Bcrp-Pgp substrates, ketamine whole brain 
homogenate concentration was found to be similar between WT, Bcrp or Pgp KO and 
dKO mice, whereas its anesthetic effect as measured by loss of righting reflex (dLORR) 
was found to be significantly higher in the dKO mice, followed by Pgp KO mice, 
compared to WT mice. Treatment with known Bcrp-Pgp inhibitor elacridar (ECD) also 
increased dLORR in the WT mice. Due to high passive permeability of ketamine, effect 
of efflux transporters in brain may not be similar to other substrates that show increased 
brain accumulation in absence of these transporters. The same was observed for another 
Pgp substrate terfenadine [97], another high permeability Pgp substrate, with no 
difference in brain uptake clearance between WT and Pgp KO mice. This raises the 
possibility of overlooking the effect of these transporters on certain compounds when 
only PK is considered as a discerning factor. In this regard, FDA guidance on assessing 
DDI states that the effect on distributing tissue(s)/organ(s) toxicity or efficacy needs to be 
considered when assessing DDIs. Therefore, we believe that the PD or toxicity of a drug, 
along with its PK, should be an additional factor of consideration during DDI assessment. 
In addition, long-term administration of ketamine is well-known to cause toxicity in the 
urinary bladder and kidney [252] [322] [323]. Therefore, based on our current knowledge 
of the effect of Pgp, Bcrp and OCT1/2 transporters on ketamine [98] [95], it will be 
interesting to see if these transporters play any role on the peripheral tissue toxicity of 
ketamine.  
 
 While our current investigation does not specifically identify any biomarker for 
Bcrp/Pgp activity, we identified several putative endogenous substrates of Bcrp and/or 
Pgp which might be interesting candidates for further investigation. However, our studies 
with PhA as a dietary marker of gastrointestinal Bcrp activity showed the possibility of 
utilizing a fluorescent substrate/marker for high-throughput screening of Bcrp inhibitors 
in vivo. A 50-fold window of difference in serum concentration of PhA between WT and 
Bcrp KO mice created a prospect for identification of Bcrp substrates in vivo by 
measuring serum fluorescence. Our results from rats on regular diet showed that PhA is 




interesting, as it creates an opportunity to utilize dietary PhA, which is a chlorophyll 
catabolite, to be utilized as a dietary biomarker of BCRP activity in humans as well, since 
chlorophyll is a dietary component in humans. A future modification of this study with 
more soluble PhA analogues that are also Bcrp substrates and gives a better tissue 
distribution and absorption compared to PhA can also be useful to assess systemic 
inhibition of Bcrp and associated increase in tissue concentration of its substrates.  
 
 In conclusion, this research work created a new understanding of the endogenous 
role of Bcrp and Pgp efflux transporters, their effect on the PK and PD of the 
anesthetic/analgesic drug ketamine, and development of an assay for identification of 
Bcrp inhibitors in mice. Further studies need to be done with focused goals specifically 
(i) to elucidate the effect of the transporters on microbiome and associated metabolic 
changes, (ii) how peripheral toxicity can be modified by efflux transporters Bcrp and 
Pgp, with a model substrate ketamine, (iii) modification of the existing protocol of PhA 
in vivo assay, with carefully selected Bcrp substrate(s) and inhibitors for developing a 
robust fluorescence-based assay that can detect systemic as well as oral Bcrp inhibition in 
vivo, and (iv) elucidating the pharmacometabolomics of drugs that interact with Bcrp and 
Pgp transporters, thereby creating better understanding of long term systemic inhibition 
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